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Abstract 
Clostridium difficile infection (CDI) is associated with significant patient 
morbidity, mortality and financial burden.  Until recently, antimicrobial 
treatment options were limited to metronidazole and vancomycin, but both 
agents are associated with recurrence rates of approximately 20%. 
 
The human gastrointestinal tract harbours a complex microbial community 
which exist in planktonic and sessile form.  Sessile organisms are known to 
cause chronic infection such as cystic fibrosis.  Mucosal biofilms exist on 
surfaces of the gastrointestinal tract, but the existence and role of C. difficile 
in these structures remains unknown. 
 
The present study describes the process undertaken to adapt and validate an 
in vitro human gut model to study the planktonic and biofilm mode of 
growth of C. difficile and the indigenous gut microbiota.  A triple stage 
chemostat gut model, primed with a human faecal emulsion was used to 
induce and treat simulated CDI.  A glass rod system was incorporated into 
the third vessel to facilitate the formation and subsequent analysis of 
mixed-species biofilms. 
 
Sessile and planktonic gut microbiota and C. difficile populations within an in 
vitro gut model are similar in the absence of antimicrobial intervention.  
Differences in behaviours of the two modes of growth are evident upon 
antimicrobial administration, with a delayed response in sessile populations.  
The sessile mode of growth of C. difficile within mature biofilm structures is 
complex and variable.  Within the redesigned biofilm gut model, sessile 
C. difficile remained in spore form for the duration of the experiment, despite 
- v - 
induction of simulated CDI, treatment of CDI and recurrence of disease 
evident within planktonic communities. 
 
Recalcitrant spores within biofilms may be seeded into the planktonic fluid 
of the gut model after apparent successful initial treatment and contribute to 
recurrence of CDI.  The role of sessile C. difficile in recurrent CDI should be 
further investigated. 
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1.0 Introduction 
1.1  Clostridium difficile 
1.1.1 History 
In 1935 Hall and O’Toole first isolated Clostridium difficile from the stool of 
neonates1.  They referred to this isolate as ‘Bacillus difficilis’ due to the 
difficulty encountered whilst culturing the organism.  Snyder carried out 
further work and described this organism as a Gram-positive, anaerobic 
bacillus with lethal toxigenic properties when injected subcutaneously or 
intra-peritoneally into animals2.  However, he also noted that the bacterium 
was commensal in the gut of infants; hence, colonised infants were 
asymptomatic. 
Pseudomembranous colitis (PMC) was first reported in 1893 by Finney, who 
noted diphtheritic colitis in a surgical patient3.  The incidence of PMC 
increased greatly with the widespread use of antimicrobial agents4.  Early 
work linked the use of clindamycin to the development of the disease, 
stimulating interest in this area5.  It was known that stool samples from 
patients with PMC contained high levels of cytotoxic activity6, 7; but it was 
not known which agent produced this toxin.  Reports from several 
laboratories noted that the cytotoxic activity was neutralized by gas 
gangrene antiserum4, 5, which led investigators to research the neutralizing 
effect of the antiserum of several clostridial species, C. sordellii being the 
most effective8, 9.  As a result, it was believed that C. sordellii was the 
aetiological agent in PMC, but the organism was almost never isolated from 
the stool of patients.  It was subsequently demonstrated that C. difficile could 
be isolated in high numbers from the stool of patients with PMC and that it 
produced toxins that could be neutralized by the antiserum of C. sordellii10, 11. 
The prevalence of this anaerobic, Gram-positive, spore-forming bacterium 
within the hospital setting has increased with the use of antimicrobial 
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agents.  The highly resistant characteristic of C. difficile spores gives rise to 
their persistence in close proximity to vulnerable patients which facilitates 
CDI and allows infection to spread in healthcare institutions leading to 
epidemics12-14. 
 
1.1.2 Clinical Manifestations 
Clostridium difficile infection (CDI) symptoms range from mild, self-limiting 
diarrhoea to fulminant colitis with megacolon or perforation15, 16.  The wide 
spectrum of disease is a consequence of both host-specific (immune status, 
age, comorbidities, level of colonisation resistance) and pathogen-specific 
(virulence of infecting strain) factors.  Interestingly, a high percentage of 
infants are carriers of C. difficile and harbour high levels of toxin in their 
faeces without showing any signs or symptoms of infection17.  
Asymptomatic carriers may act as a reservoir for C. difficile and facilitate the 
spread of spores and subsequent infection of at-risk patients13. 
Mild diarrhoea is common with antimicrobial therapy, and is often 
associated with an osmotic imbalance within the colon18.  
Approximately 20% of antibiotic-associated diarrhoea cases are due to 
C. difficile.  Disease is usually mild and in 15-25% of all cases symptoms cease 
when antimicrobial therapy is discontinued19.  Colitis with the formation of a 
pseudomembrane produces more serious illness with abdominal pain, 
nausea, fever and malaise often present20.  PMC is the characteristic 
manifestation of CDI and may be fatal21.  Fulminant colitis infection occurs in 
a small proportion of patients and manifestations include toxic megacolon, 
marked leukocystitis, colonic perforation and death22. 
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1.1.3 Pathophysiology and Disease Risk factors 
The intestinal tract is home to a diverse microbial population.  Conservation 
of this microbiota is necessary to maintain a healthy gut, and its disruption 
can lead to the colonisation and proliferation of intestinal pathogens, 
including C. difficile23.  C. difficile can form part of the microbiome of 
approximately 50% of neonates and 6% of adults without causing disease17, 
24-27.  This asymptomatic carriage may be due to the maintenance of a healthy 
gut microbiota so that the level of C. difficile present is not sufficient to cause 
disease23; the strain of C. difficile present may not be toxigenic28; or the patient 
may have mounted as sufficient (antitoxin) antibody response to prevent 
disease29. 
C. difficile often persist within hospital environments as spores30, 31.  These 
spores can survive the acidic environment of the stomach and once exposed 
to certain conditions in the small bowel, can germinate and form vegetative 
cells32.  If there has been disruption to the commensal gut microbiota, and 
conditions are favourable, vegetative C. difficile proliferate in the colon 
where flagella may assist them to translocate to the mucous membrane33, 34. 
Bacteria must then gain access to the underlying epithelial cells where 
receptors bind to toxins, causing cytoskeleton changes that result in 
disruption of tight junctions35 and loosening of the epithelial barrier, 
resulting in cell death or the production of inflammatory mediators that 
attract neutrophils and monocytes.  The release of immunomodulatory 
mediators from the epithelial cells, phagocytes and mast cells is induced by 
the cytotoxic effects of toxin, resulting in inflammation and the accumulation 
of neutrophils36. 
Colonisation resistance is the mechanism whereby the intestinal microbiota 
protects itself against incursion by new and often harmful microorganisms.  
The barrier effect of these microbes against C. difficile is very effective and 
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disease will only occur once this barrier has been disrupted, usually by 
antibiotics.  Larson et al 37 have validated this hypothesis when hamsters 
challenged with C. difficile only showed signs of disease when they had been 
pre-treated with antibiotics.  Further to this, they also showed that hamsters 
pre-treated with antibiotics remained healthy until they were exposed to 
C. difficile, indicating that disruption of the microbiota and colonisation are 
both prerequisites to the onset of CDI37. 
Antibiotics can be inactivated in the gut by metabolism or adsorption38, 39.  
Any active antimicrobial agent present in the gut may affect the commensal 
microbiota of the intestine.  If the concentration of antibiotic in the gut is 
sufficient to inhibit the growth of commensal microbiota, this provides 
potentially pathogenic microorganisms (PPMO) with greater nutrient and 
spatial availability, potentially allowing the colonisation and proliferation of 
C. difficile.  C. difficile spores are able to survive the passage through the 
stomach and duodenum and into the jejunum, where the concentration of 
primary bile salts and nutrients are high40.  It is postulated that the 
availability of cholate derivatives and glycine enable spores to germinate 
and pass through the ileum into the colon, where anaerobic bacteria are able 
to metabolise the cholate derivatives into deoxycholate.  Bile acid, 
deoxyxcholate, potentially prevents outgrowth of the vegetative cell from 
the germinated spore and the host remains uncolonised.  If the commensal 
anaerobic bacteria have been inhibited by antimicrobial agents and are 
unable to metabolise the cholate derivatives, vegetative growth may be 
possible32. 
One to the most significant risk factors associated within the onset of CDI is 
antibiotic exposure41.  Most antimicrobial agents have been linked to the 
onset of CDI but those most commonly associated are broad-spectrum 
antibiotics, particularly clindamycin, third-generation cephalosporins and 
fluoroquinolones42-44.  In the past, clindamycin has been associated with a 
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high propensity to induce CDI, but clindamycin use has since been severely 
reducued and other antibiotics with widespread use have become the main 
causative agents for CDI.  Antibiotics that are rarely associated with CDI 
include aminoglycosides, glycopeptides and tetracyclines.  A recent report 
published by the Health Protection Agency (HPA) highlighted that the most 
commonly reported antimicrobial agents associated with CDI onset were 
co-amoxiclav and piperacillin-tazobactam, both of which are in common use.  
Caution should be taken when analysing such data as these may reflect 
trends in prescribing practices (including the use of multiple antibiotics)45. 
As well as the use of antibiotics, other risk factors for the development of 
CDI have been identified.  McFarland et al 46 carried out a prospective cohort 
study of 399 patients on a single ward over 11 months in an endemic 
situation.  They identified older age, severe underlying illness, use of 
cephalosporins or penicillins, gastrointestinal stimulants, stool softeners and 
enemas as risk factors for the development of CDI.  Other researchers have 
also identified gastric acid-suppressive therapy such as proton pump 
inhibitors; increased length of hospitalisation, abdominal surgery, intensive 
care unit admission, contact with healthcare institutions and severe 
underlying disease as other contributions to the onset of disease47-52. 
 
1.1.4 Virulence Factors 
1.1.4.1 Toxins A and B 
The major virulence factors for C. difficile are the two highly related toxins, 
toxin A (TcdA); a 308 kDA enterotoxin and toxin B (TcdB); a 250 kDA 
cytotoxin53, 54, which share 63% amino acid similarity55. Toxin yield varies 
amongst C. difficile strains and is influenced by environmental conditions.  
Toxin synthesis increases as cells enter stationary phase and is controlled by 
growth temperature, cellular growth phase, nutrient levels of butyric acid, 
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certain amino acids, carbohydrate sources, growth-limiting levels of biotin 
and certain antibiotics56, 57,58, 59,60. 
Both toxins comprise four domains with distinct functional properties; the 
catalytic domain, the cysteine protease domain, the translocation domain 
and the receptor binding domain55, 61, 62.  The translocation domain facilitates 
the delivery of the N-terminal catalytic domain across the membrane of the 
host cell where it is then cleaved and released into the cytosol by 
autoproteolysis63, 64.  Rho, Ras and Cdc42 are GTPases which regulate tight 
junctions and the actin cytoskeleton65.  Once inside the cytosol, the catalytic 
domain inactivate GTPases by glucosylation of threonine residue leading to 
disruption of the actin cytoskeleton and tight junctions, causing cell 
rounding66, 67. 
 
1.1.4.1.1 Toxicity of Toxin A and B 
The exact roles and contributions of toxin A and B in causing disease remain 
unclear.  Animal models such as the rabbit and rat ileal loop models, and 
golden Syrian hamster model have been used to demonstrate the 
inflammatory response that occurs in PMC and can be used to assess the 
relative role of the two toxins.  However, inter-species differences in clinical 
manifestations are evident, therefore extrapolation of data from one to the 
other should be tentative68.  Originally, the major role in disease was 
attributed to toxin A.  Lyerly et al69 reported that intragastric administration 
of toxin A to hamsters and mice caused haemorrhagic secretion in the small 
intestine, but toxin B only caused damage if the bowel was damaged prior to 
toxin B exposure.  Whilst toxin B lacks enterotoxic effects in experimental 
animals, it is extremely cytotoxic to cultured mammalian cells, including 
those from the human intestine70, and is reported to be ~1000 times more 
potent than toxin A in most cells lines.  This led to the hypothesis that 
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toxin A is required to bind to its receptor on the lateral surface of the 
epithelial cells causing initial damage to the tight junction and allowing the 
subsequent passage of toxin B through the epithelial cells to its receptor on 
the basal surface of the cell.  However, the existence of toxinA- toxinB+ 
strains, which are able to cause disease in hamsters71 and  are present in up 
to 10% of clinical human specimens72,73-76, contradicted the hypothesis that 
toxin A was required for pathogenicity. 
 
Lyras et al77  developed mutated strains of C. difficile to provide evidence that 
toxin B (not A) is essential for virulence.  Hamsters challenged with a 
toxin A-inactivated mutant were as likely to die as those challenged with the 
wild-type strain, whereas hamsters challenged with a toxin B-inactivated 
mutant were much more likely to survive.  More recently Steele et al showed  
that the administration of anti-toxinB antibodies protected 100% of piglets 
from C. difficile challenge from morbidity and mortality whilst the 
administration of anti-toxinA antibodies resulted in 100% of piglets 
displaying signs of severe gastrointestinal and systemic disease, 
with 67 - 83% fatality78. 
 
1.1.4.1.2 Receptors for Toxins A and B 
In order to elicit cytotoxic effects toxins must first be internalised into the 
host cell via endocytosis, which requires the binding of the C-terminal 
domain of the toxin to a receptor.  Several potential carbohydrate receptors 
for toxin A have previously been identified. The glycan sequence 
αGal(1,3)βGal(1,4)βGlcNAc, which is present on  rabbit erythrocytes and 
hamster brush border membranes was first identified as a potential receptor 
for toxin A79.  However, this carbohydrate is not present in humans80.  Later, 
carbohydrates Galβ(1,4)Fuα(1,3) GlcNAc (Lewis X), 
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Galβ(1,4)GlcNAcβ1 (Lewis Y) and Galβ(1,14)GlcNacβ(1,3)Galβ(1,4)(Glc) 
(Lewis I)  which are present in human intestinal epithelial cells were 
suggested as possible receptors for toxins A81.  The receptor for toxin B has 
been less well characterised.  Due to the cytotoxic effects on a wide range of 
intestinal cells lines it is thought that the toxin B receptor is ubiquitous63, 82. 
 
1.1.4.1.3 The Pathogenicity Locus 
The genes encoding toxin A and B are situated within a chromosomal region 
designated as the pathogenicity locus (PaLoc)83.  The PaLoc (figure 1.1) 
is 19.6-kb in length and contains five genes that regulate toxin expression.  In 
non-toxigenic strains (tcdA-tcdB-) the PaLoc is replaced by a 115 bp region of 
non-coding sequence84.  Variation in the PaLoc gives rise to C. difficile strains 
with varied toxigenicity. 
 
The pathogenicity locus contain genes tcdA and tcdB which encode toxins A 
and B respectively; along with three other genes, tcdR, tcdC, tcdE.  The open 
reading frames encoding tcdR, tcdB, tcdE and tcdA are transcribed in one 
direction with tcdC oriented in the opposite direction83 (depicted by arrow 
direction in figure 1.1). 
 
 
 
 
 
 
Figure 1.1: Pathogenicity locus of toxigenic C. difficile strains83. 
 
  tcdR       tcdB               tcdE            tcdA             tcdC 
      PaLoc (19kb) 
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The tcdR sequence encodes a positive regulator of tcdA and tcdB; and tcdC 
encodes a putative negative regulator of tcdA and tcdB85, 86.  TcdR initiates 
toxin gene expression as an alternative RNA polymerase sigma factor, 
directing RNA polymerase to transcribe the toxin genes as well as its own 
encoding gene, resulting in a rapid increase in toxin production87.  As is the 
case for the toxin genes, tcdR expression is controlled by cellular growth 
phase, growth medium and temperature59, 86. 
 
The mechanism of TcdC action has not been fully elucidated.  TcdC is 
divergently transcribed from the toxin genes and is expressed during rapid 
exponential phase growth and displays reduced expression during 
stationary phase growth88.  The converse is true for TcdR and the toxin 
genes, indicating the putative negative role of tcdC in toxin expression.  
Evidence suggests that tcdC negatively regulates C. difficile toxin gene 
expression by destabilising the formation of a tcdR-containing RNA 
polymerase holoenzyme, thereby hampering its ability to recognize the tcdA 
and tcdB promoters rather than by directly interacting with the target 
promoters89.  Some strains, (PCR ribotype 027) have a mutated negative 
regulator gene tcdC which potentially leads to increased toxin yield and has 
contributed to these strains being classified as ‘hypervirulent’.  However, 
recently the role of TcdC has been disputed90, 91.  In vivo and in vitro studies 
on the importance of TcdC on toxin production show conflicting results92, 93.  
Mutation and subsequent restoration of tcdC of C. difficile PCR 
ribotype 027 strains found no association between tcdC genotype and toxin 
production92. Conversely, tcdC complementation in a C. difficile PCR 
ribotype 027 strain resulted in reduced toxin production and virulence 
within a hamster model93. 
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TcdE is a small, hydrophobic protein of 166 amino acids which contains 
structural features similar to those of the class I holins of which phage λ S 
protein is a member94.  Dupuy et al demonstrated that TcdE has a holin-like 
activity and is required for efficient secretion of toxins into the extracellular 
environment without inducing cellular lysis95. 
 
1.1.4.1.4 PaLoc Variation Amongst C. difficile Strains 
Toxin production varies amongst C. difficile isolates.  Patients infected with 
C. difficile PCR ribotype 027 often suffer from increased morbidity and 
mortality96, which is hypothesised to be due to an increase in toxin 
production.  Ribotype 027 has an 18 base pair deletion in the tcdC gene 
which is a putative negative regulator of toxin gene expression97.  This 
deletion causes a frame shift mutation and the formation of a truncated 
protein.  It is speculated that this therefore inhibits or reduces the expression 
of the tcdC gene during exponential growth, allowing the transcription of 
tcdA and tcdB earlier, or for longer, than in other strains. 
Warny et al97 have compared ribotype 027 toxin yields to that of a 
non-027 strain in batch culture and reported a 16 and 23 times increased 
toxin yield in toxin A and B respectively.  However, Baines et al utilised an in 
vitro continuous culture model of simulated CDI to demonstrate an equal 
level of maximum toxin production compared with a PCR 
ribotype 001 strain.  By contrast, the duration of toxin production by 
the 027 strain was greater than the 001 strain98. 
 
1.1.4.2 Binary Toxin 
An additional binary toxin, CDT (C. difficile transferase), is found in 
approximately 6% of C. difficile strains99, 100.  PCR ribotype 027 strains carry 
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the gene for CDT, and it has been postulated that the toxin could be 
associated with increased virulence97.  It consists of a binding and an 
enzymatic component displaying an actin ribosyl transferase activity.  The 
cdtA and cdtB sequences encode the binding and enzymatic component of 
the toxin respectively.  These genes along with a gene encoding a 30 kDa 
regulatory protein (CdtR) are located on the cdT locus101. 
The binding domain of the toxin is involved in binding and transporting the 
enzymatic domain into the cytosol of the target cell.  Once inside the cell, the 
enzymatic domain catalyses the ADP-ribosylation of the G-actin monomers 
at Arginine-117102.  This inhibits actin polymerisation by acting as a capping 
protein at barbed ends of the actin filament preventing incorporation of 
further actin monomers.  ADP-ribosylating toxins also induce the formation 
of microtubule-based protrusions on the surface of epithelial cells, 
potentially leading to increased adherence of these C. difficile strains103.  
Whilst the effects of ADP-ribosylating toxins on actin are well understood, 
their role as virulence factors is less clear. 
Barbut et al104 showed no statistically significant increase in the severity of 
CDI caused by CDT+ strains compared with CDT- strains and Geric et al105 
demonstrated no disease in hamsters with TcdA-TcdB-CDT+ strains.  Whilst, 
Bacci et al found that patients infected with strains possessing 
tcdA+tcdB+CDT+ genes displayed higher 30-day case-fatality rates, compared 
with strains possessing toxin A and B genes only106.  In addition, 
TcdA-TcdB-CDT+ strains have been isolated from both symptomatic and 
asymptomatic patients107, indicating that CDT may provide an adjunctive 
role to toxins A and B during the disease causing processes. 
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1.1.4.3 Hydrolytic Enzymes 
Anaerobic bacteria produce a variety of hydrolytic enzymes which are 
thought to play a role in the aetiology of infection, causing connective tissue 
degradation, leading to colitis and pseudomembrane formation108. C. difficile 
produces hyaluronidase, chronditin-4-sulphatase, gelatinase and 
collagenase109.  The precise role in pathogenicity is unknown but it has been 
postulated that the enzymes may be involved in the degradation of host 
proteins, releasing nutrients beneficial to C. difficile.  Proteolytic enzyme 
production is associated with increased virulence within the hamster 
model108,110.  Cwp84 is a protease of C. difficile which is associated with the 
S-layer proteins and shows degrading activity against fibronectin, laminin 
and vibronectin111. 
 
1.1.4.4 Flagella 
Flagellar mediated motility is an important trait required for survival, 
colonisation and virulence in some organisms112-115.  Flagella expression by 
C. difficile is variable with conflicting evidence regarding the correlation 
between flagella presence and virulence116.  Flagella allow the chemostatic 
movement of organisms.  Borriello et al117 demonstrated that human gut 
mucus acts as a chemo-attractant for C. difficile and the degree of chemotaxis 
is positively correlated with the virulence of the strain. 
 
Flagellin FliC is a major structural component of the flagellar filament 
(encoded by fliC), and FliD is a hook-associated component of the filament 
cap (encoded by fliD).  Evidence suggests that the presence of the flagellar 
proteins FliC and FliD increase the adherence of C. difficile strains; Tasteyre 
et al118 reported a 10-fold increase in tissue association in flagellated strains 
when compared with non-flagellated strains.  Conversely, Dingle et al119 
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have demonstrated the increased colonisation of Caco-2 intestinal epithelial 
cells by C. difficile fliC- fliD- mutants compared with the wild-type stain.  
Moreover, this mutant strain displayed increased virulence in hamster 
compared with the wild-type, indicating that the presence of FliC and FliD 
reduce virulence.                
                                                                                                                                                                                                                                                         
1.1.4.5 Adhesins 
Association and persistence of C. difficile in the gastrointestinal tract is an 
important precursor to disease manifestation.  Several putative adhesins of 
C. difficile vegetative cells have been identified including S-layer proteins, 
Cwp66 and heat-shock proteins. 
Borriello first reported the association of C. difficile to the gut mucosa 
following recovery of C. difficile from a washed colonic  biopsy specimen 
from a patient with PMC120.  Borriello et al121 later compared the efficacy of 
the adherence of poorly virulent and highly virulent strains to the mucosal 
surface, demonstrating that a poorly virulent, toxigenic strain colonised less 
efficiently than a highly virulent strain.  The co-administration of crude 
preparations of C. difficile toxins with a non-toxigenic strain resulted in a 
significantly greater adherence to the small bowel mucosa comparable with 
that of the toxigenic strain.  It was hypothesised that C. difficile toxins A and 
B may  be involved in the promotion of mucosal association121.  Waligora et 
al122 compared the adherence of toxigenic and non-toxigenic strains, 
demonstrating that C. difficile adherence to Vero cells (as opposed to 
mucosal association), was not promoted by toxigenic status. 
Vegetative C. difficile have been shown to bind to intestinal cell lines such as 
Caco-2, HT29-MTX and Vero cells122, 123, with binding mediated by a 
proteinaceous component123-126.  This allows vegetative cells to persist within 
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close proximity to the epithelial cells, hence in close proximity to toxin 
receptors. 
 
The structures on the surface of the vegetative cell responsible for mediating 
adherence to the gut epithelium were until recently poorly characterised.  
Surface layer proteins have been shown to be required for virulence of some 
bacteria.  Unlike most bacterial species, C. difficile expresses two distinct 
S-layer proteins, P36 a low molecular weight protein and P47 a high 
molecular weight protein127.  Both proteins are derived from a common 
precursor and mediate cellular adherence, with P47 showing strong and 
specific binding to gastrointestinal tissues and some extracellular matrix 
proteins.  P47 is highly conserved amongst strains whilst P36 displays high 
sequence diversity128.  C. difficile surface layer proteins bind to collagen I, 
vibronectin and thromospondin, but not to collagen IV, fibronectin or 
laminin129. 
 
C. difficile cell surface protein, Cwp66, mediates in vitro adherence to Vero 
cells126.  The Cwp66 protein possesses a cell-wall anchoring N-terminal 
domain and a cell surface exposed C-terminal domain with adhesive 
properties126. Cwp66 displays homology to S-layer proteins and the genes 
encoding these proteins are located near each other in a 37-kb DNA cluster 
in the C. difficile genome 130. 
The heat shock proteins GroEL131, Hsp60, Hsp70 and the fibronectin-binding 
protein Fbp68132 have also been reported to play a role in the adhesion of 
C. difficile to the gut mucosa. 
Attachment of C. difficile spores to gut mucosa may be an important factor in 
colonisation and relapse of CDI.  The ability of a spore to adhere to a surface 
is governed by factors such as its hydrophobicity, the formation of 
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appendages and the presence of an exosporium.  Panessa-Warren et al133 
have shown that the endospores of C. difficile develop a thickened exosporial 
extension from one end of the spore in the early stages of germination, 
which facilitates attachment to agar surfaces.  Further studies have shown 
that spores are able to rapidly attach to Caco-2 cells133, 134. 
 
1.1.4.6 Other Putative Virulence Factors 
C. difficile can persist on the mucosal surface of the gastrointestinal tract 
despite the presence of large numbers of polymorphonuclear leukocytes 
(PMN).  Dailey et al135 determined that antibody-mediated opsonisation was 
required for phagocytosis and that toxigenic strains of C. difficile are more 
resistant to phagocytosis than non-toxigenic strains.  It was speculated that 
toxigenic strains may possess an antiphagotic capsule.  Davies and Borriello 
later confirmed the presence of this capsule using ruthenium red dye to stain 
the capsular glycocalyx136.  Correlation between capsule expression and 
virulence status of C. difficile strains with a hamster model of CDI proved 
unrelated136. 
Another factor that may contribute to the virulence of C. difficile is its ability 
to produce a phenolic compound, para-cresol.  C. difficile can withstand 
concentrations of up to 0.5% of this compound whilst the growth of other 
anaerobic bacteria is inhibited by this product137, 138. The increased tolerance 
of C. difficile to this compound may potentially provide a competitive 
advantage over other gut microbiota, thus allowing C. difficile to proliferate. 
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1.1.5 C. difficile spores 
1.1.5.1 Spore Durability 
Some Gram-positive bacteria have evolved to form spores, which are 
resistant to adverse environmental conditions such as extreme heat, 
radiation and acidity, adverse atmospheric conditions, desiccation and 
chemical substances, and have been recovered from numerous surfaces in 
the nosocomial environment139-142. 
The ability of C. difficile strains to sporulate and their subsequent ability to 
adhere and persist in the hospital setting, on surfaces and on the hands of 
healthcare workers143 may affect virulence, explaining why some strains 
persist in the nosocomial environment to a greater extent than others.  
Spores are resistant to many hospital cleaning agents144, 145.  Wilcox et al144 
compared the sporulation levels of an epidemic C. difficile strain (P24), a 
clinical isolate (B31), both of which produce toxin A and B, and a 
non-toxigenic environmental strain C. difficile (E4).  They showed that the 
epidemic strain produced significantly more spores than the non-prevalent 
strains and that sporulation was further enhanced when the strain was 
exposed to non-chlorine based cleaning agents. Other research groups have 
reported the apparent increased sporulation capacity of C. difficile PCR 
ribotype 027146 147, which may contribute to its increased infection rate, 
outbreaks and disease severity.  However, a more recent study reported that 
sporulation rates amongst a diverse range of clinical isolates, 
including 28 separate PCR ribotype 027 isolates, did not display increased 
sporulation characteristics for the 027 strain compared with strains of other 
ribotypes148.  Moreover, sporulation rates differed amongst 
different 027 isolates148. 
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1.1.5.2 Spore Structure 
C. difficile spores have a complex outer structure, with one or more spore 
coats, a cortex and core (protoplast)149.  The core of the spore contains DNA, 
RNA, ribosomes, enzymes and calcium, manganese, potassium and 
phosphorus150, 151.  The cortex, which is involved in the maintenance, but not 
creation of the dormant state consists largely of peptidoglycan.  The coats 
are largely protein, of which five proteins, CotA, CotB, CotC, CotD and CotE 
are produced by C. difficile152.  The main function of the coat is to protect the 
spore and regulate the conversion from dormant to vegetative state, a 
process known as germination.  The outer most structure of C. difficile spores 
is the exosporium153, 154, a multi-layered shell surrounding the coat, present in 
some but not all strains.  Studies based on Bacillus subtilis have identified the 
exosporium composition as protein, lipids and carbohydrate. The role of this 
structure is largely unknown, but it is postulated that it may allow the 
colonisation of specific niches149, 155. 
 
1.1.5.3 Sporulation and Transmission 
The process of sporulation begins with a vegetative cell, which undergoes 
asymmetric cell division forming two cell compartments, the smaller of 
which is referred to as a prespore.  The mother cell then engulfs the 
prespore, forming a distinct cell termed the forespore.  The 
peptidoglycan-composed spore cortex is then synthesized, followed by 
spore coat formation156.  The spore becomes dehydrated as it matures, 
becoming increasingly refractile, before being eliminated from the mother 
cell154, 157, 158.  The spore is protected from adverse conditions until the 
environment becomes more favourable. 
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Spo0A is a master regulator that controls the signal transduction pathway of 
sporulation initiation.  This pathway has been most extensively studied in 
the genus Bacillus159.  Within Bacillus subtilis five sensory histidine kinase 
molecules (KinA – KinE) respond to environmental and cellular signals, 
which indicate when vegetative cell growth is no longer viable160.  These 
kinases initiate sporulation by modulating the activity of Spo0A through an 
autophosphorelay.  Phosphorylation of the active site aspartate of Spo0A 
promotes binding to a specific target sequence (0A box) in or near to the 
promoters of genes under Spo0A control, resulting in gene expression or 
repression161, 162.  Orthologues of Spo0A encoded by C. difficile are similar to 
that of B. subtilis, and are essential for initiation of sporulation in C. difficile163. 
It has been suggested that the sporulation master regulator Spo0A may 
directly or indirectly affect toxin production164, 165, but conflicting reports 
have also been published.  Underwood et al published further data 
confounding the role of Spo0A in toxin production, where they utilised 
ClosTron technology to inactivate the spo0A gene, which resulted in a 
marked defect in toxin production166. 
Conversely, recent work demonstrated that supernatant derived from a 
spo0A mutant  displayed no less cytotoxicity towards Vero cells than the 
wild-type strain167.  In addition, spo0A mutants gene in 027 ribotype 
C. difficile caused increased morbidity within murine model of CDI, with 
increased level of toxin A and B produced during stationary phase growth of 
the mutant 027 strain compared to the wild-type163.  Other conclusions 
reached from similar experiments suggested that spo0A mutants exhibited 
retarded colonisation, persistence and relapse compared to the wild-type163.  
The ability of C. difficile to transmit infection from human-human and persist 
within the environment is highlighted by this data. 
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1.1.5.4 Spore Germination 
Bacterial endospores undergo a complex series of events termed 
germination to form vegetative cells.  This process occurs in three stages; 
activation, germination and outgrowth.  The activation of germination is 
triggered by external stimuli such as appropriate pH, heat and atmosphere.  
This process is reversible and an activated spore, whilst still retaining its 
protective properties can revert back to its dormant state.  Germination is 
initiated by various stimuli termed germinants.  Once the spore has 
committed to germination this process is irreversible.  During this stage the 
hydrolysis of the spore peptidoglycan cortex takes place allowing enzymatic 
activity and metabolism.  The spore can then swell and sheds its outer layers 
before the new cell can outgrow168. 
 
The conditions causing C. difficile  to germinate remain unclear, although a 
study by Sorg and Sonenshein et al demonstrated that the bile salts 
taurocholate and glycine may act together as co-germinants of C. difficile 
spores32.  The bile salts deoxycholate and chenodeoxycholate have been 
identified as germination suppressors with increased concentrations of these 
bile salts inhibiting the germination effect of taurocholate32, 169. 
 
C. difficile germination capacity has been shown to display considerable 
isolate variation.  Heeg et al170 have demonstrated a diverse rate of 
germination amongst different strains (ribotype 027 versus non-027) in 
response to a rich medium containing taurocholate and glycine.  Whilst 
some studies report the inhibitory germination properties of 
chenodeoxycholate, this group reported the varied response of its inhibitory 
properties amongst different C. difficile isolates170. These conflicting data 
highlight the complexity of germination of C. difficile spores, and indicates 
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that further work is required to gain a more comprehensive understanding 
of this process. 
 
1.1.6 Epidemiology 
1.1.6.1 Surveillance in the Nosocomial Setting 
In order to monitor the incidence of CDI within UK healthcare institutions 
comprehensively, a voluntary reporting initiative was introduced in 1990.  
Mandatory surveillance of C. difficile, initially in patients >65 years (and then 
all those >2 years old, from 2007) for acute Trusts in England was introduced 
in 2004.  This scheme is coordinated by Public Health England (PHE) 
(formerly the HPA) on behalf of the Department of Health. 
The establishment of the mandatory surveillance initiative corresponded 
with a dramatic decrease in disease incidence, with the number of reports of 
CDI in patients > 2 years declining from  40,705 in 2008 to 14,987 in 2012 
(figure 1.2)171.  Prior to this, the total number of reported cases of C. difficile 
increased steadily  from 1,194 in 1990 to 57,255 in 2007172.  Reports of C. 
difficile-associated mortality rates have also decreased, with the number of 
death certificates which mention C. difficile declining from 8.324 in 2007 
to 2,053 in 2011173. 
The incidence of CDI causes a significant clinical and financial burden on 
healthcare settings with the European Centre for Disease Prevention and 
Control estimating costs between €5,000 – 15,000 per case in England174 and a 
European wide systematic review by Wiegand et al reported incremental 
costs of each CDI case in Germany, Ireland and UK (costs adjusted 
to 2010  price levels for comparison) as £8843, £4577 and £6986, 
respectively175. 
- 21 - 
0
10000
20000
30000
40000
50000
60000
2004 2005 2006 2007 2008 2009 2010 2011 2012
N
u
m
b
e
r 
o
f 
C
. 
d
iff
ic
ile
 in
fe
ct
io
n
s 
Year
>65 years
>2 years
 
Figure 1.2: Total number of C. difficile infections in patients aged 65 years 
and over (2004-2007)176 and over 2 years (2008-2012)171. 
 
1.1.6.2 Clostridium difficile in the Community 
Whilst CDI is primarily viewed as a nosocomial infection, the number of 
community-onset cases is becoming increasingly apparent.  The definition of 
community-acquired CDI is unclear and not universally used.  The Centers 
for Disease Control and Prevention defines a patient with symptomatic 
onset 48 hours before hospitalisation as having community-onset, healthcare 
facility-associated CDI.  Patients discharged from hospital within 4 weeks of 
onset would be classified as having intermediate disease.  Patients with no 
history of hospitalisation 4-12 weeks prior to onset would be classified as 
having community-associated CDI177. 
CDI in the community was first reported in the late 1980s.  Historically, rates 
of CDI in the community have been low, with cases ranging 
from 3.2 to 16.2/100,000 individuals178-180.  Although rates of CDI in the 
community are lower than hospital-acquired rates, these numbers are 
continuing to rise, with one study reporting an increase from less than 1 case 
per 100,000 in 1994 to 22 cases per 100,000 in 2004181.  A recent report 
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highlighted that up to 41% of all CDI cases within one county in the US are 
community acquired182, with other studies also reporting large proportion of 
CDI cases being acquired in the community52, 180, 182, 183.  Community-acquired 
CDI is associated with a younger mean age, lower comorbidity scores, less 
severe disease and decrease antibiotic use compared with hospital-acquired 
disease182, 184. 
The persistence of C. difficile spores within the hospital setting may lead to 
increased colonisation of patients recently discharged, therefore Bauer et al185 
postulated that this increase in asymptomatic carriage may increase 
community exposure and hence cause the observed increase in 
community-acquired CDI cases. 
 
C. difficile has been increasingly isolated from animals186-189 and retail meat 
products190, 191 highlighting the role of animals as potential reservoirs for 
C. difficile and leading to concerns of a possible zoonotic transmission of the 
pathogen. 
C. difficile is recognised as an important causative agent of enteritis in 
neonatal pigs, with positive C. difficile recovery from diarrhoeic and 
non-diarrhoeic newborns animals, but not from animals between 
1-2 month-old186.  PCR ribotype 078 strains are predominately isolated from 
swine and calves192 in the US and Europe and isolated with increasing 
frequency in humans193.  In the Netherlands, one study reported the 
distribution of humans infected with PCR ribotype 027 strains were localised 
in rural areas where potential contact with livestock is higher193.  A recent 
study of CDI prevalence in cattle at slaughter (< 7 days old) in Australia 
identified an average C. difficile carriage rate of 53.4%, with 100% of strains 
possessing at least one toxin gene189.  Reported carriage rates from studies in 
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other countries are lower and may reflect differences in slaughter ages 
between countries194-196. 
 
1.1.6.3  C. difficile Molecular Typing Methods 
The increase in incidence of CDI observed in recent years has been 
concurrent with the increased prevalence of an apparently hypervirulent 
C. difficile strain.  In 2004 it was noted by Pepin et al that the incidence and 
morbidity of CDI in Quebec, Canada had increased between 1991 and 2003, 
particularly amongst the over 65 year olds96.  The predominant strain 
responsible for a large number of infections during this increase in incidence 
of CDI was identified by restriction endonuclease analysis (REA) as type BI, 
as North American pulse-field gel electrophoresis (PFGE) type NAP1 and as 
PCR ribotype 027 (BI/NAP1/027)97, 197, 198.  The emergence of this apparently 
hypervirulent strain was also concurrent with an increase in CDI incidence 
throughout North America and Europe199-201. 
 
In order to provide a more comprehensive study of CDI epidemiology 
typing methods have been employed to monitor patterns of C. difficile types 
prevalent within regions, as well as providing information on environment 
and patient-patient transmission within outbreaks.  An increasing number of 
C. difficile molecular typing methods have been developed including REA, 
PFGE, toxinotyping, multilocus variable repeat analysis (MLVA), multilocus 
sequence typing (MLST), whole genome sequencing and PCR ribotyping.  
Reproducibility, stability and discriminatory power are attributes required 
for typing methods. 
PCR ribotyping is the most common technique employed in Europe and the 
UK for molecular epidemiological analysis of C. difficile202.  The Clostridium 
difficile Ribotyping Network (CDRN) Service is a PHE funded initiative 
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offering ribotyping assistance to hospitals in England.  PCR ribotyping 
examines polymorphisms in the 16S-23S intergenic spacer region of the 
ribosomal RNA gene complex.  In 1999 Stubbs et al constructed a reference 
library consisting of 116 distinct PCR ribotypes from various clinical, 
environmental and veterinary sources, ribotype 001 being the most 
prevalent (55%; n= 682)202.  From 1999 until 2003/04 C. difficile PCR 
ribotype 001 was responsible for approximately 60% of cases of CDI in 
England.  In 2005 PCR ribotypes 001, 106 and 027 were equally prevalent.  
In 2007 Brazier et al carried out a surveillance study of strains causing CDI in 
England and determined that PCR ribotype 027 was the most prevalent 
(41.3%), with 106 the second most common (20.2%) and 001, which was once 
the most common reduced to 7.8% of the total203.  Recently the proportion of 
CDI cases due to PCR ribotype 027 has begun to decrease with 
compensatory increases seen in other ribotypes204.  Preliminary results from 
the CDRN for 2012 indicate that 027 is no longer the most prevalent strain in 
England (figure 1.3) (report in progress), and it is worth noting that this 
decrease in the hypervirulent 027 ribotype is concurrent with a decrease in 
CDI mortality rates in the UK.  With increasing typing of C. difficile, 
approximately 500 ribotpyes have now been identified (pers comm. MH 
Wilcox & WN Fawley). 
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Figure 1.3: Prevalence of C. difficile PCR ribotypes in the UK 
from 2007-2012205. 
 
1.1.7 Antimicrobial Resistance 
In 2005/06 the HPA (now PHE) carried out susceptibility testing 
on 881 isolates of C. difficile and revealed universal susceptibility to 
metronidazole, vancomycin, co-amoxiclav and piperacillin/tazobactam.  
Resistance to erythromycin and moxifloxacin was noted but appeared to be 
related to PCR ribotype, with the strains 001, 106 and 027 virtually always 
resistant206. 
One of the first reports of C. difficile resistance to metronidazole was 
published in 2002, detailing 6.3% of 415 isolates with minimum inhibitory 
concentrations (MIC) ≥ 16 mg/L207, but these observations have not been 
verified. 
More recently, 1010 C. difficile isolates from CDRN received 
during 2008/09 were screened for susceptibility to metronidazole and 
vancomycin208.  Overall geometric mean (GM) MICs for vancomycin and 
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metronidazole were 0.9 mg/L and 0.7 mg/L, respectively, with epidemic PCR 
ribotypes 027, 106 and 017 displaying significantly higher metronidazole 
MICs (GM = 1.73, 1.56, 1.15 mg/L respectively; p≤0.0001).  Metronidazole 
MICs of 8 mg/L were also observed in PCR ribotypes 027, 016, 015, 118208.  
Further isolation of strains showing reduced susceptibility to metronidazole 
have been reported, although MIC values appear to be method-dependant209, 
210.  Vancomycin MICs varied little amongst the top 10 most common PCR 
ribotypes (GM= 0.62-0.81 mg/L).  However, 12 isolates with MICs of 4 mg/L 
were identified208.  The CDRN continues to monitor reduced susceptibility to 
metronidazole and vancomycin and utilise MLVA to identify the possible 
clustering of reduced susceptibility isolates204.  This apparent reduced 
susceptibility of C. difficile isolates to the two main-line treatment options 
currently available for CDI could have implications in increased treatment 
failure and disease recurrence.  Reported mean metronidazole 
concentrations in the faeces of patients receiving metronidazole 
were 9.5 mg/kg211-213.  C. difficile strains displaying elevated MICs levels 
(8 to 16 mg/L) may not be inhibited by metronidazole therapy and therefore 
may be attributable to treatment failure.  Faecal vancomycin concentrations 
of 520 to 2200 mg/L were reported in patients following vancomycin 
instillation214.  MICs of vancomycin to clinically-relevant strains, including 
those displaying reduced susceptibility to vancomcyin (≤ 4 mg/L), are 
considerably lower than faecal concentrations.  Therefore, any apparent 
reduced susceptibility to vancomycin may have little or no clinical 
significance. 
 
1.1.8 Diagnosis 
With the incidence of CDI increasing in many countries, prompt and 
accurate diagnosis is vital to commence correct and timely treatment of the 
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disease, and also to reduce the risk of transmission of C. difficile spores to 
patients and/or the surrounding environment. 
Symptomatic CDI patients usually present with unformed stool or watery 
diarrhoea with a distinctive foul-smelling odour215.  There are many 
diagnostic platforms available to identify C. difficile as the causative agent of 
these symptoms and much debate exists as to which diagnostic method is 
the most specific, sensitive, and least time consuming and labour-intensive. 
 
1.1.8.1 Reference Methods 
The ‘gold standard’ reference methods for CDI diagnosis are cytotoxin assay 
(CTA) and cytotoxigenic culture (CC)216-218.  CTA detects the presence of 
toxin in faecal samples by monitoring action of faecal sample on cell 
cultures.  CC involves the culture of C. difficile from stool, and subsequent 
CTA from the culture rather than directly from stool sample.  However, 
these reference methods are time consuming, labour intensive and require 
specific laboratory facilities and staff expertise. 
 
1.1.8.2 Toxin Enzyme Immunoassay 
Many healthcare trusts in the UK have abandoned the use of ‘gold standard’ 
methods in favour of rapid enzyme immunoassays (EIA).  A recent report 
highlighted that up to 70% of hospital trusts in England and Wales use toxin 
EIA as a standalone diagnostic test219.  EIA kits detect the antigens of 
toxins A and B, are relatively simple to use, inexpensive and provide rapid 
results.  There are concerns over the performance of this diagnostic method, 
with sensitivity rates sometimes reported to be less than 50%218, 220-222.  
However, a systematic review of these tests reported sensitivity values 
of 75-95% and specificity values of 83-98% compared with CTA223.  Whilst 
CTA was considered as the reference method in this study, its sensitivity 
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rates compared to CC have been reported to range from 67.2% to 98%218, 224-
226. 
 
1.1.8.3 Glutamate Dehydrogenase 
EIA tests are also available to detect the surface-associated enzyme, GDH.  
However, GDH is produced by both toxigenic and non-toxigenic strains, 
therefore it can only confirm the presence/absence of C. difficile, but will not 
give any information on the ability of the bacteria to cause symptomatic 
disease.  The sensitivity and specificity of this diagnostic test has been 
reported to range from 89.1% to 100%, and 82.7% to 98.7%, respectively, 
when compared with CTA227. 
 
1.1.8.4 PCR Amplification 
Commercial PCR amplification/nucleic acid amplification tests (NAAT) are 
available to detect the presence of tcdB.  These tests are highly sensitive for 
the detection of tcdB, with reported sensitivity rates of 92% and specificity 
rates of 94-96% compared with CTA228,218.  One of the limitations of these 
tests is that it can only detect the presence of the tcdB gene, not toxin B, and 
gives no information on tcdA. 
 
1.1.8.5 Algorithm 
Current diagnostic tests exhibit suboptimal sensitivity and specificity values, 
or relevance to symptomatic disease when performed as standalone tests for 
the diagnosis of CDI.  Therefore, the use of multiple step algorithms to 
improve diagnosis of has been investigated.  In the UK, the Department of 
Health recently published new C. difficile testing guidelines, which outline 
the use of a two-test algorithm comprising an initial GDH EIA or 
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NAAT/PCR test to determine whether C. difficile is present, and whether 
further testing is required229.  If a positive GDH/NAAT is obtained then a 
sensitive toxin EIA should be carried out to determine whether or not toxin 
is being produced.  Only GDH/NAAT and EIA positive patients should be 
reported as part of the mandatory reporting scheme. 
Pseudomembranous colitis can be diagnosed using colonoscopy or 
sigmoidoscopy to identify the presence of raised, yellow plaques or 
lesions230. 
 
1.1.9 Treatment 
Once CDI has been diagnosed, the administration of antimicrobial agents or 
other pre-disposing medications should be discontinued where possible and 
alternatives therapies sourced.  First-line treatment for CDI in the UK is oral 
metronidazole (400mg TD for 7-10 days), with vancomycin (125mg QD 
for 7-12 days)231 generally reserved for patients with severe disease.  Early 
reports suggested that these antimicrobial agents have a similar 
effectiveness, although more recent reports provide evidence that 
vancomycin is more effective for severe cases, with rates of cure for severe 
disease for vancomycin and metronidazole 97% and 76% respectively232.  The 
cost of a metronidazole course is less than vancomycin, therefore 
metronidazole is the preferred antimicrobial in the UK for mild to moderate 
disease with vancomycin reserved for more severe cases97,98.  Fidaxomicin, a 
new macrocyclic antimicrobial agent has been approved by the FDA from 
May 2011 in the USA, and June 2012 in the UK for the treatment of CDI.  
Data from two licensing trials show that fidaxomicin can reduce the rate of 
CDI recurrence compared with vancomycin233. 
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Alternative treatments currently available or in development include 
rifaximin234, nitazoxanide235, daptomycin derivative CB_183,315236, 237, toxoid 
A/B vaccine238, 239, monoclonal antibodies240, faecal transplant241 and 
probiotics242.  Efficacy and suitability of these alternative treatment agents 
should be considered before use. 
 
1.1.10 Recurrence of Disease 
One of the most difficult situations facing clinicians in CDI treatment is the 
management of recurrence of infection seen in approximately 5% - 30% of 
CDI patients243-245.  There is evidence to suggest that this proportion of 
patients suffering from disease recurrence is increasing and the emergence 
of the apparently hypervirulent 027 strain may be a contributory factor246, 247.  
Studies highlight that increased age (>65 years), the administration of 
concomitant antimicrobial therapy, poor immune response, gastric acid 
suppression medicine, increased underlying disease severity and increased 
hospitalisation are more likely to predispose recurrent CDI46, 246, 248. 
A treatment response is considered successful when the frequency and/or 
consistency of stool decreases or improves.  Recurrent infection is 
manifested by the increased frequency of stool for at least two consecutive 
days, or other new signs of disease development, and microbiological 
evidence of toxin-producing C. difficile in the stool after successful 
treatment249. 
Recurrence of disease can occur either because of the persistence of the 
original infecting C. difficile strain within the gastrointestinal tract, which 
germinates within the colon when antimicrobial therapy has ceased 
(relapse), or re-infection by a new organism250.  Little is known about the 
persistence of C. difficile in the gut but recurrent bacterial infections have 
been associated with the presence of biofilms251.  Therefore, it is possible that 
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the existence of mucosal biofilms within the gut may harbour and protect a 
population of C. difficile spores, vegetative cells or toxin, leading to a 
recurrence of symptoms.  The onset of initial CDI is associated with the 
disruption of the gut microbiota by antimicrobial agents.  Hence, prolonged 
antimicrobial therapy (including the use of anti-CDI therapy) may continue 
this disruption, providing conditions that allow the subsequent 
re-establishment of C. difficile populations through relapse or re-infection252, 
253. 
The European Society of Clinical Microbiology and Infectious Diseases 
(ESCMID) recommend treatment of a first case of recurrent infection by 
continuing with the initial treatment therapy unless disease has developed 
from mild to severe.  If a second episode of recurrence, or subsequent 
recurrences have occurred then the use of tapered vancomycin dosing where 
the frequency of dosing is gradually decreased and then pulsed is 
recommended where possible249. 
Faecal transplant, or faecal biotherapy, is a novel treatment option available 
for patients with multiple episodes of recurrent disease.  It involves the 
instillation of a faecal emulsion from a healthy donor into the upper 
gastrointestinal tract of the patients via a nasogastric tube, or into the colon 
via a colonoscopy, or distal colon via enema.  A faecal transplant 
reintroduces healthy microbiota into the patient’s gastrointestinal tract 
which can re-establish a population and provide a colonisation resistance to 
C. difficile re-infection.  A systematic review of faecal biotherapy 
in 2011 identified disease resolution of 92% (89% after single treatment; 95% 
after retreatment) amongst 317 patients treated across 27 case series and 
reports241.  Standard protocols for the administration of this therapy are not 
currently in place and randomized controlled trials have not yet been 
reported.  As a result different health care facilities adopt varying protocols 
regarding its route of administration, quantity of donor stool, and other 
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treatment options.  The review highlighted above identifies that variations in 
method procedures may affect resolution rates although other groups have 
reported that faecal transplant is an effective treatment option for recurrent 
CDI regardless of the instillation route254.  A randomized controlled study is 
required to draw conclusions about these variations. 
This therapy is generally considered as a last resort option and is not widely 
adopted in health-care facilities, although the reported high cure rates are 
resulting in increased interest. 
 
1.1.11 Current CDI Models 
1.1.11.1 In vivo 
CDI has been studied in a number of animal species including hamsters, 
mice, guinea pigs, rabbits and rats255-258, with the Golden Syrian hamster 
model most widely used to investigate host-pathogen interactions68.  
Identification of C. difficile as the causative agent of CDI was determined 
within a hamster model5 and has proven to be a reliable model of the 
pathogenesis of CDI.  Hamsters pre-treated with clindamycin, and 
challenged with C. difficile spores manifest fulminant disease, correlating 
with clinical observations in humans259, 260, although the full spectrum of 
disease in humans is not represented within the hamster model. 
Mouse models, including conventional and gnotobiotic models, have also 
been used extensively to study CDI261-263.  Normal mice are not as readily 
susceptible to disease of hamsters, although Chen et al261  have developed a 
‘conventional’ mouse model of CDI that appears to resemble disease in 
humans, and disease severity correlates with challenge dose. Germ-free 
murine models are widely used as they reliably develop C. difficile 
colonisation and intestinal pathology264.  Lawley et al265 demonstrated that 
virulent C. difficile strains can asymptomatically colonise immunocompetent 
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mice and establish a long-term carrier state, with antibiotic treatment 
triggering a supershedder state, and later used the same mouse model to 
evaluate the role of microbiota dysbiosis and restoration in CDI266. 
 
1.1.11.2 In vitro 
Early studies of C. difficile pathogenesis involved simple batch/continuous 
culture experimental systems or in vivo hamster models; both of which may 
be considered poorly reflective of the human colonic environment105, 267, 268.  
Ethical and practical issues have led to the development of more complex in 
vitro systems.  Macfarlane et al developed and validated a triple stage 
chemostat model of the human gut, designed to reflect the physicochemical 
and microbiological environment of the colon from proximal to distal, and 
validated it against the intestinal contents from sudden death victims269.  
Baines et al have utilised the same triple stage chemostat gut model as an in 
vitro system in which to study the effects of antimicrobial administration on 
human gut microbiota and C. difficile270.  This has proven to be a reliable and 
reproducible model in which to study the response of C. difficile to 
antimicrobial administration.  Thus, antimicrobials with a recognised 
propensity to induce CDI in vivo facilitated C. difficile spore germination, 
proliferation and high-level cytotoxin production in the gut model, e.g. 
clindamycin and moxifloxacin271, 272.  Conversely, the absence of 
antimicrobial administration, and agents considered low-risk for CDI 
induction, did not induce simulated CDI273.  The gut model has proven 
useful in the evaluation of the propensity of existing and novel 
antimicrobials to induce and treat CDI.  Gut model studies have also 
indicated the importance of gut antimicrobial concentrations in the 
development of CDI, and allowed the comparative evaluation of epidemic 
C. difficile strains.  While this current system has proven a successful in vitro 
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model of CDI, it is unable to reflect accurately the extensive and complex 
bacterial communities that colonise intestinal mucosal surfaces in biofilm 
structures.  There is increasing interest in the development of novel 
therapies for CDI, noting the paucity of current options, and their associated 
high recurrence/relapse rates244.  There is therefore a fundamental need to 
understand the interplay between antimicrobial agents and C. difficile at the 
gut mucosal surface, since this is where toxins bind to receptors. 
 
1.2 Gastrointestinal Tract 
1.2.1 Gut Microbiota 
The human colon is a highly complex and diverse ecosystem consisting of 
over 500 bacterial species with a total concentration of 
approximately 1012 cfu/g of faeces274.  The digestive tract of the human foetus 
is sterile.  After natural birth the tract is colonised by a variety of 
microorganisms originating from the birth canal and surrounding 
environment275, 276.  During childhood the commensal microbiota is 
established and remains relatively stable throughout life277. 
It is estimated that the human microbiota is distributed over 1,000 bacterial 
species278, the composition of which is highly variable amongst individuals.  
Firmicutes and Bacteriodetes279  are most often reported as predominant 
families, with Actinobacteria280 and Proteobacteria281 also representing high 
populations within gut microbiota communities. 
 
Before the use of metagenomic techniques, much of our existing knowledge 
of the intestinal microbiota relied on culturing planktonic faecal bacteria 
onto selective and non-selective agars.  Whilst these methods provided 
preliminary information on these bacterial communities they were unable to 
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provide information on the extent and complexity of the intestinal 
ecosystem.  Faecal culture studies provide evidence that anaerobic bacteria 
outnumber facultative anaerobic bacteria by a factor of 100-1000, with 
bacteroides, bifidobacteria, eubacteria and clostridia the predominant genera 
in humans282.  However, it is believed that only a minority of the intestinal 
microbiota species can be consistently cultured283-285. 
The initial introduction of culture-independent techniques was largely based 
on targeted sequencing of 5S and 16S ribosomal RNA genes.  Reports 
suggested that only 20-24% of molecular species recovered from faecal 
samples correspond to organisms described in culture-dependant sampling, 
the remaining represent previously unknown species279,283,280. 
The Human Microbiome Project and the European Metagenomics of the 
Human Intestinal Tract were initiated to provide more in-depth information 
on the bacterial populations that colonise human hosts, and address the 
relationship between health and disease.  These studies utilise molecular 
methods in order to gain greater insight into the gut microbiota. 
The introduction of next generation sequencing technologies (including 
pyrosequencing Roche-454286, 287 and Illumina278, 288, 289) allows the timely and 
relatively cheap generation of large volumes of sequence data necessary for 
the comprehensive characterisation of microbiota population dynamics290,291.  
Sequence determination of microbial communities can be approached using 
whole genome sequencing or targeted 16S rRNA sequencing.  Whole 
genome shotgun sequence determination provides a minimally biased view 
of microbial communities which is absent from 16S rRNA sequencing 
methods.  The depth of the reference library governs the identification of 
rare bacterial species within complex microbial communities. 
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Bacterial populations within the gastrointestinal tract exist in two forms; 
planktonic free-floating communities within the lumen, and sessile bacteria 
within mucosal-associated biofilm communities292.  Many intestinal 
microbiota studies are derived from faecal samples and only provide 
information on planktonic populations, therefore may not accurately 
represent colonic microbiota communities.  Sessile bacterial populations 
have been visualised on the mucosal surface and in the mucus layer of the 
colon293.  These communities are difficult to identify and enumerate due to 
the physical inaccessibility of this region.  Bacteroides and fusobacteria 
predominate on the mucosal layer, with other groups including eubacteria, 
clostridia and anaerobic Gram-positive cocci also present293, 294.  Another 
study identified the predominant bacterial groups from mucosal biopsies as 
Bacteroides, and the lactic acid bacteria Leuconostoc and Weisella, with 
microbial communities displaying some homogeneity281.  The degree to 
which composition and function of faecal and mucosal microbiota differ 
remains unclear, although some reports suggest a distinct difference in 
microbial composition at the two sites292. 
 
1.2.2 The Role of Gut Microbiota 
Diversity of bacterial species found in the human colon is mediated by the 
availability of nutrients such as indigestible starches, the ability to compete 
for limited resources and adhesion sites on food particles and the mucosal 
layer, with unsuccessful species being rapidly eliminated from the gut. 
Despite the presence of complex, antigenically and metabolically distinct 
microbial communities within the gastrointestinal tract, a largely mutualistic 
relationship exists between the host and indigenous gut microbiota.  
Evidence obtained through the use of germ-free animals suggested that the 
intestinal microbiota has important metabolic, trophic and protective 
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functions295.  Non-digestible dietary products, particularly carbohydrates, 
and endogenous mucus are fermented by colonic microbiota to provide 
energy and nutrients for bacterial growth128.  Bacteria possess enzymes that 
are lacking in human hosts, which are required for degradation of specific 
proteins, peptides and carbohydrates into short-chain fatty acids (SCFAs).  
These substances in turn provide the host with energy and nutritional 
resources, and increase its ability to absorb nutrients such as calcium, 
magnesium and iron.  SCFAs also increase the growth of intestinal epithelial 
cells and control their proliferation and differentiation129.  The benefits that 
these intestinal microorganisms provide the host with are largely greater 
than the possible pathogenic threat, and indeed the host and microorganism 
establish a long-term cooperative and stable relationship.  However, 
imbalance in bacterial populations, for instance through antimicrobial 
administration, may result in detrimental outcomes for the host. 
 
1.2.3 Mucous Membrane 
Mucous membranes line bodily cavities, including the gastrointestinal tract.  
At least four microhabitats of the gastrointestinal tract have been described: 
the intestinal lumen, the unstirred mucus layer (gel that covers the 
epithelium), the deep mucus layer, and the surface of the intestinal epithelial 
cells. 
In order for bacteria and host to maintain a symbiotic relationship the 
penetration of bacteria across the epithelial barrier is limited, minimising 
activation of the host immune system.  The mucus layer protects the 
underlying epithelium from the external environment, including pathogens.  
Abnormalities in the mucosal composition have been implicated in diseases 
such as ulcerative colitis296,297. 
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1.2.3.1 Mucin 
Goblet cells within the epithelium produce a mucus gel composed primarily 
of mucin glycoproteins, which are synthesised and secreted from the apical 
surface of goblet cells.  Mucins can be classified into acidic or neutral 
subgroups298.  The former predominate in the colonic epithelium and the 
latter in the gastric mucosa299.  The physiological relevance of mucin 
subgroups is not well understood, although it is speculated that acidic 
mucins protect against bacterial translocation300, 301. 
Intestinal mucus is a viscous gel with a high negative charge and a large 
hydration capacity, and is composed primarily of high molecular weight 
glycoproteins302, 303.  These glycoproteins are composed of a peptide core, rich 
in serine and threonine residues, which are protected from proteases by 
oligosaccharides linked via O- or N-glycosidic bonds304, 305.  Carbohydrate 
monosaccharides such as frucose, galactose, N-acetylglucosamine, 
N-acetylgalactosamine and sialic acid account for up to 80% of the dry 
weight of mucins306, 307.  Mucins act as the main structural component of the 
mucus layer, giving rise to its polymeric, viscoelastic and protective 
properties.  The attachment of sulphate and O-acetyl substituted sialic acids 
to terminal mucin oligosaccharides confers resistance to digestion by 
glycosidases308.  Intestinal mucins undergo O-linked glycosylation where the 
attachment of a group of oligosaccharides occurs directly to proteins 
through the hydroxyl group of threonine or serine.  In order for bacteria to 
degrade these carbohydrate structures they must synthesise deglycosylating 
enzymes309.  Miller et al suggested that a sub-population of faecal bacteria 
produce extracellular glycosidases with high specificities for certain 
oligosaccharides of colonic mucins310.  It is the sequential breakdown of these 
mucins by a population of diverse bacterial species which leads to the 
destruction of the mucus layer309. 
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1.2.3.2 Mucus Layer 
The mucus layer is composed of an outer layer which harbours symbiotic 
bacteria and a protected inner layer which is largely resistant to bacterial 
penetration311-313.  A study of healthy ileal and colonic biopsy samples 
identified bacterial populations predominantly associated with the outer 
mucus layer, with no bacteria detected in association with epithelial cells313.  
The mucus gel is constantly exposed to acids and irritants and is often 
sloughed off due to peristaltic movements of the gastrointestinal tract.  In 
the stomach, the mucus layer can reach a thickness of 450 μm, gradually 
decreasing through the intestine to 285 μm in the rectum306, 312.  Under 
normal conditions goblet cells continuously synthesise and secrete mucins to 
replenish the mucus layer and to maintain its thickness.  When goblet cells 
are exposed to potent secretagogues (substances which increase the rate of 
mucin production) 314, 315, such as bacterial toxin316, mucin is released in an 
accelerated fashion. 
 
The ability of the intestinal gut microbiota to metabolise mucus offers 
ecological advantages including the provision of a source of carbohydrates, 
peptides, vitamins and minerals317.  Bacteria capable of colonising mucus 
may avoid expulsion from the intestine via peristalsis. 
Both commensal and pathogenic bacteria may derive significant benefits 
from their ability to chemically regulate mucin synthesis or secretion from 
host goblet cells.  However, some enteric pathogenic bacteria have the ability 
to degrade the inner and outer mucus layer, providing access to the 
underlying epithelia cells and enabling attachment to receptors, thus causing 
disease.  Sub-populations of faecal microbiota have been shown to degrade 
the oligosaccharide side chains of hog gastric mucin, which structurally 
resembles human epithelial mucin310.  Once bacteria have gained entry to the 
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epithelial cells, many intestinal pathogens actively down-regulate 
microbicidal mechanisms of macrophages, allowing survival and replication 
in host tissues318. 
 
1.2.3.3 Mucosal Epithelium 
The intestinal epithelium comprises simple columnar, immune and goblet 
cells.  In order for pathogens to cause disease they must traverse the inner 
mucus layer to gain entry to the underlying epithelial cells and evade or 
overcome the immune response of the host (i.e. inhibiting chemotaxis; 
negating opsonisation; avoiding phagocytosis).  Epithelial cells such as 
Paneth cells secrete antimicrobial peptides which contribute to the 
destruction of bacteria that have gained entry to the inner layer319.  If bacteria 
are detected within close proximity to the epithelia, B lymphocytes induce 
the production and secretion of bacteria-specific IgA which reduce the 
number of epithelial-adherent bacteria 320, 321.  Bacteria that cross the 
epithelial barriers often succumb to rapid phagocytosis and elimination by 
macrophages322. 
 
1.3 Biofilms 
1.3.1 Discovery of Biofilms 
Biofilms were first observed by Antonie Van Leeuwenhoek in the 17th 
century when he used an early microscope to view ‘animalcules’ in the 
dental plaque on teeth.  In the 1940s, researchers began to publish reports on 
the adherence of marine bacteria to surfaces323.  It is now the general 
consensus amongst microbiologists that, in their natural state, most bacteria 
exist within biofilms and possess unique characteristics, which distinguish 
them from their planktonic counterparts. 
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1.3.2 Ubiquity of Biofilms 
A biofilm is traditionally defined as a community of microbial cells 
irreversibly bound to a surface and embedded in a self-produced 
exopolysaccharide matrix. 
Biofilms are ubiquitous in nature and almost any surface may facilitate 
biofilm formation, including contact lenses, ship hulls, teeth, rocks in 
streams, indwelling medical devices and industrial water systems324, 325,326-328.  
Whilst biofilms are associated with beneficial functions such as nutrient 
recycling, bioremediation and colonisation resistance, adverse effects such as 
infection, recalcitrance to antimicrobial mechanisms and contamination have 
led to biofilms becoming a topic of focus for researchers. 
It is becoming increasingly clear that biofilms elicit a major impact on 
healthcare, owing to their formation on medical devices and role in 
persistent infections.  It has been estimated that biofilms are associated 
within the US 65% of nosocomial infections with treatment of such infections 
costing over $1 billion annually329, 330.  Within industry, biofilms prove 
problematic, leading to corrosion of pipes, reduced heat transfer in cooling 
water systems and biofouling of ship hulls331-333. 
 
1.3.3 Biofilm Development 
Biofilm formation is a highly complex and diverse process, which has been 
studied extensively.  Although every biofilm forms under a unique set of 
conditions, the biofilm life cycle is typically divided into four steps; initial 
reversible adhesion, irreversible adhesion, maturation and dispersal. 
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1.3.3.1 Initial Reversible Adherence 
The solid-liquid interface between a surface and an aqueous medium 
provides an ideal environment for the attachment and growth of bacteria.  In 
order for these bacteria to translocate to a conditioned surface they do so in a 
directed (i.e. via chemotaxis and motility) or random fashion (i.e. propelled 
to the surface by the natural movement of the liquid in which they are 
suspended).  Once the organism reaches close proximity to a surface, factors 
such as the level of attractive and repulsive forces, temperature, substratum 
composition, environmental conditioning factors and hydrodynamics of the 
liquid determine whether or not attachment will commence. 
 
1.3.3.1.1 Substratum and Fluid Properties 
The composition of a surface material determines the extent, rate and type of 
species colonising the surface.  Biotic surfaces may contain specific ligands 
and receptors which aid the adhesion of specific organisms.  Abiotic surfaces 
lack these specific adhesion sites and colonisation relies on non-specific 
factors, such as substratum material hydrophobicity and roughness, or 
conditioning of the surface with an organic film334. 
Increased roughness of an abiotic material provides an increased surface 
area and reduces the shear forces surrounding the area, encouraging the 
attachment of microbes to the surface.  There is also evidence to suggest that 
hydrophobic, non-polar surfaces facilitate greater adherence of microbial 
organisms335-337. 
A substratum material surface submerged within a liquid environment 
becomes colonised by organic compounds such as polysaccharides or 
glycoproteins.  Within an in vivo environment a surface may be conditioned 
by tears, saliva, and other secretions, often within minutes338 339.  This 
conditioning film develops on a surface over time, and may mask the 
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properties of the surface underneath, enhancing the attachment of a greater 
diversity of bacterial species.  Temperature, pH, nutrient availability and 
ionic strength of the aqueous medium in which the substratum material is 
submerged may influence the extent of colonisation340-343. 
Biofilm formation is not limited to association with a solid surface.  Certain 
organism form pellicles at the liquid-air interface344, 345, allowing sessile 
bacteria access to aqueous and gaseous phases. 
 
1.3.3.1.2 Cell Properties 
Once bacterial cells come into contact with a surface they must overcome 
repulsive forces to adhere to that surface.  Properties of the bacterial cell, 
such as cell surface hydrophobicity and charge, presence of fimbriae, pili, 
flagella and adhesins all influence the rate of colonisation342, 346-348.  Most 
bacteria are negatively charged but still contain hydrophobic surface 
components.  Fimbriae contribute to this hydrophobicity and play a role in 
overcoming the initial electrostatic repulsion that exists between cell and 
substratum material349.  Similarly, flagella help bacteria overcome 
electrostatic repulsive forces, allowing translocation of bacteria to the 
substratum material.  Pratt and Kolter demonstrated that E. coli require 
flagellum-mediated motility to initiate initial attachment for biofilm 
development347.  Whilst O’Toole and Kolter350 utilised Pseudomonas aeruginosa 
mutants to demonstrate that flagella mutant strains exhibit diminished 
adherence to plastic surfaces compared to the wild-type.  Furthermore, 
P. aeruginosa strains displaying type IV pili mutants were able to form a 
monolayer of attached cells but subsequent formation of microcolonies was 
retarded350. 
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1.3.3.2 Irreversible Adhesion 
Once initial interaction between a bacterial cell and surface has been 
initiated, if not immediately separated, bacteria can anchor themselves to the 
surface using strong cellular surface-adhesins and host- or tissue- specific 
interactions.  Once committed to adhesion, certain species may upregulate 
specific adhesion genes and/or begin to synthesise extra polymeric substance 
(EPS) material which contributes to the irreversible attachment and 
transition to the sessile mode of growth of these organisms.  This theory is 
supported by the observation that P. aeruginosa organisms that have recently 
attached to a surface upregulate algC , which is required for EPS alginate 
synthesis351. 
Once this second stage of attachment is complete, adherent bacteria can only 
be removed from the surface by physical or chemical intervention.  These 
first colonists facilitate the arrival of other bacterial species by providing 
more diverse adhesion sites and beginning construction of the extracellular 
matrix that holds the biofilm together. 
 
1.3.3.3 Co-aggregation 
Many bacterial species possess multiple adhesion sites that facilitate 
adhesion to a substratum surface and also inter-bacterial adhesin-receptor 
interactions.  The adherence of an initial coloniser to another genetically 
distinct species is known as co-aggregation, and allows increased diversity 
amongst multi-species sessile communities. 
There are an abundance of studies focusing on co-aggregation in oral 
microbiology, with reports of co-aggregation of over 1000 oral bacteria 
strains352.  The utilisation of FISH technology identified that initial 
colonisation of oral biofilms in vivo involved the co-aggregation of 
Streptococcus spp. and Actinomyces spp., and that as the biofilms matured 
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Streptococcus populations were replaced by an increase in Fusobacterium 
nucleatum populations353, 354. 
Donelli et al have recently outlined evidence that mono- and dual- species 
biofilms exist in vitro between selected intestinal strains.  More specifically 
Finegoldia magna and Clostridium difficile, Fusobacterium necrophorum and 
Veillonella spp., and Finegoldia magna and Bacteroides fragilis pairs appeared to 
enhance biofilm growth when grown in mixed cultures as opposed to single 
species cultures355.  Ledder et al356 have also demonstrated that C. perfringens 
appears to co-aggregate with B. adolescentis and B. fragilis but weakly 
co-aggregates with other enteric and oral bacterial species. 
 
1.3.3.4 Maturation 
Once bacteria have successfully completed the second, irreversible stage of 
attachment, proliferation and maturation of the biofilm can commence. 
During maturation, density and complexity of the biofilm increases as 
existing bacteria proliferate, and new bacterial species are recruited.  The 
biofilm begins to change shape and size, and water channels form, providing 
nutrients to cells deep within the structure357.  Certain unique characteristics 
of a biofilm such as antibiotic resistance are often conferred once the biofilm 
has developed in maturity358. 
The maturation and lifecycle of the biofilm is dependent on the availability 
of nutrients in the immediate vicinity of the biofilm, the transportation of 
nutrients into all areas of the biofilm, and the removal of any waste or toxic 
products into the surrounding environment359.  Other factors such as 
hydrodynamic forces, pH, availability of gaseous substances, carbon sources 
and osmolarity all influence the maturation of a biofilm.  Once a biofilm has 
formed on a surface in vivo, it typically remains relatively stable and is often 
beneficial to the host. 
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There is evidence to suggest that biofilm maturation is dependent on 
quorum sensing molecules known as acyl-homoserine lactones (AHL)360.  
P. aeruginosa strains with mutated genes encoding an enzyme for the 
synthesis of an acyl-AHL undergo the early stages of biofilm formation, but 
maturation, and the typical architecture of the biofilm is absent. 
 
1.3.3.5 Dispersal 
Once a biofilm has reached a defined biomass the outermost layer of the 
biofilm begins to detach from the main structure, generating planktonic 
organisms.  This can be a passive or active process and is caused by factors 
such as increased fluid shear, response to changes in nutrient levels, 
enzymatic degradation, quorum sensing, or by the release of EPS or 
surface-binding proteins361-364.  In some species detachment seems to be a 
strategy by which bacteria actively colonise new niches.  Within a clinical 
setting this has implications in the dissemination of infection. 
The enzymatic degradation of the biofilm matrix is a mechanism of biofilm 
dispersal where bacteria produce extracellular enzymes that degrade specific 
targets of the biofilm matrix365-367.  Dispersin B is a matrix-degrading 
glycosidase enzyme produced by Aggregatibacter  actinomycetemcomitans.  
Mutant bacterial strains deficient in dispersin B production were able to 
form mature biofilms but unable to release and disperse cells368. 
 
There are numerous mechanisms for biofilm dispersal: swarming/seeding 
dispersal369; clumping dispersal and surface dispersal.  Swarming dispersal 
involves the release of individual cells (often motile) in to the bulk fluid or 
surrounding environment from within hollow cavities of the biofilm 
structure370, 371.  Clumping dispersal occurs when aggregates of cells are shed 
as clumps or emboli361.  These aggregates are still surrounded by EPS and 
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constitute a form which is physiologically similar to sessile bacteria, 
potentially retaining their protective properties372.  Cell aggregates released 
in this manner often contain high cell densities, in some cases exceeding the 
infective dose for pathogenic bacteria361.  The active movement of 
self-propelled single cells across a surface away from a biofilm through 
swimming, sliding or twitching motility is known as surface dispersal373.  
These individual cells no longer possess the protected biofilm phenotypes, 
although surface motility of whole biofilm structures has been identified, 
causing a major problem in medical devices such as endotracheal tubes, 
which may lead to dissemination into the lungs374. 
 
1.3.4 Biofilm Structure 
1.3.4.1 Biofilm Architecture 
Biofilms form under a unique set of conditions which facilitates the 
formation of unique, complex structures, although some structural 
components can be considered universal375.  Most mature biofilms comprise 
sessile bacteria within matrix-enclosed, heterogeneous microcolonies, which 
form a three-dimensional structure interspersed with open water channels.  
The architecture of the biofilm alters over time and space in response to 
external and internal processes and conditions. 
Developments in digital imaging techniques allow researchers to study 
biofilm structure in greater definition.  Confocal Scanning Laser Microscopy 
(CSLM) has proven particularly suitable for the study of microbial biofilms 
as it allows non-destructive imaging of these hydrated structures with depth 
selectivity in situ.  Coupling the use of this digital imaging technique with 
fluorescent probes allows the visualisation of specific or non-specific 
structures within the biofilm376. 
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The structural visualisation of P. aeruginosa microcolonies within biofilms 
demonstrates a mushroom like structure, with the majority of cells localised 
in the ‘crown’ of the mushroom shape with fewer present in the ‘stalk’.  The 
former display motility and the latter non-motility377. 
 
1.3.4.2 Extracellular Matrix 
Once bacteria have irreversibly attached to a surface they produce extra 
cellular material which is often referred to as the biofilm matrix. 
This matrix accounts for over 90% of the dry mass of a biofilm, with 
microorganisms accounting for only 10%378.  The matrix itself is highly 
hydrated with reports suggesting that 97% of its structure comprises 
water379.  The remaining components, EPS, are hydrated biopolymers 
including polysaccharides, nucleic acids and lipids, which are mostly 
secreted by cells within the biofilm380-382.  Biofilm matrix also retains the 
components of lysed cells, including DNA, which may represent a reservoir 
of genes for horizontal gene transfer383.  The presence of uronic acids or 
ketal-linked pyruvates gives the biofilm anionic properties, allowing 
cross-linking of polymer strands to provide greater integrity384.  The matrix 
can also protect organisms against desiccation, host immune responses, and 
some antimicrobial agents. 
 
The biopolymers within the matrix are responsible for the macroscopic 
appearance of biofilms.  Although the ability to produce an extracellular 
matrix appears to be a common feature of some biofilm bacteria, the 
structure of biofilms produced is remarkably diverse.  Matrix structures 
form the scaffold for the three-dimensional architecture of the biofilm and 
are responsible for cohesion.  EPS immobilises biofilm cells, keeping them in 
close proximity, allowing for cell-cell communication and the formation of 
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synergistic micro-consortia.  Bacteria deficient in EPS synthesis produce 
biofilms with altered morphology.  For example, alginate is a well 
characterised EPS expressed by mucoid strains of P. aeruginosa382.  Whilst 
alginate is not essential for the formation of a biofilm, overexpression 
produces a structurally mature biofilm, with similar reports pertaining to the 
role of colonic acid in E. coli biofilms in vitro385, 386.  Mutations in Vibrio 
cholera387 and Staphylococcus epidermidis388, which elicit defective EPS 
production, render these strains defective in the initial stages of biofilm 
formation. 
 
1.3.5 Biofilm Properties 
1.3.5.1 Cell-Cell Communication 
Quorum sensing is the regulation of gene expression in response to 
fluctuations in cell-population density, occurring both within and between 
bacterial species.  Quorum sensing bacteria produce small chemical 
signalling molecules known as autoinducers389.  These autoinducers increase 
in concentration as a function of cell density, with an increase in bacterial 
density resulting in AHL accumulation until a threshold concentration is 
reached, thereby inducing altered gene expression390. 
Gram-positive and Gram-negative bacteria use quorum sensing 
communication circuits to regulate a diverse array of physiological activities, 
including surface attachment, extracellular polymer production, virulence 
factor production, conjugation, antibiotic susceptibility, motility, sporulation 
and biofilm formation391-394.  It has been demonstrated that many species, 
including P. aeruginosa activate EPS production at high cell densities, and 
organisms with mutated AHL genes produce densely packed cells which are 
only a few layers thick360, rather than mature biofilm.  Other species, such as 
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Vibrio cholerae populations terminate EPS production once cell densities 
levels reach a threshold level395. 
 
1.3.5.2 Antimicrobial Resistance 
Biofilm infections pose a major problem to healthcare facilities worldwide 
and cause chronic infections due, in part, to their recalcitrance to 
antimicrobial therapy.  Furthermore, biofilm infections are often able to 
evade host defences, even in individuals with competent immune systems396-
398, although tissues adjacent to biofilms may undergo collateral damage by 
immune complexes and invading neutrophils. 
In vitro biofilm models have shown the survival of sessile bacteria at 
antimicrobial concentrations up to 100 - 1000 times the MIC of planktonic 
cultures399-401.  In vivo antimicrobial agents suppress the initial symptoms of 
infection, but once therapy has ceased symptoms can return, which can lead 
chronic infections and often surgical intervention is required to eradicate the 
infection402-405. 
Several theories exist to explain the mechanisms which confer resistance of 
biofilm bacteria to antimicrobial agents exist, and these are summarised 
below. 
 
1.3.5.2.1 Barrier Effect 
The highly hydrated biofilm matrix has many functions and it has been 
suggested that one of its roles is to protect bacterial cells within the biofilm 
from the action of antimicrobial agents.  Initially it was postulated that this 
matrix structure may prevent the penetration of antimicrobial agents to the 
bacterial cells within.  However, mathematical models have since 
demonstrated that the diffusion of molecules the size of antibiotics through 
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the biofilm matrix should not be retarded.  It has since been hypothesised 
that antibiotic deactivation, binding or reaction within the biofilm matrix 
may occur faster than diffusion of the molecule through the matrix. 
There have been many conflicting reports pertaining to the biofilm barrier 
effect, with Hatch and Schiller406 demonstrating that a 2% suspension of 
alginate isolated from P. aeruginosa inhibited diffusion of gentamicin and 
tobramycin, and that this effect was reversed when alginate lyase was used. 
Other groups have demonstrated that, because of their positive charge, 
aminoglycosides bind to negatively charged polymers within the biofilm 
matrix, thus retarding penetration407, 408. 
Furthermore, it was observed that ampicillin demonstrated reduced 
penetration and antimicrobial activity against wild-type Klebsiella pneumonia 
biofilms, but β-lactamase-deficient Klebsiella pneumoniae biofilms allowed the 
penetration of ampicillin but remained resistant to this agent409. 
Whilst there is increasing evidence to suggest that the presence of the matrix 
alone does not prevent the penetration of antimicrobial agents, the 
penetration of larger immune response objects may well be retarded by the 
matrix of some biofilm structures410. 
 
1.3.5.2.2 Slow Growth Rate 
It is well established amongst microbiologists that non-dividing bacteria are 
less susceptible to many antimicrobial agents. Biofilm communities 
experience nutrient limitation, therefore a subpopulation of sessile bacteria 
often referred to as ‘persisters’, exist in a slow-growing/dormant state411.  
These bacterial cells exhibit a distinct phenotype which is associated with the 
chronic nature of biofilm infections and their inherent resistance to 
antimicrobial chemotherapy.  Once antimicrobial therapy has ceased it is 
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postulated that persister cells within the biofilm repopulate the site and lead 
to disease recurrence. 
Research into this particular area is limited because the measurement of 
divisional activity is difficult.  Certain antibiotics are able to exert an effect 
on non-growing cells and these antibiotics have demonstrated an enhanced 
activity against sessile bacteria compared with those antibiotics whose 
mechanism of action require an actively growing cell for activity412-414. 
The use of acridine orange stain identified that inner areas of biofilm 
structures display low relative RNA content, indicating slow growing 
bacterial growth, whilst the outer edge of the biofilm display relative high 
RNA content, indicating high bacterial growth415.  Furthermore, there is 
evidence to suggest that oxygen levels and potentially nutrients are depleted 
in the centre of microcolonies411. 
 
1.3.5.2.3 Induction of Biofilm Phenotype 
There is an abundance of data detailing the physiological diversity of sessile 
bacteria from their planktonic counterparts416-418.  Sessile bacteria display 
unique gene expression patterns some of which are not observed in 
planktonic bacteria371, 382, 419. 
The increasing availability of complete genome sequences coupled with 
microarray technologies allows researchers to compare the genomic 
expression of biofilm and planktonic organisms.  Data from several reports 
revealed genomic up- or down-regulation is apparent in sessile compared to 
planktonic organisms, although no common expression patterns were 
identified.  Stanley et al showed that in B. subtilis, 519 genes were 
differentially expressed during the time-course of biofilm formation, with 
more than 55% expressed at only one of three time points investigated, 
indicating temporal control of gene expression420.  DNA microarray analysis 
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of P. aeruginosa identified 1% of genes with altered expression in the biofilm 
structures compared to planktonic cells421.  These were assigned as proteins 
encoding motility, adherence, translation, metabolism, transport and 
regulation functions.  Temperate ‘phage genes were the most highly 
activated421. 
 
1.3.5.2.4 Heterogeneity 
The biofilm is a diverse and heterogenetic structure, with distinct 
microcolonies with separate nutrient availabilities, signalling systems and 
waste products.  Therefore bacteria within biofilms exist within distinct 
environments and thus may express different phenotypes.  This increases 
the chances of a subpopulation of bacteria evading the mechanism of 
antimicrobial action. 
Studies utilising a fluorescent probe specific for respiratory activity have 
shown that after challenge with a biocide, the outer most edge of a biofilm 
incurred the greatest loss of respiratory activity whilst the inner portion of 
the biofilm maintained the greatest respiratory activity422. 
 
1.3.5.2.5 General Stress Response 
More recently is has been postulated that the slow growth rate of cells 
within a biofilm may be a consequence of a general stress response where 
cells undergo physiological changes in response to environmental stresses 
such as pH, temperature and chemical agents423.  The master regulator of this 
stress response in E. coli is the alternate sigma factor, RpoS.  RpoS is typically 
expressed by cells under conditions of nutrient deprivation or stress, or as 
cells enter the stationary phase of growth.  Studies have indicated that RpoS 
may also be expressed at high cell densities424,425.  King et al have 
demonstrated that certain E. coli strains with attenuated RpoS levels display 
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lower levels of resistance to external stress426.  Furthermore, environmental 
E. coli strains with functioning RpoS genes possessed a greater capability for 
long-term survival than those with RpoS disrupting mutations427. 
 
1.3.6 Biofilms in Medicine 
Biofilms have been implicated in numerous chronic infections such as 
urinary tract infections, middle ear infections, cystic fibrosis and dental 
caries, as well an association with indwelling medical devices327, 428-430.  Some 
of these infections are exacerbated by their recalcitrance to antimicrobial 
therapy. 
A biofilm-associated feature which may confer disease persistence is the 
ability of a biofilm to shed individual cells or slough off sections of its 
structure into surrounding areas.  This may cause recurrent acute disease 
and allow reseeding of distinct biofilm structures at a different site.  
Identification of a biofilm-associated infection is important to help clinicians 
manage treatment options.  However, biofilm infections are often difficult to 
identify.  Parsek and Singh431 have composed a four point criterion to help 
define a biofilm-associated infection and these are: the pathogenic bacteria 
are surface-associated; examination reveals bacteria in clumps and encased 
in a matrix material; the infection is localised; and it is resistant to relevant 
antibiotics. 
The gastrointestinal tract harbours a diverse and complex microbial 
community which provides protection from colonisation by numerous 
opportunistic pathogens.  The characterisation of the biofilm forming 
properties of these species remains largely unexplored due to the difficulties 
in accessing the colon of healthy adults.  However, the adhesive and biofilm 
forming properties of an enteroaggregative E. coli strain within the 
gastrointestinal tract have been well studied432, 433.  Due to the abundance of 
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evidence regarding the role of biofilms in chronic infections in other parts of 
the body, and additional evidence pertaining to the existence of pathogenic 
bacteria within mucosal biofilm structures in the gastrointestinal tract, it is 
postulated that other pathogenic bacteria such as C. difficile could cause 
infection when associated with gastrointestinal biofilms. 
 
1.3.7 Biofilm Models 
1.3.7.1 Model Organisms for Biofilm Study 
Biofilm formation and behaviour of P. aeruginosa has been extensively 
studied, and much of our current knowledge on the biofilm mode of growth 
is based on work using this organism.  P. aeruginosa is a common causative 
agent of chronic lung infection in cystic fibrosis patients, and which is widely 
regarded as a biofilm-based infection430.  Cystic fibrosis patients are 
commonly colonised by both the mucoid and non-mucoid P. aeruginosa 
phenotypes, the former of which is recognised as causing morbidity, with 
the infection persisting despite prolonged and aggressive antimicrobial 
therapy. 
The biofilm-forming properties of B. subtilis have also been well 
documented, and since this Gram-positive, spore forming organism shares 
common properties inherent to Clostridium species, it is often used as a 
model organism for clostridial investigations.  Observations of the behaviour 
of B. subtilis may be extrapolated to gain insights into the biofilm mode of 
growth of C. difficile, which remains largely uncharacterised. 
Spo0A is a master regulator which controls cellular function.  As described 
previously, this regulator controls sporulation in many Gram-positive bacilli 
including B. subtilis and C. difficile.  Differential phosphorylation of Spo0A in 
response to environmental conditions such as nutrient limitation can directly 
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or indirectly regulate the transcription of genes involved in matrix 
production, cannibalism and motility as well as sporulation434-436. 
Biofilms are composed of heterogeneous bacterial populations and gene 
expression is spatio-temporally regulated.  Cell types which exist within 
biofilms can be classified as motile, matrix-producing or sporulating.  Within 
B. subtilis, high level phosphorylation of Spo0A (Spo0A-P) induces the 
irreversible induction of the sporulation cascade, whilst low levels of 
Spo0A-P induce the expression of a regulator and its agonist SinR/SinI, 
thereby regulating genes involved in the production of extracellular matrix 
and sporulation.  Whilst less well understood, there is also evidence to 
suggest that Spo0A is involved in the repression of a flagellin motility gene 
(hag)434 and cannibalism435. 
Vlamakis et al434 demonstrated that B. subtilis gene expression is dynamic 
throughout biofilm development.  They highlighted that during early 
biofilm formation (12 hours) the majority of cells express the motility gene 
hag promoter but this declined as the biofilm matured.  After 24 hours, 
biofilm expressed peak levels of matrix-production gene yqxM promoter, 
whilst expression of the sporulation gene sspB promoter commenced 
after 48 hours.  Furthermore, motile cells began to localise on the edge and 
base of biofilm structures as time progressed, whilst matrix-producing cells 
remained distributed throughout the biofilm, and sporulated cells were 
localised at the upper aerial structures.  These results indicate that 
sporulation, motility and extracellular matrix production are all related and 
are necessary to construct an architecturally mature biofilm. 
 
1.3.7.2 In vitro Models 
The use of in vitro models allows researchers to manipulate and control 
certain factors and/or conditions, thus providing a valuable tool for many 
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areas of research including biofilms.  Many in vitro biofilm model systems 
have been utilised and can provide a reproducible and defined system to 
study the biofilm mode of growth of pure or mixed cultures.  Some of these 
models are been highlighted below. 
 
1.3.7.2.1 Microtiter Tray-Based Models 
One of the simplest forms of biofilm models are those based on microtiter 
plates.  Bacterial cultures are inoculated into the microtiter plate (most 
commonly 96-well) where biofilms grow on the bottom or walls of the wells.  
Whilst this format is useful due to its ease of use and low cost, the 
batch-culture like nature can be a limitation.  As there is no flow in or out of 
the system, waste products will increase and nutrient levels will decrease 
unless fluid is regularly replaced, making the environment inconsistent with 
in vivo conditions. 
Microtiter-based models are often used to screen large numbers of samples 
simultaneously and have also been adapted by Ceri et al to analyse 
antimicrobial susceptibility to biofilms399.  This system is known as the 
Calgary Biofilm Device (CBD) or Minimum Biofilm Eradication 
Concentration assay (MBEC).  The system utilises pegs which are attached to 
the lid of a microtiter plate and immersed in a bacterial culture, allowing 
biofilm formation on the pegs.  The lid and peg system is then transferred to 
a second plate and immersed in a serial antimicrobial dilution.  After a 
certain period the lid can be removed and biomass/sessile bacterial 
population enumerated using viable counting or microscopic techniques. 
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1.3.7.2.2 Flow Displacement Model 
Unlike the microtiter-based model, flow displacement models are 
continuous culture systems in which growth medium and nutrients are 
supplied into the system as waste products are removed. 
The Modified Robbins Device (MRD), which was developed at the 
University of Calgary, allows the formation of biofilm on a variety of 
substratum materials at a controlled flow rate437.  The MRD is usually 
constructed out of plastic or stainless steel and contains ports in which to 
insert numerous coupons, which can be composed of a variety of material 
types.  The model is typically inoculated with a suspension of 
microorganisms and the flow rate, temperature and nutrient input can be 
controlled.  This device allows biofilm formation and removal from a variety 
of substratum materials, and under differing conditions to be monitored 
relatively cheaply and has widespread use in biofilm research. 
The Centers for Disease Control group designed a biofilm reactor which 
comprises a glass vessel with removable polypropylene rods inserted into 
the lid.  Each rod supports biofilm formation.  In this biofilm reactor, 
identical biofilms can be formed simultaneously and easily removed over 
time for analysis438.  This model has also been utilised to evaluate the efficacy 
of antimicrobial agents against Staphylococcus aureus biofilms439. 
The constant depth film fermenter is often used to study the long-term 
formation of oral biofilms440.  The biofilm depth can be manipulated by 
mechanically removing excess biofilm, a process designed to reflect the 
movement of the tongue over the teeth. 
Other continuous flow fermentation models have been employed by many 
research groups with various adaptations441-443.  Bowden et al utilised a 
modified chemostat with ports to accept rods, which provided a surface for 
bacterial adhesion.  The accumulation of oral bacteria onto glass surfaces has 
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been characterised using this model444.  The Sorbarod biofilm fermenter 
employs cellulose acetate filter plugs which provide a large surface area for 
the adherence of bacterial populations under a continuous flow system443.  
The growth rate, expression of target proteins and effect of antibiotics over 
extended periods on bacteria in the biofilm mode of growth can be studied 
with this model443, 445.  MacFarlane et al investigated the colonization and 
degradation of mucin by faecal bacteria utilising a pH-controlled 
fermentation system for the growth of planktonic and sessile intestinal 
bacterial ecosystems446.  Probert and Gibson utilised a similar model system 
coupled with fluorescence in situ hybridization (FISH) to compare sessile 
and planktonic populations in a simulated human colon environment447. 
 
1.3.7.2.3 Cell-Culture Model Systems 
Whilst the majority of model systems described previously have been based 
on biofilm formation on abiotic surfaces, formation on biotic surfaces has 
also been studied.  A reconstituted human epithelia model448 has been 
utilised to form a Candida albicans dimorphic fungus biofilm on the 
epithelial-like structure, and can be used to study the interaction between 
microorganisms and epithelial tissue, although the simulation of the 
commensal microbiota is absent from this system.  Similar model systems 
are in place for other cell lines, including human microvascular endothelial 
cells449 and HeLa cells450.  These models allow the biofilm formation on 
clinically relevant tissues to be monitored, and the damage caused to these 
tissues by their exposure to certain microorganisms. 
 
1.3.8 Gastrointestinal Tract Biofilms 
The microorganisms present in the gastrointestinal tract often form 
multispecies sessile communities attached to the mucosal layer292-294.  
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Mucosal populations are difficult to investigate in healthy individuals due to 
the physical inaccessibility of the gut; thus, there has been restricted study of 
these communities. 
MacFarlane et al have shown that bacterial populations strongly adhere to 
particulate matter in stools with bacteroides and bifidobacteria 
predominating451.  Confocal laser microscopy revealed a mixture of living 
and dead bacteria existing in microcolonies at the interface with the 
substratum.  Bacteroides, eubacteria, bifidobacteria, clostridia and 
Gram-positive cocci have been detected in human mucosal surfaces293, 294.  
Microscopic investigation of the 3D structure of colonic biofilms has shown 
that microbial mucosal bacteria are distributed throughout the mucus layer, 
although they are not usually found in healthy crypts452.  Live/dead staining 
and 16S rRNA FISH probes show that most of the bacteria are alive, 
particularly those that are close to the mucosal surface451.  These finding 
suggest that the bacteria were actively growing in the mucus layer and that 
their presence was not due to the passive transference of the cells from faecal 
material in the gut lumen. 
Zoetendal et al292 utilised 16S rRNA to evaluate the mucosa-associated 
bacterial communities in different areas of the colonic biopsies.  They 
identified that mucosa-associated bacterial populations were host-specific 
and uniformly distributed along the colon, but differed significantly from 
faecal communities. 
Examination of mucosal-associated microorganisms from the healthy colon 
wall of sudden death victims identified that predominant bacterial 
populations were Bacteroides and Fusobacterium spp., although species 
isolated varied between individuals.  Microscopy revealed that 
microorganisms were present with the mucus and displayed complex 
microbial structures, but major variation along the colon was not evident294. 
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In vitro continuous culture flow systems have been used to mimic the 
conditions of the gastrointestinal tract and to investigate the formation of 
biofilms on mucins.  MacFarlane et al developed a two-stage continuous flow 
model which reflects the proximal and distal colon, and uses a faecal 
emulsion to provide the indigenous microbiota of the human colon446.  
Porcine mucin gels were used to provide an interface similar to the mucus 
layer covering the gastrointestinal tract.  Rapid colonisation of mucin gels by 
faecal bacteria occurred in both culture vessels.  However, bifidobacteria 
grew slowly on the mucin and only under the nutrient-limited conditions of 
vessel 2, where they achieved high cell numbers.  In general, anaerobic 
bacteria in the mucin biofilms did not reach the cell population densities 
seen in the planktonic phase.  It was also evident that mucin biofilm 
communities contained proportionally higher numbers of enterobacteria 
than the planktonic phase within the chemostats.  FISH, with a mixture of 
three genus-specific 16S rRNA oligonucleotide probes, showed that the 
predominant biofilm bacteria bacteroides and enterobacteria grew in close 
juxtaposition to each other in the mucus, and bacteroides often formed 
microcolonies446. 
Probert and Gibson designed an in vitro fermentation system to model the 
human colonic microbiota447, utilising a framework of mucin alginate beads 
to facilitate the adhesion of bacteria.  These beads were encased in a dialysis 
membrane and inoculated with a faecal emulsion.  Populations from this 
biofilm system were compared to those from a conventional single-stage 
chemostat.  FISH was used to enumerate the bacterial populations and 
demonstrated that the biofilm fermentation vessel supported a greater cell 
density than the conventional culture chemostat, notably supporting a 
greater population of clostridia and E. coli. 
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1.4  Clostridium difficile Biofilm Research 
CDI is primarily a nosocomial disease associated with high levels of 
morbidity.  Despite most patients responding well to initial medical therapy, 
~20% of patients suffer clinical recurrence following withdrawal of 
antimicrobial therapy243.  Many patients enter a repetitive cycle of recurrent 
disease, which introduce difficulties in treatment management.  The 
pathophysiological mechanisms of recurrent CDI are not fully understood, 
but likely involve continued disruption of the host gut microbiota, 
persistence of C. difficile spores and inadequate host immune response. 
First-line CDI treatment options in the UK are predominantly metronidazole 
or vancomycin therapy231.  Whilst clinical cure of these two agents is often 
successful, recurrence of disease is sometimes evident.  These agents 
demonstrate good activity against C. difficile vegetative cells.  However, they 
do not possess anti-spore activity, potentially allowing spores to germinate 
within the disrupted post-antibiotic colonic environment, once antimicrobial 
therapy has been withdrawn. 
Chronic infection is often associated with persistence of microbial organisms 
within a protected biofilm structure.  The gastrointestinal tract is covered by 
a complex biofilm community adherent to the colonic mucous membrane.  
C. difficile is known to adhere to colonic cells and mucus124, 453; however, there 
is a paucity of information regarding its existence and behaviour within 
colonic biofilms.  Since persistent spores likely mediate recurrent disease it is 
important to understand the role of biofilms in CDI. 
Current understanding of the role of biofilms in CDI remains rudimentary.  
Whilst in recent years several research groups have begun to focus on this 
particular hypothesis454, 455, much of this work utilises basic in vitro systems 
which are poorly reflective of conditions in vivo.  There is therefore a 
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fundamental need to carry out more complex experiments which more 
accurately reflect conditions in vivo. 
Studies of human gut biofilms indicate distinct differences between sessile 
and planktonic bacterial populations and metabolic activities within the gut 
lumen452, 456.  It is unknown whether these differences affect responses by gut 
microbiota and/or C. difficile to antimicrobial exposure. 
Whilst work regarding the existence and behaviour of C. difficile within a 
mixed-species mucosal biofilm remains largely unexplored, recent work has 
begun evaluating the ability of C. difficile to form pure culture biofilms in 
vitro.  Laning et al457 successfully grew vegetative C. difficile pure culture 
biofilms on polycarbonate membranes and colony architecture was 
monitored from 24 hours to 6 days using CLSM and phase contrast 
microscopy.  Results indicated that 24-hour biofilms comprised mainly 
vegetative cells but, 6-day-old biofilm contained very few vegetative cells 
limited to the outer edge of the biofilm with an abundance of spores within 
the inner biofilm structure. 
Western immunoblot analysis was performed to identify the presence of 
toxin antibodies within biofilm structures.  Biofilms were cultured for five 
days using toxigenic and non-toxigenic strains and western blot analysis 
identified signals at around 300kDa, suggesting the presence of toxin, within 
the toxigenic strain biofilm whereas no signal was evident in the 
non-toxigenic strain biofilm.  As this author previously identified that 
vegetative C. difficile within 3-day-old biofilms had begun sporulation and 
at 6 days, C. difficile were comprised entirely of spores; they therefore 
expected to find greater amounts of toxin within younger biofilms.  
However, western blot analysis indicated that toxin concentration actually 
increased over time from 1-day-old biofilm to 6-day-old biofilms even 
though sporulation began at day 3.  This may be due to the increased cell 
mass of older biofilms which have undergone increased cellular division.  
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These results remain unclear and further work is required to help clarify 
these observations. 
Key surface and regulatory proteins required for biofilm formation in 
C. difficile have been identified using isogenic mutations454.  Cysteine 
protease, Cwp84, flagellin protein FliC,  putative quorum sensing modulator 
enzyme, LuxS, and sporulation and matrix production master regulator 
Spo0A mutants all resulted in defective biofilm formation when compared 
with the wild-type strains, indicating that individually these genes all play a 
role in the formation of biofilm structures.  SleC (a germination protein) 
mutants form biofilm-like structures although they are thinner and uneven.  
Binary toxin components CdtA and CdtB mutations did not adversely affect 
biofilm formation. 
Within the same study, exposure of 1- and 3-day-old biofilms to 10x MIC of 
vancomycin resulted in 5- and 12-fold increased survival of sessile cells 
compared with planktonic cultures.  This resistance appeared to be mediated 
by the matrix or other mechanism rather than a genetic change in the biofilm 
bacteria.  Furthermore, sub-inhibitory concentrations of vancomycin did not 
significantly induce biofilm formation whereas inhibitory levels did increase 
biofilm formation.  These results indicate that C. difficile form complex 
biofilm structures in vitro and that biofilm formation is a multifactorial 
process which remains to be fully elucidated. 
Furthermore, recent work has outlined the presence of C. difficile within dual 
species biofilms.  C. difficile formed moderately adherent mono-species 
biofilms in vitro, however, when grown in the presence of another intestinal 
strain Finegoldia  magna a thick, dense biofilm formed indicating a synergy 
between the two species355. 
Dawson et al455 have recently characterised the biofilm-forming properties of 
C. difficile and the role of Spo0A.  They provide evidence that sporulation 
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master regulator Spo0A may play a key role in biofilm formation.  Mutations 
in the spo0A gene resulted in decreased biofilm formation and increased 
sensitivity to oxygen stress.  Six day old biofilm grown on abiotic surfaces 
possessed greater levels of spores and decreased populations of vegetative 
cells compared with 3-day-old biofilms.  Intact 3-day-old biofilms when 
exposed to oxygen stress for 24 hours resulted in 45% vegetative cell 
survival with increased populations of spores.  Three-day-old biofilm 
structures disrupted by vortex when exposed to oxygen stress displayed 
vegetative cells below the level of detection, with spore survival.  The 
authors concluded that the protected environment of an intact biofilm 
protects C. difficile from oxygen stress455. 
Cyclic diguanylate (3’, 5’-cyclic diguanylic acid) (c-di-GMP) is a second 
messenger which has been well characterised in Gram-negative bacteria and 
has been shown to mediate the transition from planktonic to the biofilm 
mode of growth.  C-di-GMP facilitates biofilm formation by increasing 
adhesin and EPS production458-460, whilst reducing the transcription of 
flagellar genes461, 462 and disrupting pilus assembly463, 464.  C-di-GMP has also 
been shown to coordinate responses to the entry of cells into stationary 
phase465, expression of virulence genes466, 467, resistance to antibiotics and host 
immune responses468, 469. 
The sequenced genome of C. difficile 630 identifies 37 proteins thought to be 
involved in c-di-GMP metabolism470.  Purcell et al471 identified that elevated 
levels of c-di-GMP represses C. difficile motility and induces the formation of 
C. difficile cell aggregates, a function often related to biofilm formation, 
thereby providing additional evidence of the potential biofilm forming 
properties of C. difficile. 
The recent surge in projects pertaining to the biofilm forming properties of 
C. difficile and the role of biofilms in CDI highlights the importance of further 
investigation of this area. 
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1.4.1 Project Aims 
It is proposed to develop and validate a human gut model system as a 
model in which to study biofilm-forming behaviour of C. difficile and 
indigenous gut microbiota.  It is anticipated that this new model will provide 
valuable data regarding the interplay between antibiotics, C. difficile biofilms 
and gut microbial biofilms and further our understanding of CDI.  
Importantly, such developments can contribute significantly to the 
development of therapeutic agents for CDI. 
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2.0 Materials and Methodology 
2.1 Clostridium difficile Isolation, Culture and Identification 
Brazier’s cycloserine cefoxitin egg-yolk agar (LabM, Leeds, UK) 
supplemented with 5 mg/L lysozyme (LabM), 2% lysed horse blood (E & O, 
Bonnybridge, Scotland), 250 mg/L cycloserine and 8 mg/L cefoxitin (LabM) 
(CCEYL) was routinely used throughout these experiments for the isolation 
of C. difficile vegetative cells and spores.  CCEYL supplemented with 2 mg/L 
moxifloxacin (Bayer, Berkshire, UK) (CCEYLM) was used for the isolation of 
C. difficile vegetative cells during use of the gut model system 
(chapters 4.0-8.0). 
CCEYL and CCEYLM plates were pre-reduced for 24 hours at 37° C in an 
anaerobic cabinet (Mk III Anaerobic Workstation, Don Whitley Scientific, 
Shipley, UK) prior to use.  C. difficile colonies isolated on CCEYL and 
CCEYLM were identified based on the typical characteristics described by 
Brazier & Borriello472; colonies are 3-5 mm in diameter, irregularly edged, 
opaque and brown/grey in colour with a distinct odour of para-cresol. 
2.2 Enumeration and Identification of Gut Microbiota 
Selective and non-selective agars were used to identify cultivable gut 
microbiota species, as described previously for a human gut model system270, 
473, 474, these agars are detailed in table 2.1 and appendix A3. 
Planktonic and sessile cultures were serially diluted 10-fold in pre-reduced 
peptone water (Oxoid, Basingstoke, UK) to 10-7.  Twenty microlitres of four 
appropriate dilutions were inoculated to quarter plates of each culture 
medium in triplicate (figure 2.1).  All sample manipulations were performed 
anaerobically.  Culture media selective for anaerobic organisms were 
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pre-reduced for 24 hours prior to use.  Inoculated plates were incubated 
anaerobically (obligate anaerobes) or aerobically (facultative anaerobes) 
at 37° C for 48 hours.   
C. difficile spores were enumerated by exposing planktonic and biofilm 
cultures to 1:1 v/v 100% ethanol (VWR) for at least 1 hour, after which the 
ethanol:culture mixture was enumerated by serial dilution as described 
above.   
Bacterial colonies were identified on the basis of medium selection, colony 
morphology, Gram staining, biochemical activity, antimicrobial selectivity 
and UV fluorescence.  Bacterial populations were converted to log10cfu/g 
(sessile) or log10cfu/mL (planktonic) using the following equations: 
mean colony forming units (cfu) per 20 μL x 50 = cfu/mL 
cfu/mL x 10Z = actual cfu/mL (Z = dilution factor) 
viable counts expressed as log10cfu/mL 
actual cfu/mL*(1/Y) = cfu/g (Y = weight of pellet of 1 mL of culture) 
Viable counts expressed as log10cfu/g 
Standard errors of mean bacteria counts (log10cfu/mL or log10cfu/g) were 
determined. 
 
2.3 Clostridium difficile Spore Preparation 
C. difficile was inoculated onto a single CCEYL plate and incubated 
anaerobically at 37° C for 48 hours.  All growth was removed and 
sub-cultured onto 10 Columbia blood agar plates (FBA) (Leeds Teaching 
Hospitals, Leeds, UK) and incubated anaerobically at 37° C for 7-10 days.  
All growth was removed and emulsified into 1 mL of sterile saline 
(Sigma-Aldrich, Poole, UK), to which 1mL of 99.6% ethanol (VWR 
International, Lutterworth, UK) was added.  The suspension was vortexed 
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for 30 seconds and stored aerobically at room temperature.  The total viable 
count of this suspension was determined by 10-fold serial dilution in 
pre-reduced peptone water under anaerobic conditions to a dilution of 10-7.  
Twenty microlitres of the appropriate dilution was inoculated in triplicate 
onto CCEYL and converted to cfu/mL (figure 2.2). 
 
 
Figure 2.1: Schematic representation of the serial dilution procedure used for 
bacterial enumeration. (TVC, Total viable counts; PW, peptone water). 
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Figure 2.2: Schematic representation of the preparation of C. difficile spores. 
 
 
Subculture from -70oC 
storage vial
Single colonies 
subcultured to FBA
x 10 
Plates
All growth 
removed
1mL Sterile 
Saline
Equal Volume 99.6% Ethanol 
added to emulsified colonies
1h, room 
temperature
Refrigeration until 
required Approx. 108
cfu/mL
Pre-reduced CCEYL agar plate
48h, ANO2
Centrifugation 
16,000g, 10-mins
Re-suspension in 
1mL saline
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Medium Target species 
Fastidious anaerobe agar 
(FAA) 475 
Total anaerobes and 
total clostridia 
Bacteroides Bile Aesculin agar 
(BBE) 
B. fragilis group. 
LAMVAB476 Lactobacillus spp. 
Beerens agar477 Bifidobacterium spp. 
Nutrient agar Total facultative 
anaerobes 
MacConkey agar Lactose-fermenting 
Enterobacteriaceae 
Kanamycin Aesculin Azide 
agar 
Enterococcus spp. 
 
Table 2.1: Solid culture medium used for the isolation and identification of 
indigenous gut microbiota.  (Manufacturer’s details and supplements 
Appendix A3). 
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2.4 Cytotoxin Assay 
Vero cells (African Green Monkey Kidney Cells, ECACC 84113001) were 
cultured in flat bottom tissue culture flasks (Nunc, Rochester, USA) 
containing 20 mL of Dulbecco’s Modified Eagles Medium (DMEM) (Sigma) 
supplemented with 50 mL newborn calf serum (Gibco, Paisley, UK), 5mL 
antibiotic/antimycotic solution (Sigma) and 5 mL L-glutamine (Sigma) and 
incubated in 5% CO2 at 37° C (Sanyo, Watford, UK) until Vero cell 
monolayers were confluent upon examination under an inverted microscope 
(Olympus UK Ltd, Middlesex, UK). 
Upon satisfactory growth the monolayer of Vero cells was harvested by 
discarding the DMEM and rinsing the flask with 1 mL of Hanks Balanced 
Salt Solution (Sigma) containing 0.25 g/L trypsin-EDTA (Sigma) 
(HBSS-EDTA) and discarding.  A further 6 mL of HBSS-EDTA was 
inoculated into the flask and incubated in 5% CO2 at 37° C for 10 minutes or 
until the monolayer of cells were no longer adherent to the flask.  The 
HBSS-EDTA cell mixture was then diluted 1:20 in fresh DMEM for further 
passage or seeding into a 96F microtiter tray (Nunc).  One hundred and sixty 
microlitres of the harvested Vero cells were inoculated into the wells to 
which antitoxin would be added and 180 μL of trypsinsed Vero cells were 
added to all other wells and incubated in 5% CO2 at 37° C for 2 days or until 
Vero cell monolayers were confluent upon examination under an inverted 
microscope.  The Vero cells were continuously passaged for the duration of 
each experiment (figure 2.3). 
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Figure 2.3: Vero cell cytotoxin assay. 
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One millilitre samples for toxin enumeration were centrifuged at 16000 g 
for 15 minutes and the supernatant stored at 4° C.  Sample supernatant and 
positive cytotoxin controls (48 hour culture of C. difficile in Brain Heart 
Infusion broth (BHI) (Oxoid) were serially diluted 10-fold in sterile 
phosphate buffered saline (PBS-pH7) to 10-5.  Serial dilutions were 
aseptically transferred into microtiter trays containing Vero cell monolayers.  
Twenty microlitres of C. sordellii antitoxin (Prolab Diagnostics, Neston, UK) 
was used to neutralise any cytotoxic effect and ensure that cell rounding 
observed was specific to C. difficile.  A sample was designated as positive if 
~80% of the Vero cell monolayer was rounded (figure 2.4).  A relative unit 
was used to quantify the level of cytotoxin present by assigning a titre to the 
sample based on the greatest dilution of which a positive cytotoxic effect 
was observed (i.e. if toxin was present in the neat only dilution this was 
assigned a titre of 1; if a positive cytotoxin effect was observed in 
the 10-1 dilution then it was assigned a titre of 2, etc.). 
 
 
Figure 2.4: Vero cell monolayer a) intact monolayer, b) C. difficile cytotoxic 
effect. 
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2.5 Collection of Human Faecal Material 
Faecal material was donated by at least 3 healthy elderly (>60 years) 
volunteers with no history of antimicrobial therapy for at least 2 months 
prior to donation.  Samples were stored in sealed anaerobic zip lock bags 
(Becton Dickinson, Sparks, MD, USA) for no longer than 12 hours during 
transportation and transfer to an anaerobic cabinet. 
2.6 Screening of Faecal Material 
To ensure the absence of C. difficile populations within the faecal material, 
samples were plated directly onto CCEYL agar in duplicate and incubated 
anaerobically at 37° C for 48 hours.  Faecal material from any donor testing 
positive for C. difficile was eliminated from the study. 
2.7 Preparation of Faecal Emulsion 
Faecal emulsion was prepared by suspending 10% w/v C. difficile-negative 
faeces in pre-reduced PBS (Sigma), and the suspension emulsified in a 
stomacher (Stomacher Lab-Blender 400, Borolabs, Aldermaston, UK) until a 
smooth slurry was formed.  Any large material was removed by filtration 
through a sterile muslin cloth (Bigger Trading Limited, Watford, UK). 
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3.0 Batch Culture Experiments 
3.1 Background 
It is generally accepted within the C. difficile research community that the use 
of batch culture experiments for this organism has limited use due to the 
lack of reliable and consistent data.  Batch culture experiments do not reflect 
the continuous removal and replacement of nutrients and waste products 
observed in vivo.  Nutrient availability is known to affect the physiology of 
C. difficile and numerous studies have highlighted that results obtained using 
batch culture methods are inconsistent and sometimes contradictory to 
clinical observations478,56, 57, 479,479, whilst other results demonstrated some 
similarity with observations in vivo480, 481. 
Borriello and Barclay23 devised an in vitro batch culture model of 
colonisation resistance to C. difficile, demonstrating the inhibition of 
proliferation and toxin production in the presence of human faecal material.  
This inhibitory capacity was absent from heat or filter sterilised faecal 
emulsions, thus implicating the importance of an as yet unidentified 
component/s of the faecal microbiota in providing this resistance.  This 
research also identified the varying degree of colonisation resistance.  Faecal 
emulsions from healthy adult volunteers (age range 21-57 years) elicited a 
greater resistance to C. difficile germination and toxin production than the 
emulsions from geriatric volunteers (age range 71-92 years)23. 
Whilst it is important to consider these limitations, batch culture systems can 
still provide useful preliminary information, so these systems were used to 
investigate the ability of different C. difficile strains to form pure culture 
biofilms in vitro. 
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3.2  Materials and Methodology 
3.2.1 Microtiter Tray Assay 
3.2.1.1 Rationale 
Microtiter tray assays are often used in biofilm research as they allow 
researchers to screen a large number of organisms/strains quickly and with 
ease.  This format has been widely used in biofilm research to assess the 
biofilm forming capabilities of organisms such as P. aeruginosa, 
Staphylococcus aureus482, Listeria monocytogenes483 and B. subtilis484 whilst 
C. difficile research using this method remains rudimentary355,454, 455. 
The microtiter tray model uses batch growth conditions, therefore 
potentially limiting the formation of mature biofilms, which require 
increased time frames for some organisms.  However, it has provided 
researchers with valuable information regarding the initial stages of biofilm 
formation485. In addition, microtiter trays are commercially available in a 
variety of materials, allowing the investigation of substratum material on 
biofilm growth. 
Our group hoped to identify strong biofilm forming C. difficile strains, 
allowing us to focus our research accordingly. 
 
3.2.1.2 Organisms 
An initial panel of 7 C. difficile clinical isolates were studied for their ability 
to adhere to inanimate surfaces (table 3.1).  These C. difficile strains were 
chosen as a representative selection of UK epidemic ribotypes205.  
S. aureus 8325-4486, a known biofilm-producing stain supplied courtesy of 
Dr Alex O’Neil, University of Leeds, UK and Clostridium perfringens 
ATCC 13124346 served as positive controls. 
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3.2.1.3 Culture Media 
Brain heart infusion broth (BHI), cooked meat medium (CM), Tryptic soy 
broth (TSB) were prepared according to the manufacturer’s instructions. 
All laboratory media were purchased from Oxoid, Basingstoke, UK and 
prepared according to the manufacturers’ instructions unless otherwise 
stated. 
 
3.2.1.4 Substrata 
Polystyrene (Nunc), glass (Porvair, Leatherhead, UK) and polyethylene 
(Nunc) 96F-well microtiter trays were used in these assays. 
 
3.2.1.5 Experimental Assay 
C. difficile strains were cultured onto CCEYL and C. perfringens was cultured 
onto Columbia Blood Agar (FBA) and incubated anaerobically at 37° C 
for 48 hours.  S. aureus was cultured onto FBA and incubated aerobically 
at 37° C for 24 hours. 
A 0.5 McFarland suspension (approximately 1.5x108 cfu/mL) of each strain 
was prepared in each growth medium and incubated anaerobically at 37° C 
overnight.  The overnight culture was diluted 1:10 in pre-reduced growth 
medium within the microtiter tray.  Two wells of each tray were inoculated 
with growth medium only and served as a negative control.  
S. aureus 8325-4 and C. perfringens served as positive controls.  Each assay 
was performed in duplicate using the same bacterial cultures and growth 
conditions and the plates were placed in a plastic box containing air holes 
and a moist paper towel and incubated anaerobically at 37° C 
for 24 or 48 hours. 
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Contents from each well were discarded and wells washed three times with 
sterile PBS (Sigma) before 200 µL of crystal violet solution (0.1% w/v) was 
added into each well and allowed to stand for 15-20mins.  Excess stain was 
discarded and wells washed three times with sterile water before 200 µL of 
ethanol (96%) (VWR) was added to solubilise the stain bound to adherent 
cells. 
The optical density (OD) of the contents of each well was determined 
at 570 nm using a microplate spectrophotometer (Spectra Max 250, 
Molecular Devices).  Positive biofilm growth was classified as an OD of three 
standard deviations above the mean for the negative control. 
 
PCR ribotype Isolate designation Isolate origin 
027 SM Outbreak of CDI 
Stoke-Mandeville 
Hospital, 2005 
027 210 Outbreak at Maine Medical 
Centre, Portland, MA, 2005 
106 36/64 Clinical isolate from LGI 
078 BM Clinical isolate from Beaumont 
Hospital, Ireland 
001 P24 Clinical isolate from LGI 
153 153 Clinical isolate 
010 E4 Non-toxigenic strain isolated 
from LGI 
Table 3.1: List of C. difficile isolates used in the microtiter tray assay. (LGI; 
Leeds General Infirmary). 
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3.2.2 Mucin Alginate Batch Culture Experiments 
3.2.2.1 Rationale 
Microtiter tray experiments provide information regarding the ability of 
organisms to adhere to inanimate surfaces, but conditions in vivo will 
provide a vastly different environment.  The colon is covered in a layer of 
mucus which provides the epithelial cells with a protective barrier from the 
harsh conditions of the intestinal lumen312.  In order to provide a more 
realistic substratum material, mucin alginate (MA) beads were used in a 
batch culture system to investigate the ability of C. difficile to form pure 
culture biofilms on a biotic surface.  Gibson et al previously utilised MA 
beads to provide a framework for complex intestinal microbiota biofilms in 
vitro447. 
 
3.2.2.2 C. difficile Strains 
Four C. difficile strains associated with human infection (027 (210), 
106 (36/64), 078 (BM) and 001 (P24)), which are epidemiologically 
representative of prevalent strains in the UK were selected for this study 
(table 3.1). 
 
3.2.2.3 Culture Media 
BHI (Oxoid) and saline (Sigma) were prepared according to the 
manufacturer’s instructions.  Biofilm gut model growth medium (Appendix 
A1) was prepared as described by Gibson et al447. 
 
3.2.2.4 Mucin-Alginate Bead Preparation 
MA beads were produced based on the method described by Probert and 
Gibson447.  Hog gastric mucin (2 % w/v: Sigma) and sodium alginate (2 % 
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w/v: Sigma) were added to warm sterile water, stirring continuously until a 
smooth paste was formed.  The MA mixture was fed into peristaltic pump 
through E1000 tubing (Fisher Scientific, Loughborough, UK) which was 
suspended from a height of approximately 40 cm and allowed to fall into 
stirred, 0.3 M CaCl2 (Sigma), to give each bead a mean diameter of 2.9 mm.  
The beads were allowed to cure overnight and stored at 4° C.  MA bead 
preparation was carried out within a sheltered structure where possible to 
reduce the likelihood of environmental contamination.   
 
3.2.2.5 Experimental Assay 
Fifty percent (w/v) MA beads were added to each culture medium and 
inoculated with 300 µL of C. difficile spore suspension (section 2.3).  Cultures 
were incubated anaerobically at 37° C for 72 hours. 
 
3.2.2.6 Sampling of Planktonic Bacteria 
Planktonic bacteria were sampled immediately upon addition of MA beads 
and C. difficile spores to the media and then daily for 3 days.  
Approximately 5 mL of culture media and beads were removed for analysis.  
MA beads were isolated for bead-associated analysis (section 3.2.2.7).  The 
planktonic culture fluid was inoculated in triplicate onto CCEYL and 
C. difficile spores and TVCs enumerated as described in sections 2.1 and 2.2.  
Viable counts were expressed as log10cfu/mL. 
 
3.2.2.7 Sampling of Bead-Associated Bacteria 
MA beads were transferred to pre-weighed tubes and the weight of beads 
determined.  Beads were re-suspended in 5 mL pre-reduced peptone water, 
gently agitated to remove loosely adherent bacteria, and peptone water 
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discarded.  Two millilitres of 0.001% (w/v) cetyltrimethlyammonium 
bromide (CTAB)447, diluted in sterile water, was added to the beads to 
dissociate adherent bacterial cells and shaken intermittently for 30 mins.  
The CTAB and bead-associated mixture was serially diluted 10-fold under 
anaerobic conditions in pre-reduced peptone water to 10-7 and the 
bead-associated culture inoculated in triplicate onto CCEYL and C. difficile 
spores and TVCs enumerated as described in sections 2.1 and 2.2.  Viable 
counts were expressed as log10cfu/g of beads. 
 
3.2.3 CTAB Inhibition Assay 
3.2.3.1 Rationale 
CTAB is a cationic surfactant which can be utilised to dissociate bacteria 
from MA beads as described by Probert and Gibson447.  Salton et al487 
highlighted potential bactericidal properties of CTAB.  Therefore it was 
necessary to determine the effect of CTAB exposure on faecal and C. difficile 
populations. 
 
3.2.3.2 Organisms 
C. difficile strain 027 (210) (table 3.1) was used for this study. 
 
3.2.3.3 Preparation of Faecal Emulsion 
A 10% faecal emulsion was prepared from faecal samples donated from 
healthy adult volunteers as described in sections 2.5-2.7. 
 
3.2.3.4 Experimental Assay 
One millilitre of an overnight Schaedler’s broth culture (Oxoid) of C. difficile 
PCR ribotype 027 (210) (~ 108  cfu/mL) was inoculated into the 10% faecal 
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emulsion.  Two C. difficile-positive faecal emulsion samples were centrifuged 
at 16000 g for 5 mins before being transferred to anaerobic conditions.  The 
supernatants were discarded.  One pellet was re-suspended in 2 mL of 
pre-reduced 0.001% CTAB and the other pellet was re-suspended in 2 mL 
pre-reduced sterile water.  Bacterial populations were 
enumerated 30 mins, 120 mins and 240 mins after exposure to CTAB using 
the selective and non-selective agars as described in sections 2.1 and 2.2.  The 
faecal suspension was enumerated and used as a non-CTAB exposed 
control. 
 
3.2.4 Mucin Degradation Assay 
3.2.4.1 Rationale 
Certain bacteria are able to utilise mucin as a source of nutrition when 
substrate availability is low (such as in the distal colon).  The exposure of 
MA beads within a model of the human gut resulted in the gradual 
degradation of these beads (see chapter 5.0).  An assay was designed to 
establish the source of this degradation.  A minimal growth medium was 
used so that the glycoproteins present represented the only major carbon 
source available for bacterial growth. 
 
3.2.4.2 Organisms 
Indigenous gut microbiota strains evaluated were: Lactobacillus plantarum, 
Bacteroides thetaiotaomicron, Bifidobacterium adolescentis, Clostridium innocuum, 
Enterococcus faecium, Proteus mirabilis, Klebsiella oxytoca and C. difficile PCR 
ribotype 027 (210) (table 3.1).  All bacterial strains (except C. difficile) were 
isolated from the human gut model, providing a mixture of Gram positive, 
obligate and facultative anaerobes, and were identified using 16S-rRNA 
PCR. 
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3.2.4.3 Culture Medium 
Mucin or MA (0.5% w/v) with or without 1% glucose (w/v) was incorporated 
into minimal growth medium B consisting of tryptone (Oxoid, 7.5 g/L); 
casitone (Beckton Dickinson, 7.5 g/L); yeast extract (Oxoid, 3.0 g/L); meat 
extract (Fluka, 5.0 g/L); NaCl (Sigma, 5.0 g/L); K2HPO4 .3H2O 
(AnalR, 3.0 g/L); KH2PO4 (AnalR, 0.5 g/L); MgSO4.7H2O (Sigma, 0.5 g/L); 
cysteine HCl (Sigma, 0.5 g/L); resazurin (Sigma, 0.002 g/L); D-(+)-glucose 
(Sigma, 10 g/L); porcine gastric mucin (type III) (Sigma), 5; agar technical 
number 3 (Oxoid), 15.  The media was adjusted to pH 7.2±0.2 with 2M 
NaOH488, 489. 
Molten medium B, with or without glucose (1% w/v) was poured into Petri 
dishes and allowed to set. 
 
3.2.4.4 Experimental Assay 
A 0.5 McFarland suspension (~ 108 cfu/mL) of each bacterial isolate was 
prepared in fastidious anaerobe broth (BioConnections, Leeds, UK) and 
incubated, anaerobically overnight at 37° C, except for E. faecium, K. oxytoca 
and P. mirabilis which were incubated aerobically.  A 10% (w/v) faecal 
emulsion prepared from a healthy adult volunteer, as described in 
sections 2.5-2.7 was used as a positive control.  The same faecal emulsion 
was autoclaved and used as a negative control.  Agar plates were dried prior 
to inoculation.  Bacterial species were inoculated onto the surface of the agar 
using a multipoint inoculator to achieve a final inoculum of 104 cfu/spot.  All 
agars were then incubated anaerobically at 37° C for 72 hours.  Agar plates 
were subsequently stained with 0.1% amido black (Sigma), dissolved in 3.5M 
acetic acid for 30 min, and then washed with 1.2M acetic acid.  The formation 
of a mucinolytic zone around the colony was measured using callipers 
accurate to 0.1mm.  This method was modified from that of Zhou et al490. 
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3.2.5 Adherence Assay 
3.2.5.1 Rationale 
The unbound/planktonic indigenous gut microbiota populations were 
monitored in this experiment so that the inverse binding relationship could 
be used in order to estimate the levels of adherence of bacteria to different 
bead materials.  Rather than directly enumerating adherent populations, 
decreases in planktonic populations can be used to reflect the transition from 
planktonic to bead-adherent states.  Total planktonic populations of bacterial 
groups at t = 0 mins were enumerated and recorded as 100% of the faecal 
emulsion populations.  The relative decrease in this baseline population 
could be calculated when exposed to MA or glass beads over time.  A 
greater decrease in percentage of faecal baseline population would indicate a 
greater number of bacteria which were bound to the beads, rather than 
remaining in the enumerated planktonic form. 
 
3.2.5.2 Organisms 
C. difficile strain 027 (210) (table 3.1) was used for this study. 
 
3.2.5.3 Experimental Assay 
A 10 % faecal emulsion was prepared as described previously 
(sections 2.5-2.7).  Fifty percent (w/v) MA (section 3.2.2.4) and glass beads 
(2 mm diameter) (VWR) were added to separate 30 mL faecal emulsions 
along with 200 μL of an overnight Schaedler’s broth culture of C. difficile 
(~ 108  cfu/mL).  Planktonic samples were taken at time (t) = 0 (faecal 
emulsion prior to exposure to beads as a control), 1, 2, 4, 24 and 48 hours 
after the addition of the beads.  Planktonic bacterial populations were 
enumerated as described previously (sections 2.1 and 2.2).  The bacterial 
counts were converted to a percentage of the t = 0 mins control and plotted 
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against time.  All experimental procedures were carried out anaerobically 
at 37° C. 
 
3.2.6 Biofilm Removal Assay 
3.2.6.1 Rationale 
One of first stages of biofilm formation is the irreversible attachment of 
bacteria to a substratum material.  Once a bacterium has committed itself to 
attachment to a surface and begun the process of biofilm formation its 
subsequent removal may be difficult.  In order to enumerate the bacterial 
populations associated with surfaces accurately it is necessary to remove 
adherent bacteria. 
One of the greatest problems facing clinicians and industrial workers is the 
effective removal of these biofilm structures.  Numerous techniques and 
technologies have been utilised to maximise the removal of the adherent 
bacteria, although many require direct interaction with the site which can be 
problematic.  Various techniques to remove the biofilms in research settings 
include sonication491, vortexing492, disinfectants493, scraping494 and shaking 
with beads493.  Not all of these methods are suitable for this study as bacterial 
removal need to be non-destructive of the substratum material and allow the 
subsequent enumeration of adherent bacterial populations.  Three 
techniques (CTAB, sonication and vortexing) were selected for this assay 
due to their ease of use and non-destructive nature and are described below. 
 
3.2.6.2 Organisms 
C. difficile strain 027 (210) (table 3.1) was used for this study. 
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3.2.6.3 Experimental Assay 
Fifty percent (w/v) glass or MA beads (section 3.2.2.4) were added 
to 3 x 20 mL BHI broths and inoculated with 100 µL of an overnight 
Schaedler’s broth culture of C. difficile (~ 108 cfu/mL).  After 24 hours, culture 
medium was removed and discarded, and the beads re-suspended in 5 mL 
pre-reduced peptone water to remove loosely adherent bacteria.  One set of 
each bead type was either re-suspended in 20 mL pre-reduced 0.001% CTAB 
and shaken for 30 mins; re-suspended in 20 mL pre-reduced saline and 
placed into a sonicating water bath for 30 mins; or re-suspended in 20 mL 
pre-reduced saline and vortexed intermittently for 30 mins. 
From this point on the samples were treated the same and sessile C. difficile 
populations were enumerated as previously described (sections 2.1 and 2.2). 
Positive bacterial adherence in each growth medium was defined as an 
OD570 value of 3 standard deviations above the mean for the negative 
control.  This value was subtracted from each adherence assay absorbance 
reading and displayed in figures 3.3.1a and 3.3.1b. 
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3.3 Results 
3.3.1 Microtiter Tray Assay 
A microtiter tray format was used to screen seven C. difficile clinical isolates 
for their ability to adhere to inanimate surfaces.   
Growth medium choice and incubation time appeared to affect the 
adherence of C. difficile to inanimate surfaces.  Substratum material did not 
provide any affect on biofilm formation, therefore only polystyrene results 
are presented here.  In general, BHI elicited the greatest level of bacterial 
adherence, with maximum absorbance readings amongst C. difficile 
isolates 300% greater when grown in BHI compared with the minimum 
absorbance value for that strain.  CM elicited only minimal adherence by 
most strains.  Adherence was substantially decreased after 48 hours 
incubation compared with 24 hours incubation.  Maximal adherence was 
observed for S. aureus in BHI incubated for 24 hours.  Amongst strains of 
C. difficile, PCR ribotype 078 exhibited the greatest level of adherence when 
grown in BHI for 24 hours, with maximum absorbance values 17.7 % greater 
than other strains.  All C. difficile and positive control strains were deemed to 
provide positive biofilm growth when grown in CM and TSB for 24 hours.  
All C. difficile strains (with the exception of P24) and positive control strains 
produced positive biofilm growth when grown in BHI for 24 hours.  Biofilm 
growth appeared more variable with greater standard error values 
after 24 hour incubation compared with 48 hour growth. 
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Figure 3.3.1a: 
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Figure 3.3.1b: Absorbance values at 570 nm (±SE) of adherence by a panel of 
C. difficile isolates to polystyrene microtiter trays when incubated in different 
growth media for 24 (figure 3.3.1a) and 48 (figure 3.3.1b) hours. (BHI, brain 
heart infusion; CM, cooked meat medium; TSB, tryptic soy broth). 
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3.3.2 Mucin Alginate Batch Culture Assay 
Incubation of C. difficile PCR ribotype 106, 078, 001 and 027 spores in biofilm 
gut model growth medium elicited spore germination and vegetative cell 
proliferation, detected within the planktonic culture fluid within 1-2 days, 
whilst spore populations decreased to around the limit of detection (LOD) 
for the remainder of the experiment (figures 3.3.2.1-3.3.2.2; appendix D1 an 
D2).  Due to the low levels of spores present in this medium the association 
of spores with the MA beads could not be analysed.  Vegetative C. difficile 
populations associated with MA beads reached populations of ~3 log10cfu/g 
beads for PCR ribotypes 106, 078 and 027.  There was no bead-associated 
C. difficile detected for PCR ribotype 001 in biofilm gut model growth 
medium. 
When C. difficile PCR ribotype 106, 078, 027 and 001 spores were exposed to 
MA beads in BHI broth,  TVC of C. difficile detected within the planktonic 
culture fluid were up to ~2.5 log10cfu/mL greater than spore counts, 
indicating that germination and proliferation had occurred, but the majority 
of the C. difficile population remained as spores.  Bead attachment occurred 
at levels of ~2-5 log10cfu/g and comprised predominantly spores 
(figures 3.3.2.3-3.3.2.4; appendix D3 and D4). 
C. difficile PCR ribotype 001, 106, 078 and 027 spores incubated in saline 
remained quiescent for the duration of the experiment (figures 3.3.2.5-3.3.2.6; 
appendix D5 and D6).  C. difficile spore association with MA beads was 
present at a population of ~3-5 log10cfu/g. 
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Figure 3.3.2.1: Mean populations (±SE) of C. difficile PCR ribotype 027 (210) 
in planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in 
biofilm gut model growth medium. (TVC, total viable counts; limit of 
detection (LOD, ~ 2 log10cfu/g, ~ 1.5 log10cfu/mL). 
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Figure 3.3.2.2: Mean populations (±SE) of C. difficile PCR ribotype 001 (P24) 
in planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in 
biofilm gut model growth medium. (TVC, total viable counts;  
LOD, ~ 2 log10cfu/g, ~ 1.5 log10cfu/mL). 
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Figure 3.3.2.3: Mean populations (±SE) of C. difficile PCR ribotype 027 (210) 
in planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in 
brain heart infusion broth. (TVC, total viable counts; LOD, ~ 2 log10cfu/g,  
~ 1.5 log10cfu/mL). 
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Figure 3.3.2.4: Mean populations (±SE) of C. difficile PCR ribotype 001 (P24) 
in planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in 
brain heart infusion broth. (TVC, total viable counts; LOD, ~ 2 log10cfu/g,  
~ 1.5 log10cfu/mL). 
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Figure 3.3.2.5: Mean populations (±SE) of C. difficile PCR ribotype 027 (210) 
in planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in 
saline. (TVC, total viable counts; LOD, ~ 2 log10cfu/g, ~ 1.5 log10cfu/mL). 
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Figure 3.3.2.6: Mean populations (±SE) of C. difficile PCR ribotype 001 (P24) 
in planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in 
saline. (TVC, total viable counts; LOD, ~ 2 log10cfu/g, ~ 1.5 log10cfu/mL). 
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3.3.3 CTAB Inhibition Assay 
CTAB (0.001%) did not have a deleterious effect on the indigenous gut 
microbiota analysed in this study after exposure for 240 mins (figure 3.3.3.1). 
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Figure 3.3.3.1: Mean (±SE) populations (log10cfu/mL) of members of 
indigenous gut microbiota after 0 (no exposure) and 240 minutes of 
exposure to 0.001% CTAB. 
 
3.3.4 Mucin Degradation Assay 
Faecal emulsion inoculation onto mucin and MA-containing medium B agar 
elicited the formation of a mucinolytic halo around inoculation spots.  The 
asymmetrical shape of the mucinolytic halo made accurate measurement 
difficult; therefore maximum halo sizes were estimated.  Approximate zone 
sizes on mucin-containing agar were larger than on MA-containing agar.  
The heat-inactivated faecal emulsion and all other test strains produced no 
mucinolytic halo on any agar.  When 1% glucose was incorporated into the 
agar, faecal emulsion produced a small, weak mucinolytic halo on 33.3% of 
technical replicates on mucin agar, and 16% of technical replicates on MA 
agar. 
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3.3.5 Adherence Assay 
At early stages of incubation (up to 4 hours), less than 10% of all viable 
bacterial populations were associated with MA beads. 
After 48 hours, Enterococcus spp., C. difficile, Lactobacillus spp. and 
lactose-fermenting Enterobacteriaceae bound readily to MA beads.  Less 
than half (~30-55%) of bacterial populations remained in planktonic form 
(figure 3.3.5.1), indicating that ~45-70% of bacteria were adherent to the 
beads.  However, even at 48 hours there was no increase in the percentage of 
viable Clostridium spp., Bacteroides spp. and Bifidobacterium spp. bound to the 
MA beads. 
Indigenous gut microbiota bound to glass beads less readily than to MA 
beads; only C. difficile and Lactobacillus spp. were bound to glass beads at 
greater than 10% of the population after 48 hours (figure 3.3.5.2). 
 
3.3.6 Biofilm Removal Assay 
C. difficile bound to MA beads more readily than glass beads, with the 
number of vegetative cells recovered from MA beads using CTAB, vortex 
and sonication methods 1.2-, 2.9- and 2.2-log10cfu/g greater than glass beads 
respectively (figures 3.3.6.1 and 3.3.6.2).  The vortex removal method 
provided 11.5-20.1% greater biofilm retrieval for both vegetative cells and 
spores from each bead type.  Sonication provided the second greatest biofilm 
retrieval and CTAB the least.  Spores were not removed from glass beads 
using the sonication method (figure 3.3.6.2).  If the LOD (~1.5 log10cfu/g) for 
this assay is considered then it is evident that C. difficile spore populations 
for other methods are at LOD. 
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Figure 3.3.5.1: Populations of indigenous gut microbiota in planktonic form 
when exposed to mucin alginate beads. 
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Figure 3.3.6.1: Mean populations (log10cfu/g) (±SE) of C. difficile total viable 
counts (TVCs) and spores recovered from glass beads using three different 
biofilm removal techniques.  Dotted line represents the approximate limit of 
detection for this assay. 
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Figure 3.3.6.2: Mean populations (log10cfu/g) (±SE) of C. difficile total viable 
counts (TVCs) and spores recovered from mucin-alginate beads using three 
different biofilm removal techniques.  The dotted line represents the 
approximate limit of detection for this assay. 
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3.4 Discussion 
Whilst the possible sequestration of C. difficile within biofilm structures in 
the human colon has been hypothesised to be associated with recurrent CDI, 
there has been a paucity of research investigating this hypothesis.  Studies 
examining C. difficile pure culture biofilms were recently reported (i.e. since 
the onset of the present PhD studies)355, 454, 455, yet our understanding of the 
existence and behaviour of these biofilms both in vitro and in vivo remains 
elementary. 
In the present study results obtained when growing pure culture C. difficile 
biofilms in microtiter trays were inconsistent, with large variations in 
absorbance values between biological replicates.  Attempts to increase 
consistency by investigating other growth media and substratum materials 
were unsuccessful.  Even though the results presented here demonstrate that 
pure culture C. difficile biofilm biomass is largely inconsistent, positive 
results were obtained.  This study also provides evidence that C. difficile 
adherence within microtiter trays decreases from 24 to 48 hours.  This 
increased incubation time may elicit increased yield of C. difficile cultures, 
although increased adherence was not evident.  This may be due to 
increased levels of sporulation after increased time frames.  C. difficile spores 
may display a reduced ability to adhere to microtiter trays than their 
vegetative counterparts, possibly due to reduced expression of surface 
adhesins. 
The use of microtiter trays to assay the adherence of C. difficile  to inanimate 
surfaces has been carried out by a number of research groups455,355, 454.  
C. difficile pure culture biofilms were measured as moderately adherent 
whilst strains of other Clostridium spp. and anaerobic bacteria were 
measured as strongly adherent in a microtiter tray assay355.  Finegoldia magna 
strain FmBs21 produced a thick, dense biofilm.  When this strain was grown 
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in the presence of C. difficile they formed a homogenous biofilm with a dense 
and thick appearance which appeared visually distinct (visualized using 
scanning electron microscopy)  from that of the F. magna biofilm alone; 
whilst only a thin, sparse biofilm was produced when C. difficile was  grown 
as  a monospecies biofilm.  The authors postulated that either C. difficile 
when grown in close proximity to Finegoldia magna developed the ability to 
form thick, mature biofilms; or that C. difficile can co-exist within a mature 
biofilm produced by another bacterial species. Either theory has strong 
implications for the existence of C. difficile in complex biofilm communities 
within the gastrointestinal tract and provides evidence that C. difficile may 
have the ability to exist within mature biofilms in vivo. 
Dawson et al encountered similar difficulties when growing pure culture 
C. difficile biofilms in microtiter trays (L. Dawson, personal communication).  
Greater success was achieved when growing C. difficile biofilms in larger 
vessel sizes455.  A biofilm can be defined as a consortium of bacteria adherent 
to a substratum material or other bacterial cells and encased in a 
self-produced extracellular matrix.  These results only provide evidence of 
the ability of C. difficile to adhere to inanimate surfaces in vitro, the existence 
of extracellular matrix and a true biofilm mode of growth has not been 
explored in these preliminary experiments. 
Ethapa et al utilised 24-well microtiter plates, describing the 
medium-dependent nature of  C. difficile pure culture biofilm formation, 
with glucose promoting biofilm formation in strain 630, but not R20291454. In 
addition, maximal biofilm formation of strains 630 and R20921 was evident 
after five and one day’s incubation, respectively. 
Whilst the data presented here and from other groups provides strong 
evidence that C. difficile is able to adhere to inanimate surfaces, there is 
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uncertainty as to whether or not a mature biofilm, encased in extra cellular 
material is produced. 
Dawson et al visualised EPS matrix providing a scaffold for 3-day-old pure 
culture C. difficile biofilms455 and Ethapa et al454 utilised multiple staining 
procedures to identify the presence of a complex biofilm matrix comprising 
bacterial proteins, DNA and surface polysaccharides.  However, Donelli et al 
observed a thin, sparse monolayer of adherent C. difficile cells after 48 hour 
incubation, although co-culture of C. difficile with F. magna elicited increased 
levels of EPS production355.  The production of this extracellular material is a 
definitive feature of a biofilm and may be responsible for the unique 
characteristics associated with sessile communities.  However, evidence 
suggests that when C. difficile is grown in the presence of other biofilm 
producers or for increased periods, it can exist within this protected 
environment, and may develop into the sessile mode of growth which 
provides further survival advantages. 
The inanimate surfaces investigated in the microtiter tray experiments are 
not structurally or biologically representative of the human gastrointestinal 
tract.  Therefore, other biofilm models with greater biological significance 
were explored. 
Hog porcine gastric mucin is structurally similar to human epithelial mucin 
therefore this was combined with alginate to provide a framework for the 
beads304, which more accurately reflects the colonic environment.  Four 
clinically important C. difficile strains (001, 106, 078 and 027) were able to 
associate with MA beads in spore and/or vegetative cell forms.  This 
suggests that these C. difficile strains may have adherence factors enabling 
cells to bind to the mucosal surface, the first step necessary for biofilm 
formation.  This experiment was conducted without the use of biological 
repeats therefore data should be interpreted with caution.  Results from the 
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microtiter tray experiments suggested that C. difficile PCR ribotype 001 was 
unable to produce a positive biofilm result after 24 hours although all other 
ribotypes tested did.  These results coupled with the inability of PCR 
ribotype 001 to adhere to MA beads when grown in biofilm human gut 
model media may provide evidence that this ribotype has an inherent 
reduced ability to adhere to surfaces in mono-culture when compared with 
other ribotypes tested in this study. 
The association of C. difficile to mucus ex vivo and in vivo in mice models, and 
to mucosal surfaces in hamsters and human has previously been 
demonstrated120, 121, 495.  However, in vivo, C. difficile spores or vegetative cells 
migrating toward the colonic mucosa will firstly encounter biofilm 
communities, covering the colonic mucus.  Therefore, recruitment of 
C. difficile into these multispecies consortia is vital for their persistence 
within the colon.  Subsequent translocation of C. difficile or their toxins 
through the mucus to the epithelium is a potential pathogenetic pathway. 
The adherence of intestinal microbiota to MA substratum material was 
superior to that of glass beads.  MA-facilitated adherence of Enterococcus spp. 
C. difficile, Lactobacillus spp. and LFE, but not Clostridium spp., 
Bifidobacterium spp. or B. fragilis group.  Adherence of other intestinal 
bacterial species, including clostridia, bacteroides and enterobacteria446, 447, to 
mucin/MA and glass surfaces has also been characterised, although 
Lactobacillus populations were not always detected.  The association of 
bifidobacteria with mucin within continuous culture systems has only been 
reported within nutrient-limited conditions446.   Some of these results 
provide a level of disagreement with results from batch culture experiments 
in this study.  Other researchers utilised a continuous culture system, which 
potentially mediates adherence of distinct bacterial groups from batch 
culture systems due to differences in nutrient availability.  Other groups 
have reported rapid bacterial colonisation of mucus, typically occurring 
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within 15 mins of exposure to bacterial cells496, 497.  However, only minimal 
bacterial association of MA beads described here was evident two hours 
after exposure. 
Despite minimal levels of adherence of gut microbiota to glass beads, 
C. difficile spore adherence to glass beads was demonstrated within the 
biofilm removal experiment (section 3.3.6), although a greater level of 
adherence was observed to MA.  Other groups have also demonstrated the 
adherence of spores to glass and stainless steel surfaces133, 498. 
The adherence assay was designed to compare the adherence of faecal 
bacterial groups to MA and glass beads and also the relative proportion of 
binding of each bacterial group.  However, these results must be interpreted 
with caution, because the control was not monitored throughout the 
duration of the experiment.  Therefore, it is not known whether or not 
bacterial population fluctuations (i.e. cell death or proliferation) occurred 
naturally.  Moreover, settling of planktonic bacteria to the bottom of the 
culture vessel due to gravity may be evident, thus preventing adherence.  It 
is unlikely that the decrease in planktonic bacteria observed in the MA 
experiment is due to cell death, because this was not observed in the 
presence of glass beads to the same degree.  Degradation or utilisation of 
mucin as a carbon source elicit may changes in culture conditions, such as 
increased levels of fermentation products499 and pH, thereby potentially 
promoting cell death within MA, but not glass-exposed populations. 
The main virulence factor of C. difficile is the production of toxins A and B, 
which bind to receptors on the epithelial cells of the gastrointestinal tract.  
The human gastrointestinal tract is covered by a layer of mucus which must 
be translocated in order for pathogenic bacteria (such as C. difficile) and/or 
their toxins in order to access underlying epithelial cells and cause infection. 
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Binding to mucin provides bacteria with an ecological advantage, 
preventing expulsion from the gastrointestinal tract via the peristaltic 
motion of the bowel.  However, certain bacteria are also able to utilise mucin 
as a carbon source when substrate availability is low (such as in the distal 
bowel)500.  Mucins are large complex molecules composed of protein 
backbones and branched oligosaccharides304.  Before they can be assimilated 
by intestinal microorganisms, mucins need to be degraded by glycosidases 
with appropriate specificities for each of the glycoside linkages within the 
oligosaccharide side chains, as well as proteases that act on the protein 
core302.  Prizont and Konigsberg demonstrated that these degradative 
enzymes are bacterial in origin501 and Hoskins and Boulding demonstrated 
that an unidentified sub-population of human faecal bacteria degrade 
oligosaccharide side chains of hog gastric mucin309.  Several bacterial groups 
have been shown to produce these glycoprotein hydrolyses including 
Bifidobacterium bifidum502, Clostridium perfringens503, Clostridium cocleatum504 
and Bacteroides fragilis505, demonstrating their ability to contribute to mucin 
degradation.  Certain bacterial species may be able to degrade the 
oligosaccharide side chains of mucins but not posses the proteases necessary 
fully to degrade the mucin including the core.  This would produce no 
mucinolytic zone.  Bacteria capable of fully degrading hog gastric mucin 
may be able to translocate through human gastrointestinal mucins and gain 
entry to the underlying epithelial cells or allow the passage of other 
potentially pathogenic organisms. 
A mucinolytic zone was visible around a faecal emulsion inoculum when 
grown on a minimal medium agar, with mucin representing the major 
carbon source.  However, heat inactivated faecal emulsion and the 
individual indigenous gut microbiota species tested were unable to produce 
a mucinolytic zone when grown on this agar.  This suggests that the faecal 
microbiota present within the faecal emulsion used in these studies 
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contained an unidentified population of mucin-degrading bacteria, which 
upon autoclaving were inactivated.  These results indicate that faecal 
emulsion contains additional organisms with the ability to degrade mucin, 
or allow the sequential breakdown of distinct regions of the mucin 
glycoproteins.  In order to determine further whether extracellular enzymes 
were responsible for this degradation it would be necessary to include 
filtered faecal emulsion samples into the investigation. 
The mucinolytic zone around a faecal inoculum on MA agar was smaller 
than that on mucin only agar, suggesting that the incorporation of alginate 
may reduce mucin degradation.  The incorporation of glucose into the 
minimal medium was intended to provide an easily utilised nutrient source 
rather than the complex mucin structures506-508.  A small, weak mucinolytic 
zone was produced by 16 - 33% of the faecal emulsions on 
glucose-containing media suggesting that faecal bacteria may utilise a small 
amount of mucus in addition to glucose as a carbon source.  These results 
should perhaps be interpreted with caution due to this unexpected result.  
Whilst this result is unexpected, other results suggest that individual 
bacterial groups are unable to degrade mucin, whilst full mucin degradation 
is possible by complex microbial communities present in the faecal emulsion.  
Stanley et al demonstrated that the degradation of gastric mucin was not 
affected by the presence of glucose in growth medium509. 
C. difficile is known to adhere to mucus121, although the mucin degradation 
properties of this organism have not been evaluated in appropriately 
designed studies.  The mucin degradation experiment presented here 
suggests that C. difficile is unable to degrade mucus.  However, it is possible 
that during antimicrobial therapy the decrease in commensal faecal bacteria 
may allow for a subpopulation of mucin degrading bacterial species to 
thrive and hence increase the degradation of the mucus layer.  In healthy 
adults this subpopulation of bacteria may be maintained at numbers low 
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enough so that the synthesis of mucus by the goblet cells is equal to the 
bacterial degradation and natural shedding of the mucus layer.  If the 
integrity of this layer is reduced by disease this could lead to the passage of 
C. difficile into the epithelial cells.  Kindon et al have presented evidence that 
the presence of colonic mucin glycoproteins at the time of addition of 
C. difficile toxin A to a human colonic cancer-derived T84 cell line 
significantly prevented disruption of the monolayer barrier510.  These results 
suggest that the integrity of the mucosal barrier is important for the 
prevention of CDI. 
CTAB is a cationic surfactant which was used to dissociate bacteria from MA 
beads447.  It alters the surface properties of objects to which bacteria are 
attached, which facilitates the dissociation of bacteria from these objects 
hence it is often used as a biofilm removal chemical.  Salton has published 
data concerning the possible bactericidal properties of CTAB against 
bacteria487 at concentrations of 45 μg/mL (0.0045% w/v).  For biofilm removal 
in this experiment CTAB was used at the lower concentration of 0.001%, 
which was not inhibitory to faecal bacteria.  Comparison of surfactants 
(CTAB), vortexing and sonication for bacterial dissociation from beads 
showed vortexing to be the most efficient and suitable method and was 
therefore used in subsequent studies.  However, only one C. difficile strain 
was utilised in this study, therefore the removal of indigenous gut 
microbiota and other C. difficile strains using different techniques could not 
be determined from this experiment. 
As well as the negligible binding of bacterial populations to glass beads, the 
sampling procedures also proved difficult due to the density of the beads.  
Since the gastrointestinal mucosal layer is composed of mucin, porcine 
gastric mucin offers the most realistic substratum surface and in all 
likelihood, the most accurate results therefore, the use of MA beads will be 
investigated further.  Furthermore, the most effective biofilm removal 
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techniques and an explanation for the degradation of MA beads observed in 
mucin alginate investigational gut model experiments (chapter 5)  allowed 
more informed decisions to be made in subsequent experiments. 
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4.0 Triple Stage Biofilm Analysis 
4.1 Background 
Bacterial growth dynamics within continuous culture systems vary greatly 
from those within batch cultures, with the former more accurately reflecting 
conditions in vivo.  As a result, continuous culture models are becoming 
increasingly utilised.  Macfarlane et al511 developed and validated a triple 
stage chemostat model of the human gut which Baines et al later utilised to 
study the effects of antimicrobial administration on the human gut 
microbiota and C. difficile512.  One of the limitations of the current model is it 
can only be used to monitor the planktonic mode of growth.  Adaptations to 
this model system will be investigated to analyse its potential to study the 
biofilm mode of growth. 
The macroscopic formation of biofilm is consistently observed on the inner 
walls of the original triple stage human gut model vessels270.  The removal of 
this biofilm provides an opportunity to investigate the in vitro biofilm mode 
of growth of the indigenous gut microbiota and C. difficile.  However, 
removal of the biofilm is a destructive process, requiring dismantling of the 
model, therefore sampling could only take place upon the completion of 
each experiment. 
Experimental protocols on the planktonic mode of growth of the original gut 
model were carried out by research staff as a separate study and not 
presented here.  Upon completion of 10 separate gut model experiments 
with distinct experimental designs biofilm was removed and analysed as 
part of this study.  The indigenous gut microbiota, C. difficile vegetative cells, 
spores, cytotoxin and antimicrobial activity were all analysed in each biofilm 
analysis experiment. 
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4.2 Materials and Methodology 
4.2.1 Triple Stage Chemostat Gut Model 
The triple stage gut model consists of three glass fermentation vessels 
(Soham Scientific, Ely, UK) connected in a weir cascade system (figure 4.2.1).  
The working volumes are 280 mL, 300 mL and 300 mL, for 
vessel 1, 2 and 3 respectively.  Vessels were maintained at 37° C via a water 
jacketed system connected to a circulating heated water bath (Grant 
Instruments, Cambridgeshire, UK).  The pH values of the vessels were 
maintained at 5.5 (±0.2), 6.2 (±0.2), 6.8 (±0.2) for vessel 1, 2 and 3, respectively 
and were monitored by pH probes (P200 chemotrode, Hamilton, Reno, NV, 
USA) and controlled by delivering 0.5M NaOH/HCl into the vessels using a 
pH controller unit (Biosolo 3, Brighton Systems, UK).  The anaerobiosis of 
the system was maintained by the continuous sparging of oxygen free 
nitrogen into each vessel.  Vessels were magnetically stirred to allow even 
distribution of constituents.  The system was top fed with a complex growth 
medium (section 4.2.2; Appendix A1) through Tygon E1000 tubing (Fisher) 
at a controlled rate (flow rate; 13.2 mL/h) using a peristaltic pump.  
Excessive foaming was prevented by the addition of 0.5 mL of 10% (w/v) 
polyethylene glycol (Sigma) ad libitum. 
 
4.2.2 Preparation of Gut Model Growth Medium 
The model was top fed with a complex growth medium which was prepared 
in 2L volumes.  The constituents of this medium are listed in Appendix A1.  
Growth medium was prepared in Büchner flasks plugged with a bung 
adapted to incorporate media delivery ports.  Sterilisation of the growth 
media was achieved by autoclaving at 123° C for 15 minutes (Priorclave, 
London, UK) after which resazurin (Sigma; 0.005 g/L) and glucose 
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(Sigma; 0.4 g/L) were filter sterilised into the medium through 0.22 μm 
syringe filters (Millipore Corporation, Billerica, MA, USA). 
 
4.2.3 Preparation of the Gut Model 
Each vessel of the gut model was inoculated with approximately 150 mL of 
pooled faecal emulsion (prepared as described in sections 2.5-2.7).  
Vessel 1 was topped up to approximately 280 mL with growth medium and 
the media pumped started. 
 
4.2.4 Clostridium difficile Strains 
The strain used throughout the biofilm gut model experiments unless 
otherwise stated was the C. difficile PCR ribotype 027 (table 3.0) which was 
isolated during an outbreak of CDI at the Maine Medical Centre, Portland, 
MA, USA. 
 
4.2.5 Planktonic Sampling Protocol and Bacterial Enumeration 
Planktonic culture samples were removed from each vessel of the gut model 
via a sample outlet port which is secured via a glass stopper.  One millilitre 
volumes of planktonic culture fluid were centrifuged (10 mins, 16,000 g), 
supernatants removed and weight of remaining pellet determined.  
Planktonic C. difficile TVC, spores (vessels 1-3), and indigenous gut 
microbiota (vessels 2 and 3 only) populations were enumerated and 
expressed as log10cfu/g as described in sections 2.1 and 2.2.   
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4.2.6 Sessile Sampling Protocol and Bacterial Enumeration 
Once the original human gut model experiment had been completed and no 
further interventions were necessary macroscopic biofilm was scraped from 
the vessel walls and glass ports of each vessel of the gut model using a 
sterile spatula and transferred to a pre-weighed universal tube.  The weight 
of biofilm was determined before re-suspending in pre-reduced sterile saline 
(Sigma) and vortexed for 1 minute.  One millilitre volumes of biofilm culture 
fluid were centrifuged (10 mins, 16,000 g), supernatants removed and pellet 
weight determined.  Sessile indigenous gut microbiota (vessels 2 and 3 only), 
C. difficile TVC and spore populations (vessels 1-3) were enumerated and 
converted to log10cfu/g (as described in sections 2.1 and 2.2). 
 
4.2.7 Detection and Enumeration of Cytotoxin 
One millilitre samples of biofilm and planktonic cultures fluid from each 
vessel of the gut model were centrifuged (15 mins, 16,000 g) and the 
supernatants stored at 4° C for cytotoxin assay (as described in section 2.4). 
 
4.2.8 Detection and Quantification of Antimicrobial Activity 
One millilitre planktonic and sessile samples from each vessel of the gut 
model were centrifuged (15 min, 16,000 g) and the supernatants sterilised by 
filtration through 0.22 µm syringe filters and stored at -20° C.  The 
concentration of active antimicrobial agent was determined by an in-house, 
large plate bioassay.  See table 4.1 for assay specificities. 
Indicator organisms were inoculated onto fresh FBA and incubated 
aerobically (37° C) overnight.  A 0.5 McFarland suspension (~108 cfu/mL) of 
indicator organism was prepared in sterile saline and 1 mL added to 100 mL 
molten (50° C) agar.  Inoculated agars were mixed by inversion, poured 
into 245 mm x 245 mm bioassay plates (Nunc) and allowed to set.  
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Inoculated agars were dried (37° C) for 10 min and 25 wells (each 9 mm 
diameter) removed from the agar using a cork borer.  Twenty microliters of 
target agent calibrator (doubling dilution calibration series) or each 
filter-sterilised sample from the gut model were randomly assigned to 
bioassay wells in triplicate.  Bioassay plates remained at ambient 
temperature for 4 h prior to overnight aerobic incubation at 37° C.  Zone 
diameters were measured using callipers accurate to 0.1 mm.  Calibration 
lines were plotted from squared zone diameters and unknown 
concentrations from culture supernatants determined.  Coefficient of 
variation values were typically 10% and R2 values for calibration lines were 
all ≥0.97. 
Quantification of biofilm-associated antimicrobial activity was determined 
using the assumption that 1 g of biofilm was equal to 1 mL of planktonic 
culture fluid.
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Figure 4.2.1: Triple stage human gut model. 
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Target 
antimicrobial 
agent 
Indicator organism Agar Range of 
concentration 
evaluated 
Clindamycin K. rhizophila Wilkins-Chalgren 
(Sigma) 
4 – 256 mg/L 
Oritavancin S. aureus 
ATCC 29213 
Mueller-Hinton 8 – 256 mg/L 
Vancomycin S. aureus 
ATCC 29213 
Mueller-Hinton 8 – 512 mg/L 
Co-amoxiclav  Assay A: K. rhizophila 
 
Assay B: S. aureus 
Wilkins-Chalgren 
Mueller-Hinton 
0.06 mg/L –
 4 mg/L 
< 4 mg/L 
Drug Z a K. rhizophila Antibiotic 
medium 
number 1 
1 – 256 mg/L 
Fidaxomicin K. rhizophila Wilkins-Chalgren 1 – 64 mg/L 
Metronidazole b C. sporogenes 
(0.5 McFarland in 
Schaedler’s broth)  
Wilkins-Chalgren 1 – 16 mg/L 
 
Table 4.1: Indicator organism and media used for triple stage biofilm 
analysis antimicrobial bioassays. (a a potential CDI therapeutic agent under 
development; b Assay carried out under anaerobic conditions). 
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4.3 Biofilm Analysis 1 
4.3.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
figure 4.3.1.  After the gut model was inoculated with faecal emulsion no 
further interventions were made for 14 days to allow the system to 
equilibrate (period A).  On day 14 an inoculum of approximately 107 cfu 
C. difficile PCR ribotype 027 spores were added to vessel 1 of the gut model 
(period B).  This serves as an internal control period.  After 7 days a further 
inoculum of approximately 107 cfu C. difficile PCR ribotype 027 spores were 
added to vessel 1 of the gut model along with a dosing regimen of 
clindamycin (33.9mg/L QD 7 days – period C).  Both clinical observations513 
and previous use of the gut model 272 have demonstrated the high risk of 
CDI associated with clindamycin therapy.  Clindamycin was instilled to 
achieve levels equivalent to those in bile514.  Biofilm was sampled on day 55. 
Planktonic indigenous gut microbiota (periods A-D, vessels 2 and 3 only), 
C. difficile TVC, spores, cytotoxin (periods B-D, all vessels) and antimicrobial 
activity (periods C-D, all vessels) were monitored during the experiment. 
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Figure 4.3.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 027 (~107cfu); Clinda: clindamycin). 
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4.3.2 Results 
Results presented in this section detail findings from the biofilm analysis 
experiments only.  Results obtained from the planktonic gut model cultures 
(days 0-53) are not shown.  Vessel 3 is of most physiological relevance for 
CDI, therefore only indigenous gut microbiota from this vessel are presented 
in this chapter. 
 
4.3.2.1 Indigenous Gut Microbiota Populations 
Bacterial populations within the human gut model were dominated by 
lactose-fermenting Enterobacteriaceae (LFE) and Lactobacillus spp. for both 
planktonic and sessile communities (figure 4.3.2.1).  All planktonic gut 
bacterial groups identified and enumerated in the gut model were also 
present within the biofilm.  Populations of planktonic bacteria were higher 
than those in sessile form (by ~1-1.5 log10cfu/g) although the relative 
proportions of these planktonic and sessile populations were similar for all 
bacterial groups.  B. fragilis group were the least abundant bacterial group 
present in both planktonic and sessile populations.  Bifidobacterium spp. 
populations were not detected in either the planktonic or sessile form at this 
stage of the experiment. 
 
4.3.2.2 C. difficile Populations 
C. difficile vegetative cells and spores were present in planktonic 
(figure 4.3.2.2) and sessile (figure 4.3.2.3) form in all three vessels of the 
human gut model. 
Planktonic populations of C. difficile TVC (~6.3, 8.5, 8.4 log10cfu/g for 
vessels 1, 2 and 3 respectively) were greater than the biofilm populations 
(~5.2, 6.7, 5.5 log10cfu/g for vessels 1, 2 and 3 respectively) in all three vessels.  
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Planktonic spore populations were greater than sessile populations in 
vessels 2 (~5.7 log10cfu/g planktonic: ~4.0 log10cfu/g sessile) 
and 3 (~ 5.3 log10cfu/g planktonic: ~3.3 log10cfu/g sessile) however, the 
converse was observed in vessel 1 (~4.3 log10cfu/g sessile: ~3.5 log10cfu/g 
planktonic).  Planktonic and sessile TVC were greater than spore 
populations (by ≥ 2 log10cfu/g) in vessel 2 and 3, indicating the presence of 
vegetative cells.  Planktonic TVC in vessel 1 were greater than spore 
populations by ~3 log10cfu/g, whilst corresponding sessile TVC were less 
than 1 log10cfu/g greater than spore populations. 
Cytotoxin was also not detected in vessel 1 of the biofilm whilst it was 
detected in all other vessels within planktonic culture and biofilm. 
 
4.3.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm  
Clindamycin antimicrobial activity could not be demonstrated within the 
planktonic culture or biofilm of the human gut model using large plate 
bioassay. 
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Figure 4.3.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) of 
indigenous gut microbiota populations present in vessel 3 of the human gut 
model. 
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Figure 4.3.2.2: Mean (± SE) planktonic populations (log10cfu/g) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
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Figure 4.3.2.3: Mean (±SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of the 
human gut model. 
 
4.3.3 Discussion 
Before biofilm was removed and analysed, the gut model experiment had 
involved induction of simulated CDI using clindamycin.  Germination and 
proliferation of C. difficile occurred 24 days after antimicrobial cessation with 
subsequent toxin production in all vessels prior to biofilm analysis 
(figure 4.3.1, vessel 3; vessel 1 and 2, data not shown). 
Results from the original gut model demonstrate that all planktonic 
indigenous gut microbiota groups were present during the steady state 
period (period A, data not shown).  Bifidobacterium spp. populations 
declined from ~8 log10cfu/mL at the beginning of the experiment to 
~4 log10cfu/mL at the end (data not shown).  The absence of planktonic and 
sessile Bifidobacterium spp. on day 55 (figure 4.3.2.1), suggests that this 
bacterial group may have continued to decline to below the LOD.  This 
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profound reduction in Bifidobacterium spp. populations following 
clindamycin instillation has been previously observed in gut model 
experiments272, 512, 515. 
All indigenous gut microbiota populations present within the planktonic 
mode of growth on day 55 were also present in the sessile mode of growth, 
indicating that gut model-associated biofilm structures are able to support 
populations of all bacterial groups enumerated in this study.  Populations of 
sessile bacteria were comparative to their planktonic counterparts, with no 
obvious differences in their levels or composition.  This study does not 
provide evidence on the composition of these biofilm structures during the 
early stages of biofilm formation.  It remains unknown which bacterial 
groups provided initial colonisation of the abiotic surface within the gut 
model, and the relative contributions and time scales with which subsequent 
maturation of the biofilm occurred.  The in vitro adherence of several 
intestinal bacterial species have previously been characterised446, 447 and 
demonstrate similar results to this study, although sessile lactobacillus 
populations were not always detected.  The detection of sessile Lactobacillus 
populations in this study is therefore uncommon.  The in vitro chemostat 
models used to monitor the sessile mode of growth to date were utilised for 
a shorter duration than this study.  Increased biofilm maturity and 
complexity, facilitated by an increased time frame, may provide additional 
resources and conditions necessary for the recruitment of Lactobacillus 
populations into biofilms in vitro. 
In order to compare planktonic and sessile populations from a single time 
point, populations from both modes of growth were expressed as log10cfu/g.  
In general, planktonic indigenous gut microbiota populations were higher 
than their sessile counterparts.  The weight of the pellet from a 1 mL 
suspension of planktonic culture fluid or re-suspended biofilm is used to 
determine the cfu per gram of biomass.  Planktonic cultures are likely to 
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contain a high proportion of bacteria within this biomass whilst the biofilm 
comprises a large amount of extracellular material in addition to the 
bacterial mass.  In general, it is estimated that bacteria account for ≤ 10% of 
the dry mass of a biofilm, where as the matrix accounts for ≥90 %378.  This 
may explain the apparently more numerous planktonic populations 
compared with  sessile populations.  Furthermore, Macfarlane et al have also 
reported increased planktonic populations compared with sessile 
populations446.  Although Probert and Gibson reported higher populations 
within the culture fluid from a biofilm fermenter compared with that of a 
conventional planktonic chemostat447. 
Germination, proliferation and toxin production of planktonic C. difficile 
within the original gut model occurred in all vessels and this remained 
evident within the planktonic culture at the time of biofilm analysis (day 55).  
Vegetative and spore forms of C. difficile were observed within biofilm 
structures analysed here, although their presence and populations differ 
within distinct regions of the model.  Only C. difficile spores were present 
within biofilms structures in vessel 1, whilst C. difficile spores and vegetative 
cells were present within biofilm structures in vessels 2 and 3.  Toxin was 
detected in biofilm in vessels 2 and 3 only. 
Biofilm formation is dependent on environmental conditions such 
incubation time, temperature and growth medium454, 516, 517.  Biofilm 
structures within different vessels of the human gut model form under a 
unique set of conditions, differing most notably in nutrient availability and 
pH.  Biofilm biomass of vessel 1 is greater than vessels 2 and 3 (data not 
shown), correlating with the increased nutrient availability in vessel 1.  
Increased in vitro Bacillus cereus biofilm formation by certain strains in 
nutrient-rich conditions has been previously demonstrated518.  The dense 
biofilm present in vessel 1 may potentially harbour a greater total bacterial 
population and possess distinct properties from the biofilm in 
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vessels 2 and 3.  Quorum sensing, a bacterial cell-density dependant process 
is known to regulate transcription of cellular process such as sporulation and 
virulence factors391, 394, 519.  The increased bacteria cell density within 
vessel 1 may potentially activate quorum sensing pathways otherwise 
redundant in vessel 2 and 3, thus accounting for the heterogeneity of biofilm 
composition within the gut model. 
C. difficile vegetative cells were absent from the biofilm of vessel 1, despite 
their presence within the planktonic culture fluid.  Sessile C. difficile 
vegetative cells and spores were detected within biofilm structures in other 
vessels, demonstrating the capacity of C. difficile to exist within biofilm 
structures in either form.  Therefore, the absence of C. difficile vegetative cells 
within vessel 1 may not due to the inability of vegetative cells to associate 
with biofilms.  In other spore-forming bacteria both vegetative and spores 
have previously been observed in sessile communities518, 520. 
Cytotoxin was detected within the planktonic fluid of vessel 1 but absent 
from the biofilms in this vessel correlating with an absence of vegetative cells 
and suggesting that toxin sequestration is not in occurrence.  Within 
vessels 2 and 3 it is unclear whether toxin detection was due to production 
by vegetative cells, or sequestration from planktonic fluid.  The observation 
that sequestration was not apparent in vessel 1 suggests that the toxin in 
vessels 2 and 3 was actively produced by sessile vegetative cells. 
Clindamycin was not detected within the planktonic culture or biofilm of 
any vessel.  The absence of clindamycin within the planktonic culture is 
common within the original gut model, with clindamycin concentrations 
often declining to below the limits of detection approximately 4 days after 
the cessation of antimicrobial instillation 515.  The possible persistence of 
antimicrobial agents within biofilm structures in the model remained 
unexplored within the original model. 
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4.4 Biofilm Analysis 2 
4.4.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
figure 4.4.1.  Briefly, after inoculation with faecal emulsion, gut microbiota 
populations were allowed to equilibrate for 14 days (period A), before a 
single inoculum of C. difficile spores were added to vessel 1 of the model on 
day 14.  A second inoculum of C. difficile spores were inoculated into the 
model on day 21.  At this point a dosing regimen of clindamycin (33.9 mg/L, 
QD, 7 days) commenced (period C).  Following commencement of 
clindamycin dosing no further intervention were made until C. difficile 
germination, proliferation and high toxin production was observed 
(period D).  Instillation of oritavancin (64 mg/L, BD, 4 days) commenced on 
day 49.  Following cessation of therapeutic instillation the model was left 
without intervention for 21 days (period F).  Biofilm was sampled on day 74. 
Planktonic indigenous gut microbiota (periods A-F, vessels 2 and 3), 
C. difficile TVC, spores, cytotoxin (periods B-F, all vessels) and antimicrobial 
activity (periods C-F, all vessels) were monitored during the experiment. 
- 124 - 
0
50
100
150
200
250
300
0
2
4
6
8
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70
C
on
ce
nt
ra
tio
n 
(m
g/
L)
lo
g 1
0c
fu
/m
L 
(R
U
)
Time (Days)
TVC Spores Toxin [clinda] [orita]
Period A: Steady state Period B: 
Control
Period C:
Clinda 
33.9mg/L 
QD 7 days
Period D:
CDI
Period 
E:
Orita 
64 mg/L 
BD  4 
days
Period F: Recovery
CDI induction
Treat
-ment
CD spores CD spores Biofilm analysis
(day 74)
 
Figure 4.4.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling515. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 027 (~107cfu); Clinda: clindamycin; Orita: 
oritavancin). 
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4.4.2 Results 
4.4.2.1 Indigenous Gut Microbiota Populations 
Bacterial populations within the human gut model were dominated by LFE 
and Lactobacillus spp. for both planktonic and sessile (figure 4.4.2.1) 
communities.  All planktonic gut bacterial groups identified and enumerated 
in the original gut model were also present within the biofilm.  Populations 
of planktonic bacteria were generally higher than those in sessile form with 
the exception of B. fragilis group, although the relative proportions of these 
planktonic and sessile populations were similar for all bacterial groups.  
Enterococcus spp. were the least abundant bacterial group present in both 
planktonic and sessile populations.  Bifidobacterium spp. populations were 
not detected in either form at this stage of the experiment. 
 
4.4.2.2 C. difficile Populations 
C. difficile populations were present in planktonic and biofilm form in all 
three vessels of the human gut model (figures 4.4.2.2 and 4.4.2.3) and TVCs 
decreased progressively in number from vessel 1 (~5.5 log10cfu/g planktonic: 
~6.8 log10cfu/g sessile) to vessel 3 (~3.3 log10cfu/g planktonic:  ~4.6 log10cfu/g 
sessile).  Sessile populations of vegetative cells (~4.6-6.8 log10cfu/g) were 
greater than their corresponding planktonic populations (~2.0-4.3 log10cfu/g) 
in all three vessels.  Spores were absent from most vessels of the human gut 
model in either planktonic or sessile form, indicating that C. difficile 
populations are comprised mainly (in vessel 1 planktonic) or completely (all 
other vessels) of vegetative cells. 
Low levels of cytotoxin was detected in vessel 1 only from the planktonic 
cultures fluid but was present in the biofilm of all 3 vessels. 
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4.4.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm 
Antimicrobial activity was detected within the biofilm of 
vessels 2 (57.4 mg/L) and 3 (36.7 mg/L) and within the planktonic cultures 
fluid within vessel 3 (7.9 mg/L). 
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Figure 4.4.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) of 
indigenous of indigenous gut microbiota populations present in vessel 3 of 
the human gut model. 
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Figure 4.4.2.2: Mean (± SE) planktonic populations (log10cfu/g) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
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Figure 4.4.2.3: Mean (±SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of the 
human gut model. 
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4.4.3 Discussion 
Before biofilm was removed and analysed, the gut model experiment had 
involved induction of simulated CDI using clindamycin.  Germination and 
proliferation of C. difficile occurred after 6-7 days with subsequent toxin 
production in all vessels (figure 4.4.1, vessel 3; vessel 1 and 2, data not 
shown).  Treatment of simulated CDI commenced with the instillation of 
oritavancin.  Treatment was initially successful with the rapid decrease in 
C. difficile vegetative cells and toxin to below the LOD (figure 4.4.1).  
However, low levels of vegetative cells and toxin (recurrence) were detected 
in all vessels before the completion of the experiment.  Spores remained 
undetected from the commencement of oritavancin dosing. 
Results from the original gut model demonstrated that all indigenous gut 
microbiota groups were present during periods A and B, but following  
clindamycin instillation, Bifidobacterium spp. declined to below LOD and  
remained there for the duration of the experiment, as previously observed 
within the gut model512.  This explains the absence of Bifidobacterium spp. in 
planktonic and sessile form at the time of biofilm analysis (day 74). 
Upon biofilm sampling (day 74), all bacterial groups present within the 
planktonic fluid were also present within the biofilm.  Again, planktonic 
bacterial populations were generally higher than their sessile counterparts 
when expressed as log10cfu/g. 
On day 74, planktonic C. difficile populations were present in vegetative and 
spore form, and low level toxin was detected.  In vessels 2 and 3 only 
vegetative cells were detected and toxin was below LOD.  Within the biofilm 
structures, C. difficile was only present in vegetative form in all vessels and 
toxin was detected in all vessels. 
The reasons why toxin was present within the biofilm of vessels 2 and 3, but 
not in planktonic culture fluid, remains unclear.  During the original gut 
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model experiment toxin was detected within vessels 2 (0.5 RU, data not 
shown) and 3 (1 RU, figure 4.4.1) until the end of the experiment therefore its 
absence from the planktonic state of the biofilm analysis work is unexpected.  
Levels of toxin from the original model were very low and may have 
dropped below the limit of detection during biofilm analysis.  This could be 
due to degradation, or dilution of toxin out of the model.  The dilution of 
vessel contents in the planktonic phase may therefore confer a more timely 
removal of toxin compared with removal from biofilm structures. 
Clindamycin activity was absent from all vessels of the original gut model 
experiment 5 days after cessation of dosing whilst oritavancin activity 
persisted within vessel 3 for the remainder of the experiment (figure 4.4.1).  
Biofilm analysis on day 74 showed that antimicrobial activity remained in 
vessel 3 in the planktonic culture at a level of 7.9 mg/L.  Antimicrobial 
activity was also detected within the biofilm of 
vessels 2 and 3 (57.4 and 36.7 mg/L respectively).  At the time of biofilm 
removal and analysis instillation of more than one antimicrobial agent had 
occurred.  The bioassay used in this study can not accurately distinguish 
between different antimicrobial agents.  However, during the original gut 
model experiment antimicrobial activity is monitored daily therefore 
identification of antimicrobial agent responsible for inhibition is possible.  
Oritavancin persisted within the original gut model whilst clindamycin 
activity was absent 5 days post instillation.  It is therefore likely that any 
antimicrobial activity detected during biofilm analysis work was oritavancin. 
Oritavancin is a semi-synthetic lipoglycopeptide analogue of vancomycin 
currently under investigation for CDI treatment272, 515, 521.  Oritavancin 
displays multiple unknown mechanisms of action in addition to the 
inhibition of peptidoglycan synthesis.  The anti-spore activity of oritavancin 
has been investigated.  The apparent adherence of this agent to the surface of 
spores has previously been observed522, potentially allowing rapid exertion 
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of an anti-C. difficile activity once spores break dormancy.  It is speculated 
that the highly positive charge of oritavancin confers its ability to adhere to 
surfaces, potentially providing an increased affinity for components of the 
biofilm matrix.  The subsequent dispersal of biofilm aggregates may confer 
entry of sequestered oritavancin into the planktonic fluid, possibly 
explaining the prolonged detection of oritavancin within the planktonic 
culture fluid and biofilm structures.  In addition, the highly adherent nature 
and apparent anti-spore activity of this agent may explain the absence of 
detectable spores within the biofilm. 
Oritavancin displays rapid bactericidal activity against exponentially 
growing Gram-positive bacteria523.  Furthermore, it has also demonstrated 
concentration-dependant bactericidal activity against stationary phase and 
biofilm cultures of MRSA524.  Whether or not oritavancin exerts this 
bactericidal activity against C. difficile vegetative cells within complex 
biofilm communities remains unknown.  The persistence of oritavancin with 
biofilm structures potentially provides a reservoir of antimicrobial activity, 
which may act upon any residual C. difficile, thus preventing recurrent 
infection. 
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4.5 Biofilm Analysis 3 
4.5.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
figure 4.5.1.  Briefly, after inoculation with faecal emulsion, gut microbiota 
populations were allowed to equilibrate for 14 days (period A), before a 
single inoculum of C. difficile spores were added to vessel 1 of the model on 
day 14.  A second inoculum of C. difficile spores were inoculated into the 
model on day 21.  At this point a dosing regimen of clindamycin (33.9 mg/L, 
QD, 7 days) commenced (period C).  Following commencement of 
clindamycin dosing no further intervention were made until C. difficile 
germination, proliferation and high toxin production was observed 
(period D).  Instillation of vancomycin (125 mg/L, QD, 4 days) commenced 
on day 49.  Following cessation of therapeutic instillation the model was left 
without intervention for 21 days (period F).  Biofilm was sampled on day 74. 
Planktonic indigenous gut microbiota (periods A-F), C. difficile TVC, spores, 
cytotoxin (periods B-F) and antimicrobial activity (periods C-F) were 
monitored during the experiment. 
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Figure 4.5.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 027 (~107cfu); Clinda: clindamycin; vanc: 
vancomycin). 
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4.5.2 Results 
4.5.2.1 Indigenous Gut Microbiota Populations 
On day 74, populations of planktonic and sessile indigenous gut microbiota 
within the human gut model were dominated by facultative anaerobic 
species such as LFE and Lactobacillus spp. (figure 4.5.2.1).  All planktonic gut 
bacterial groups identified and enumerated in the original gut model were 
also present within the biofilm.  Clostridium spp. planktonic and sessile 
communities were the least abundant bacterial group.  Planktonic 
populations were greater than corresponding sessile populations (~1 –
 2 log10cfu/g).  Bifidobacterium spp. populations were not detected in either 
the planktonic or sessile form at this stage of the experiment. 
 
4.5.2.2 C. difficile Populations 
Sessile C. difficile vegetative cells and spores (figure 4.5.2.3) were present in 
all three vessels of the human gut model.  Planktonic C. difficile populations 
were present as spores in vessels 1 and 3 (figure 4.5.2.2) but absent in either 
form in vessel 2.  Vegetative cells were absent from all vessels in planktonic 
or sessile form.  Sessile C. difficile populations (~4.3, 4.1, 3.5 log10cfu/g in 
vessel 1, 2, 3 respectively) of were greater than the planktonic populations 
(~3.5, below LOD, 3.4 log10cfu/mL in vessels 1, 2, 3 respectively) in all three 
vessels (figure 4.5.2.3).  Cytotoxin was present in low levels in the planktonic 
fluid of vessels 2 and 3 but absent from vessel 1 biofilm.  Toxin was not 
detected in biofilm from any vessel. 
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4.5.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm 
Antimicrobial activity could not be demonstrated within the planktonic 
culture or biofilm of the human gut model using large plate in house 
bioassay. 
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Figure 4.5.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) of 
indigenous of indigenous gut microbiota populations present in vessel 3 of 
the human gut model. 
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Figure 4.5.2.2: Mean (± SE) planktonic populations (log10cfu/g) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
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Figure 4.5.2.3: Mean (±SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of the 
human gut model. 
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4.5.3 Discussion 
Before biofilm was removed and analysed, the gut model experiment had 
involved induction of simulated CDI using clindamycin.  C. difficile 
germination and proliferation occurred 10 days after cessation of 
antimicrobial instillation with subsequent toxin production in vessels 2 (data 
not shown) and 3 (figure 4.5.1).  Treatment of simulated CDI commenced 
with the instillation of vancomycin.  Treatment was successful with only 
spores detected at the LOD at the completion of the experiment with no 
further vegetative cell or toxin detection. 
On day 74, the indigenous microbiota populations present within the 
planktonic form were also present within the biofilm with the exception of 
Bifidobacterium spp. which were absent in both forms due to the 
antimicrobial interventions carried out in the original model experiment 
(data not shown). 
On day 74, planktonic C. difficile populations were in spore form within 
vessels 1 and 3 (no C. difficile present in vessel 2).  Low levels of toxin were 
detected in vessels 2 and 3.  Within biofilm structures C. difficile was present 
in spore form in all vessels, and toxin was not detected.  Biofilm analysis 
experiment 1 demonstrates that toxin is able to exist within a biofilm.  The 
absence of toxin persistence here, despite previous toxin detection within the 
planktonic fluid of the original model demonstrates that long term 
biofilm-associated toxin persistence is not always evident. 
Simulated CDI treatment within the original model was successful and only 
spores were detected at the cessation of the experiment (figure 4.5.1).  In 
addition, during sampling of the original gut model toxin was not detected 
(figure 4.5.1).  Upon biofilm removal and analysis vegetative cell growth was 
not detected in planktonic or sessile form (figures 4.5.2.2-3).  Therefore, the 
low levels of toxin detected within the planktonic culture during biofilm 
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analysis (figure 4.5.2.2) are unexpected and the reasons for this presence 
remain unclear. 
The absence of spores from the planktonic culture of vessel 2 but presence 
within the biofilm of this vessel provides further evidence of the persistence 
of C. difficile spores within the protected environment of the biofilm.  
See 4.13 for further discussion. 
No antimicrobial activity was detected within the planktonic culture fluid or 
biofilm.  Within previous original human gut model experiments, 
vancomycin 515, 525 (along with clindamycin) activity was diluted out of the 
culture fluid before completion of the experiment; therefore, the absence of 
this agent within the planktonic culture fluid is expected.  Vancomycin and 
clindamycin persistence within biofilm structures was not apparent in this 
experiment. 
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4.6 Biofilm Analysis 4 
4.6.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
figure 4.6.1.  Briefly, after the gut model was inoculated with faecal slurry, 
no further interventions were made for 26 days to allow the system to 
equilibrate (period A).  On day 26 an inoculum of approximately 107 cfu 
C. difficile 027 spores were added to vessel 1 of the gut model (period B).  
This serves as an internal control period. After 7 days a further inoculum of 
approximately 107 cfu C. difficile 027 spores were added to vessel 1 of the gut 
model along with a dosing regimen of co-amoxiclav 
(8 mg/L, 6 hourly, 7 days – period C).  Following cessation of co-amoxiclav 
instillation the model was left without intervention for 22 days (period C).  
Biofilm was sampled on day 62. 
Planktonic indigenous gut microbiota (periods A-D), C. difficile TVC, spores, 
cytotoxin (periods B-D) and antimicrobial activity (periods C-D) were 
monitored during the experiment. 
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Figure 4.6.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling473. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 027 (~107cfu); Amox: Amoxiclav). 
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4.6.2 Results 
4.6.2.1 Indigenous Gut Microbiota Populations 
On day 62, indigenous gut microbiota populations present within planktonic 
and sessile form within the gut model were dominated by B. fragilis group 
and Clostridium spp. (figure 4.6.2.1).  All planktonic gut bacterial groups 
identified and enumerated in the original gut model (data not shown) were 
also present within the biofilm.  Planktonic populations were greater than 
sessile populations for the anaerobic populations although sessile 
populations were greater for the facultative aerobes (facultative anaerobes, 
LFE, Enterococcus spp.).  Bifidobacterium spp. were recovered in the biofilm 
although no result was obtained for the planktonic populations. 
 
4.6.2.2 C. difficile Populations 
C. difficile vegetative cells and spores were present in planktonic 
(figure 4.6.2.2) and sessile (figure 4.6.2.3) form in all three vessels of the 
human gut model. 
Planktonic C. difficile TVCs were marginally greater in vessels 2 and 3 
compared with their sessile counterparts, although TVCs of sessile C. difficile 
were greater than their planktonic counterparts in vessel 1 (~5.3 log10cfu/mL 
planktonic: ~7.2 log10cfu/mL sessile). 
Vegetative cells were more populous in planktonic rather than sessile form 
in vessels 2 (~3.7 and 2.4 log10cfu/g for planktonic and sessile populations, 
respectively) and 3 (~2.7 and 1.3 log10cfu/g for planktonic and sessile 
populations, respectively) with the converse true in vessel 1 (~ 1 and 
1.9 log10cfu/g for planktonic and sessile populations, respectively).  
Cytotoxin was detected in all 3 vessels in the planktonic culture and within 
the biofilm. 
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4.6.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm 
Antimicrobial activity could not be demonstrated within the planktonic 
culture or biofilm of the human gut model using large plate in house 
bioassay. 
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Figure 4.6.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) of 
indigenous gut microbiota populations present in vessel 3 of the human gut 
model (NR- no result). 
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Figure 4.6.2.2: Mean (± SE) planktonic populations (log10cfu/mL) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
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Figure 4.6.2.3: Mean (± SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of the 
human gut model. 
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4.6.3 Discussion 
Before biofilm was removed and analysed, the gut model experiment had 
involved induction of simulated CDI using co-amoxiclav.  C. difficile 
germination, proliferation and toxin production occurred in all three vessels.  
Toxin remained present in all three vessels until the end of the experiment.  
Vegetative cells and spores were detected within vessel 2 and 3 whilst only 
spores were present within vessel 1 (data not shown). 
All indigenous gut microbiota bacterial groups present in the planktonic 
form were also present in sessile form.  No result was obtained for the 
planktonic Bifidobacterium spp. populations during the biofilm analysis 
experiment; however results from the original gut model indicate that this 
bacterial group was present up until the completion of the experiment.  It is 
therefore likely that populations will have also been present at the time of 
the biofilm analysis experiment but the absence may be due to experimental 
error, such as poor agar quality. 
Within the planktonic culture fluid on day 62, C. difficile populations and 
toxin remained as described above (observations from the original 
experiment).  Within the biofilm C. difficile existed in both vegetative and 
spore form, and toxin was detected in all vessels.  The proportions of spores 
were higher in vessels 2 and 3 when compared with the planktonic form 
although the converse was true for vessel 1. 
No antimicrobial activity was detected within the planktonic culture fluid or 
biofilm indicating that sequestration of co-amoxiclav into biofilm structures 
is not apparent. 
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4.7 Biofilm Analysis 5 
4.7.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
figure 44.7.1.  Briefly, after inoculation with faecal emulsion, gut microbiota 
populations were allowed to equilibrate for 26 days (period A), before a 
single inoculum of C. difficile spores were added to vessel 1 of the model on 
day 26.  A second inoculum of C. difficile spores were inoculated into the 
model on day 33.  At this point a dosing regimen of clindamycin (33.9 mg/L, 
QD, 7 days) commenced (period C).  Following commencement of 
clindamycin dosing no further intervention were made until C. difficile 
germination, proliferation and high toxin production was observed 
(period D).  Instillation of vancomycin (125 mg/L, QD, 4 days) commenced 
on day 70 (period E).  Following cessation of therapeutic instillation the 
model was left without intervention for 24 days (period F).  Biofilm was 
sampled on day 97. 
Planktonic indigenous gut microbiota (periods A-F), C. difficile TVC, spores, 
cytotoxin (periods B-F) and antimicrobial activity (periods C-F) were 
monitored during the experiment. 
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Figure 4.7.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling515. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 027 (~107cfu); Vanc: vancomycin). 
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4.7.2 Results 
4.7.2.1 Indigenous Gut Microbiota Populations 
On day 97, indigenous gut microbiota populations present within planktonic 
form were also recovered at similar levels from the biofilm, and were 
dominated by B. fragilis group, Lactobacillus spp. and LFE (figure 4.7.2.1).  
Planktonic populations were greater than sessile populations for all groups 
identified (by ~0.5 – 1 log10cfu/g). Bifidobacterium spp. were present in both 
the planktonic and sessile form. 
 
4.7.2.2 C. difficile Populations 
C. difficile vegetative cells and spores were present in planktonic 
(figure 4.7.2.2) and sessile (figure 4.7.2.3) form in all three vessels of the 
human gut model.  Planktonic C. difficile populations were generally greater 
than the sessile form (by ~1–2.5 log10cfu/g).  Planktonic vegetative cell 
populations were 1. -2.5 log10cfu/g with spore populations of 
~5.5-5.9 log10cfu/g in all vessels.  Sessile C. difficile spore populations were 
~5 log10cfu/g in all three vessels, with vegetative populations of 
~2.2 log10cfu/g vessels 1 and ~0.7 log10cfu/g in vessel 2.  Cytotoxin was 
detected in all vessels within the planktonic culture and biofilm with the 
exception of the biofilm in vessel 1. 
 
4.7.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm 
Antimicrobial activity from the experiment designed to detect clindamycin 
activity was detected in within the biofilm of vessel 2 (9.9 mg/L) 
and 3 (10.0 mg/L).  Antimicrobial activity from the experiment designed to 
detect vancomycin activity was present within the biofilm at concentrations 
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of 70 mg/L and 67.7 mg/L in vessel 2 and 3 respectively.  No antimicrobial 
activity was detected in the planktonic culture fluid from any vessel. 
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Figure 4.7.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) of 
indigenous of indigenous gut microbiota populations present in vessel 3 of 
the human gut model (NR- no result). 
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Figure 4.7.2.2:  Mean (± SE) planktonic populations (log10cfu/g) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
0
1
2
3
4
5
6
7
8
9
1 2 3
lo
g
1
0
c
fu
/g
 (
R
U
)
Vessel
TVC
Spores
Toxin
 
Figure 4.7.2.3: Mean (±SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of the 
human gut model. 
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4.7.3 Discussion 
The original gut model experimental design for this experiment involved 
clindamycin-induced simulated CDI followed by a treatment regimen of a 
short course of vancomycin.  Initial treatment appeared successful; however, 
in the final 3-6 days of the experiment recurrent CDI occurred with 
increasing levels of C. difficile germination, proliferation and toxin 
production in all vessels. 
Populations of indigenous gut microbiota present in planktonic form on 
day 97 were also present in sessile form.  No results were obtained for sessile 
total anaerobe and clostridial bacterial groups due to media contamination. 
Planktonic C. difficile results from the biofilm analysis experiment reported 
C. difficile vegetative cells, spores and cytotoxin in all vessels. C. difficile 
populations within biofilms demonstrated the presence of vegetative cells 
and spores in vessel 1 although toxin was not detected.  Within 
vessels 2 and 3, C. difficile was only present as spores, and toxin was 
detected. 
Antimicrobial activity was detected within the biofilm of 
vessel 2 and 3 despite its absence in the planktonic culture fluid.  
Clindamycin and vancomycin were the antimicrobial agents used in the 
original gut model experiment and the assays designed for the detection of 
each antimicrobial agent provided positive results.  It is therefore difficult to 
delineate which antimicrobial agent has been detected within the biofilm.  
Vancomycin is the most likely due to its more recent administration into the 
original gut model, although neither agent utilised previously in the model 
and subsequent biofilm analysis experiments has provided positive activity 
within the biofilm. 
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4.8 Biofilm Analysis 6 
4.8.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
figure 4.8.1.  Briefly, after inoculation with faecal emulsion, gut microbiota 
populations were allowed to equilibrate for 27 days (period A), before a 
single inoculum of C. difficile PCR ribotype 001 spores (table 3.1) were added 
to vessel 1 of the model on day 27.  A second inoculum of C. difficile spores 
were inoculated into the model on day 34.  At this point a dosing regimen of 
clindamycin (33.9 mg/L, QD, 7 days) commenced (period C).  Following 
commencement of clindamycin dosing no further intervention were made 
until C. difficile germination, proliferation and high toxin production was 
observed (period D).  A novel CDI therapeutic drug was used in this 
experiment.  Data have not yet been published and are confidential; 
therefore, this agent is referred to here as drug Z.  Instillation of drug Z 
(250 mg/L, BD, 7 days) commenced on day 52 (period E).  Following 
cessation of therapeutic instillation the model was left without intervention 
for 20 days (period F).  Biofilm was sampled on day 79.  Planktonic 
indigenous gut microbiota (periods A-F), C. difficile TVC, spores, cytotoxin 
(periods B-F) and antimicrobial activity (periods C-F) were monitored 
during the experiment. 
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Figure 4.8.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 001 (~107cfu); Clinda: clindamycin). 
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4.8.2 Results 
4.8.2.1 Indigenous Gut Microbiota Populations 
On day 79, Bifidobacterium spp. populations were the dominant bacterial 
group identified and enumerated in the human gut model and planktonic 
populations were up to ~2 log10cfu/g greater than sessile populations 
(figure 4.8.2.1).  All bacterial groups identified and enumerated from this 
model were present in both planktonic and sessile form and the relative 
populations of each bacterial group were similar.  Planktonic populations 
were slightly greater for most bacterial groups other than LFE and 
Enterococcus spp., which presented greater sessile populations compared 
with the planktonic populations. 
 
4.8.2.2 C. difficile Populations 
C. difficile vegetative cells and spores were present in planktonic 
(figure 4.8.2.2) and sessile (figure 4.8.2.3) form in all three vessels of the 
human gut model; the exception was the absence of planktonic spores in 
vessel 1.  TVCs of planktonic C. difficile were ~1 log10cfu/g greater than sessile 
TVCs in vessels 2 and 3.  Sessile TVCs were ~1 log10cfu/g greater than 
planktonic TVCs.  Planktonic C. difficile populations comprised solely 
vegetative cells (~6.2 log10cfu/g) in vessel 1 whilst sessile communities 
displayed spore and vegetative populations of ~5.5 log10cfu/g and 
~2.0 log10cfu/g, respectively.  Cytotoxin was detected in all vessels within the 
planktonic culture and biofilm. 
 
4.8.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm 
No active antimicrobial activity was detected within the gut model at this 
stage of the experiment. 
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Figure 4.8.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) of 
indigenous of indigenous gut microbiota populations present in vessel 3 of 
the human gut model. 
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Figure 4.8.2.2:  Mean (± SE) planktonic populations (log10cfu/g) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
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Figure 4.8.2.3: Mean (±SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessels 1, 2 and 3 of the 
human gut model. 
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4.8.3 Discussion 
The original gut model experimental design prior to biofilm analysis 
involved clindamycin induced CDI (PCR ribotype 001 strain) followed by a 
treatment dosing regimen of drug Z.  Treatment was initially successful 
although recurrence of simulated CDI was evident before the end of the 
experiment with C. difficile germination and proliferation in all vessels and 
toxin production in vessels 2 (data no shown) and 3 (figure 4.8.1). 
Planktonic indigenous microbiota populations were also present in sessile 
form, and antimicrobial activity was absent from the planktonic culture fluid 
and biofilm in all vessels.  Results from the biofilm analysis experiment 
shows that planktonic C. difficile comprised vegetative cells and spores 
(vegetative cells only vessel 1), and that toxin was present in all vessels.  In 
the biofilm, vegetative cells, spores and toxin were present in all vessels.  
The proportion of sessile spores was greater than the planktonic form.  This 
has previously been observed in biofilm analysis 1 and 4 and discussed 
in 4.13. 
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4.9 Biofilm Analysis 7 
4.9.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
figure 4.9.1.  Briefly, after inoculation with faecal emulsion, gut microbiota 
populations were allowed to equilibrate for 10 days (period A), before a 
single inoculum of C. difficile PCR ribotype 027 spores (table 3.1) were added 
to vessel 1 of the model on day 10.  A second inoculum of C. difficile 
PCR ribotype 027 spores were inoculated into the model on day 17.  At this 
point a dosing regimen of clindamycin (33.9 mg/L, QD, 7 days) commenced 
(period C).  Following commencement of clindamycin dosing, no further 
interventions were made until C. difficile germination, proliferation and high 
toxin production was observed (period D).  Instillation of drug Z (250 mg/L, 
BD, 7 days) commenced on day 33 (period E).  Following cessation of 
therapeutic instillation, the model was left without intervention for 20 days 
(period F).  Biofilm was sampled on day 60.  Planktonic indigenous gut 
microbiota (periods A-F), C. difficile TVC, spores, cytotoxin (periods B-F) and 
antimicrobial activity (periods C-F) were monitored during the experiment. 
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Figure 4.9.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 027 (~107cfu); Clinda: clindamycin). 
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4.9.2 Results 
4.9.2.1 Indigenous Gut Microbiota Populations 
On day 60, all planktonic gut bacterial groups identified and enumerated in 
the original gut model were also present within the biofilm (figure 4.9.2.1).  
Populations of anaerobic bacterial populations such as Clostridium spp., 
Bifidobacterium spp., and B. fragilis group were the most prevalent bacterial 
groups.  All bacterial species which are enumerated aerobically (facultative 
anaerobes, LFE, Enterococcus spp.) displayed greater sessile populations 
compared with their planktonic counterparts, whilst the converse was true 
for the anaerobic bacterial populations enumerated. 
 
4.9.2.2 C. difficile Populations 
Sessile and planktonic spore populations were ~5 log10cfu/g in all vessels 
(figures 4.9.2.2 and 4.9.2.3).  Vegetative C. difficile populations of ~2 log10cfu/g 
were present in all vessels in planktonic form and vessel 1 of the biofilm, 
with vegetative cells of ≤ 1 log10cfu/g present in vessels 2 and 3 of the biofilm 
(figures 4.9.2.2 and 4.9.2.3).  Cytotoxin was detected in all vessels within the 
planktonic culture and biofilm. 
 
4.9.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm 
Antimicrobial activity was detected using the clindamycin bioassay method.  
A concentration of ~19.6 mg/L was detected within the biofilm of 
vessel 1 only.  Antimicrobial activity was absent from the planktonic culture 
fluid of all vessels of the human gut model.  No antimicrobial activity was 
detected using the drug Z bioassay methodology. 
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Figure 4.9.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) of 
indigenous of indigenous gut microbiota populations present in vessel 3 of 
the human gut model. 
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Figure 4.9.2.2:  Mean (± SE) planktonic populations (log10cfu/g) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
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Figure 4.9.2.3: Mean (±SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of the 
human gut model. 
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4.9.3 Discussion 
The original gut model experimental design prior to biofilm analysis 
involved clindamycin-induced CDI (PCR ribotype 027 strain) followed by a 
treatment dosing regimen of drug Z.  Treatment was initially successful 
although recurrence of infection was evident as described in the previous 
experiment (biofilm analysis 6). 
Results from the biofilm analysis experiment shows that both planktonic and 
sessile C. difficile were comprised of vegetative cells and spores, and that 
toxin was present in all vessels.  Once again the proportion of sessile spores 
(most notably in vessels 2 and 3) were greater than the planktonic form. 
In this experiment, using C. difficile PCR ribotype 027, sessile C. difficile 
populations in vessel 2 and 3 are dominated by spores.  The same 
experiment using PCR ribotype 001 strain (biofilm analysis 6) found sessile 
vegetative cells and spores in vessel 2 and 3.  The reduced numbers of 
ribotype 027 vegetative cells was also evident within the planktonic phase, 
therefore does not appear to be a unique characteristic of sessile cells.  
Inter-strain spore coat heterogeneity is thought to exist within C. difficile.  
C. difficile spores form exosporial protrusions that can facilitate adherence to 
surfaces 149.  Different spore coat structures may confer a greater ability to 
form these extensions, thereby increasing the adherence of certain spore 
strains.  Furthermore, association of C. difficile with colonic mucosa was 
evident within hamsters and appeared to be strain specific121 and batch 
culture experiments (chapter 3.0) evaluated the adherence capacity of 
different C. difficile ribotypes, with PCR ribotype 001, displaying reduced 
capabilities compared with other strains.  Moreover, it has been 
demonstrated that sporulation capacity is strain dependent, with reports 
highlighting the increased sporulation of 027 spores 144.  These observations 
may explain differences in sessile and planktonic spore populations of 
ribotype 027 strains compared with 001. 
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Antimicrobial activity was not detected 4 days post-clindamycin and 5 days 
post-drug Z instillation within the original gut model.  On day 60, 
antimicrobial activity was detected in the biofilm of vessel 1 only, indicating 
sequestration of one of these agents into the biofilm structure.  Antimicrobial 
activity has not been detected within the biofilm in previous 
clindamycin-exposed biofilm analysis experiments; therefore, it is unlikely 
that the activity with the biofilm is due to clindamycin. 
Drug Z is a novel lipopeptide structurally related to daptomycin.  Diffusion 
of daptomycin into biofilm structures has been previously noted,526 although 
to our knowledge there are no data pertaining to the persistence of drug Z 
within biofilms.  The data presented here provide evidence of the possible 
sequestration and persistence of drug Z in biofilm structures; however, this 
was not observed in biofilm analysis 6. 
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4.10 Biofilm Analysis 8 
4.10.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
table 4.10.1.  Briefly, after inoculation with faecal emulsion, gut microbiota 
populations were allowed to equilibrate for 20 days (period A), before a 
single inoculum of C. difficile PCR ribotype 027 spores (table 3.1) were added 
to vessel 1 of the model on day 20.  A second inoculum of C. difficile 
PCR ribotype 027 spores were inoculated into the model on day 27.  At this 
point a dosing regimen of clindamycin (33.9 mg/L, QD, 7 days) commenced 
(period C).  Following commencement of clindamycin dosing no further 
intervention were made until C. difficile germination, proliferation and high 
toxin production was observed (period D).  Instillation of metronidazole 
(9.6 mg/L, TD, 7 days) commenced on day 54 (period E).  Following 
cessation of therapeutic instillation the model was left without intervention 
for 8 days (period F) before instillation secondary therapeutic agent, 
fidaxomicin (125 mg/L, BD, 7 days) commenced on day 69 (period G).  
Following cessation of secondary therapeutic instillation the model was left 
without intervention for 23 days (period H). Biofilm was sampled on day 99.  
Planktonic indigenous gut microbiota (periods A-H), C. difficile TVC, spores, 
cytotoxin (periods B-H) and antimicrobial activity (periods C-H) were 
monitored during the experiment. 
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Figure 4.10.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling527. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 027 (~107cfu); Clinda: clindamycin; Met: 
metronidazole; FDX: fidaxomicin). TVC – total viable count 
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4.10.2 Results 
4.10.2.1 Indigenous Gut Microbiota Populations 
All bacterial species identified and enumerated within the planktonic 
populations were also present within the biofilm and at similar levels 
(figure 4.10.2.1).  Bifidobacterium spp. were not recovered in either form in 
this experiment.  Planktonic populations were generally greater than their 
sessile counterparts, with the greatest difference observed in the 
B. fragilis group, for which planktonic populations outnumbered sessile 
populations by ~1 log10cfu/g. 
 
4.10.2.2 C. difficile Populations 
Planktonic C. difficile was only detected at a population of ~3 log10cfu/g in 
vessel 3 (figure 4.10.2.2).  Sessile C. difficile populations comprised 
~3.5 log10cfu/g spores and ~2 log10cfu/g vegetative cells in vessel 2 and 
~4.2 log10cfu/g spores and ~0.7 log10cfu/g vegetative cells in vessel 3 
(figure 4.10.2.3).  C. difficile was not recovered from vessel 1 in sessile or 
planktonic form.  Cytotoxin was not detected in any vessel within the 
planktonic phase or biofilm. 
 
4.10.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm 
The clindamycin bioassay method measured active antimicrobial levels in 
the planktonic culture fluid of ~1.9 and 5.6 mg/L in  vessels 2 and 3 
respectively, with no detectable activity in vessel 1.  Levels of activity within 
the biofilm of vessels 1 and 2 are 11.7 and 6.4 mg/L respectively, with no 
detectable activity in vessel 3.  Active antimicrobial concentrations measured 
using the fidaxomicin methodology states that antimicrobial levels were 
2.3 and 7.3 mg/L in planktonic culture fluid in vessels 2 and 3, respectively, 
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with no detectable activity in vessel 1.  Levels of activity within the biofilm 
of vessels 1, 2 and 3 are 14.3, 7.8 and 10.1 mg/L, respectively.  Levels of active 
antimicrobial measured using the metronidazole methodology were 1.5 and 
4.9 mg/L in planktonic samples from vessel 2 and 3, respectively.  No 
activity was detected in the planktonic fluid of vessel 1.  Antimicrobial 
activity was detected at 13.5, 6.7 and 6.8 mg/L, within the biofilm of vessel 
1, 2 and 3, respectively. 
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Figure 4.10.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) 
of indigenous of indigenous gut microbiota populations present in 
vessel 3 of the human gut model. 
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Figure 4.10.2.2:  Mean (± SE) planktonic populations (log10cfu/g) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
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Figure 4.10.2.3: Mean (±SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of the 
human gut model. 
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4.10.3 Discussion 
The original gut model experimental design prior to biofilm analysis 
comprised of the clindamycin induction of CDI followed by a treatment 
dosing regimen of metronidazole.  Metronidazole treatment failed and 
vegetative cells and toxin remained after cessation of the dosing regimen.  
Failure of the initial treatment was followed by a second treatment regimen 
of fidaxomicin.  The second treatment course was successful and recurrence 
was not observed.  C. difficile was only sporadically recovered in spore form 
from the commencement of fidaxomicin instillation until the end of the 
experiment (figure 4.10.1). 
On day 99, comparison of planktonic and sessile indigenous gut microbiota 
results were to those described previously.  Enterococcus spp. were again 
slightly higher in sessile than planktonic form. 
The only C. difficile populations recovered from the planktonic culture fluid 
of the biofilm analysis experiments were vegetative cells in vessel 3 at the 
LOD.  Within the original model vegetative cells were not recovered for at 
least 28 days prior to biofilm analysis.  Therefore, it is likely that these 
colonies were, in fact, derived from spores.  The value of ~3 log10cfu/g was 
the LOD of this assay, and therefore only limited interpretation is possible.  
The units used in these experiments require the weight of the pellet of a 
millilitre of planktonic culture fluid to be used to determine populations; as 
a result, the limit of detection increases as a factor of pellet weight. 
Sessile C. difficile populations were greater than planktonic populations in 
vessels 2 and 3.  Sessile populations were comprised primarily of spores 
although vegetative cells were present at ~2 and 1 log10cfu/g in 
vessels 2 and 3, respectively.  Vegetative cells were undetected from the 
planktonic fluid of the original gut model post-fidaxomicin; therefore, the 
detection of these cells within the biofilm, even at low levels, is unexpected. 
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Cytotoxin was absent in planktonic samples and biofilm on day 99 of 
original gut model (due to the successful second treatment course and lack 
of recurrent CDI).  Toxin was present for up to 26 days during earlier 
periods in the original model.  However, absence of toxin within biofilms 
indicates that prolonged sequestration of toxin is not apparent. 
Antimicrobial activity was detected in biofilm from all vessels, and in the 
planktonic fluid of vessels 2 and 3.  The identity of the antimicrobial agent 
responsible for this activity is unknown.  However, fidaxomicin was the final 
antimicrobial agent used within the original model design, and was shown 
to persist within the planktonic fluid of the original gut model (figure 4.10.1).  
It is therefore likely that fidaxomicin was the cause of residual antimicrobial 
activity.  The increased presence of sessile compared with planktonic 
C. difficile provides evidence that the protected environment of the biofilm 
provides a niche for C. difficile persistence. 
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4.11 Biofilm Analysis 9 
4.11.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
table 4.11.1.  Briefly, after inoculation with faecal emulsion, gut microbiota 
populations were allowed to equilibrate for 20 days (period A), before a 
single inoculum of C. difficile PCR ribotype 027 spores (table 3.1) were added 
to vessel 1 of the model on day 20.  A second inoculum of C. difficile 
PCR ribotype 027 spores were inoculated into the model on day 27.  At this 
point a dosing regimen of clindamycin (33.9 mg/L, QD, 7 days) commenced 
(period C).  Following commencement of clindamycin dosing no further 
interventions were made until C. difficile germination, proliferation and high 
toxin production was observed (period D).  Instillation of vancomycin 
(125 mg/L, QD, 7 days) commenced on day 43 (period E).  Following 
cessation of therapeutic instillation, the model was left without intervention 
for 19 days (period F) before instillation of a second therapeutic agent, 
(fidaxomicin 125 mg/L, BD, 7 days) that commenced on day 69 (period G).  
Following cessation of the second therapeutic instillation, the model was left 
without intervention for 23 days (period H).  Biofilm was sampled on 
day 99.  Planktonic indigenous gut microbiota (periods A-H), C. difficile TVC, 
spores, cytotoxin (periods B-H) and antimicrobial activity (periods C-H) 
were monitored during the experiment. 
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Figure 4.11.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling527. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 027 (~107cfu); Clinda: clindamycin; Vanc: 
vancomycin; FDX: fidaxomicin). 
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4.11.2 Results 
4.11.2.1 Indigenous Gut Microbiota Populations 
The planktonic and sessile bacterial populations within the human gut 
model were dominated by total anaerobes including Clostridium spp. and 
B. fragilis group (figure 4.11.2.1).  Planktonic populations were generally 
greater than sessile populations with the exception of Enterococcus spp.  
Bifidobacterium spp. were not detected in either planktonic or sessile form. 
 
4.11.2.2 C. difficile Populations 
Planktonic C. difficile was only detected at a population of ~2.9 log10cfu/g in 
vessel 1 only (figure 4.11.2.2).  Sessile C. difficile populations comprised 
spores only at populations of ~4.2 log10cfu/g and ~5.1 log10cfu/g in 
vessels 2 and 3, respectively (figure 4.11.2.3).  C. difficile was not recovered 
from vessel 1 in sessile or planktonic form.  Cytotoxin was not detected in 
planktonic culture or biofilm from any vessel. 
 
4.11.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm 
Concentrations of active antimicrobial agent utilising the clindamycin 
bioassay methodology were 1.9, 3.8 and 5.9 mg/L in the planktonic fluid 
from vessel 1, 2 and 3, respectively.  Levels of active antimicrobial using the 
clindamycin methodology were 56.0, 19.1 mg/L in the biofilm of 
vessels 1 and 2, respectively; no activity was detected in vessel 3 biofilm.  
Levels of active antimicrobial agent enumerated using the fidaxomicin 
methodology were 2.4, 4.9 and 7.0 mg/L in the planktonic fluid 
fromvessels 1, 2 and 3, respectively.  No antimicrobial activity was detected 
in the biofilm of vessel 3, but was present at levels of 72.6 and 22.3 mg/L in 
vessels 1 and 2, respectively.  No active antimicrobial agent was detected in 
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the planktonic phase of any vessel using the vancomycin methodology.  
Antimicrobial activity measured 30.5 mg/L within vessel 1 biofilm only. 
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Figure 4.11.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) 
of indigenous of indigenous gut microbiota populations present in 
vessel 3 of the human gut model. 
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Figure 4.11.2.2:  Mean (± SE) planktonic populations (log10cfu/g) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
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Figure 4.11.2.3: Mean (±SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of the 
human gut model. 
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4.11.3 Discussion 
The original gut model experimental design prior to biofilm analysis is 
described in section 4.10.1, although vancomycin was used as the initial 
treatment.  Treatment was initially successful, however; recurrence of 
simulated CDI after initial treatment was evident.  A second treatment, 
comprising fidaxomicin, was successful, with only sporadic spore recovery 
thereafter (figure 4.11.1). 
Indigenous gut microbiota results were similar for the previous experiment, 
again with increased sessile Enterococcus spp. populations compared with 
planktonic populations. 
The only C. difficile population recovered from the planktonic culture fluid 
on day 99 were in vegetative form in vessel 1 at the LOD.  However, the 
significance of this recovery should be interpreted with caution due to the 
lack of vegetative cell recovery in the original model post-fidaxomicin, and 
the very low level value obtained.  In vessels 2 and 3 C. difficile spore 
populations were present within the biofilm; although these levels were low, 
they were greater than planktonic populations, and thus provide a source of 
recalcitrant spores for possible subsequent dispersal.  Cytotoxin was not 
detected in the original gut model (due to successful treatment and lack of 
recurrent CDI) and was also not detected from the biofilm. 
Antimicrobial activity was detected the planktonic fluid of all vessels and 
the biofilm of vessels 1 and 2.  As described in section 4.10.3, it is likely that 
this activity is due to residual fidaxomicin. 
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4.12 Biofilm Analysis 10 
4.12.1 Experimental Design 
The triple stage human gut model experimental design is outlined in 
table 4.12.1.  Briefly, after inoculation with faecal emulsion, gut microbiota 
populations were allowed to equilibrate for 22 days (period A), before a 
single inoculum of C. difficile PCR ribotype 027 spores (table 3.1) were added 
to vessel 1 of the model on day 22.  A second inoculum of C. difficile 
PCR ribotype 027 spores were inoculated into the model on day 29.  At this 
point a dosing regimen of clindamycin (33.9 mg/L, QD, 7 days) commenced 
(period C).  Following commencement of clindamycin dosing, no further 
intervention were made until C. difficile germination, proliferation and high 
toxin production was observed (period D).  Instillation of fidaxomicin 
(125 mg/L, BD, 7 days) commenced on day 57 (period E).  Following 
cessation of therapeutic instillation, the model was left without intervention 
for 22 days (period F).  Biofilm was sampled on day 86.  Planktonic 
indigenous gut microbiota (periods A-F), C. difficile TVC, spores, cytotoxin 
(periods B-F) and antimicrobial activity (periods C-F) were monitored 
during the experiment. 
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Figure 4.12.1: C. difficile results from vessel 3 of the original gut model and experimental design of human gut model prior to biofilm 
sampling. Vertical line indicates last day of period.  (CD: C. difficile PCR ribotype 027 (~107cfu); Clinda: clindamycin; FDX: 
fidaxomicin).  TVC – total viable count.
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4.12.2 Results 
4.12.2.1 Indigenous Gut Microbiota Populations 
On day 86, bacterial populations within the human gut model were 
dominated by LFE, B. fragilis group and Clostridium spp. for both planktonic 
and sessile communities (figure 4.12.2.1).  All planktonic gut bacterial groups 
identified and enumerated in the gut model were also present within the 
biofilm.  Populations of planktonic bacteria were higher than those in sessile 
form, although the relative proportions of these planktonic and sessile 
populations were similar for all bacterial groups.  Bifidobacterium spp. 
populations were not detected in neither the planktonic nor sessile form at 
this stage of the experiment. 
 
4.12.2.2 C. difficile Populations 
Planktonic C. difficile populations were only detected as spores at a 
population of ~ 1.3 log10cfu/g (LOD) in vessel 1 only (figure 4.12.2.2).  Sessile 
C. difficile populations were detected in all 3 vessels (figure 4.12.2.3).  Only 
vegetative cells were present in vessel 1 (~3.5 log10cfu/g) and only spores in 
vessel 2 (~3.9 log10cf/g) and 3 (~4.8 log10cfu/g).  Cytotoxin was not detected in 
any vessel within the planktonic culture or biofilm. 
 
4.12.2.3 Antimicrobial Levels within the Planktonic Culture and Biofilm 
Active antimicrobial levels detected using the clindamycin bioassay 
methodology were 1.9, 3.8 and 5.9 mg/L the planktonic fluid of 
vessels 1, 2 and 3, respectively.  Activity was not detected in the biofilm of 
vessel 3, but was present at levels of 65.2 and 4.3 mg/L in vessels 1 and 2, 
respectively. 
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Active antimicrobial agent concentration detected using the fidaxomicin 
methodology was below the LOD (4 mg/L) in the planktonic fluid of all 
vessels.  Activity was detected within the biofilm of vessels 1 (73.9mg/L) 
and 2 (7.0 mg/L), whilst no activity was detected in vessel 3. 
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Figure 4.12.2.1: Mean (±SE) planktonic and biofilm populations (log10cfu/g) 
of indigenous of indigenous gut microbiota populations present in 
vessel 3 of the human gut model. 
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Figure 4.12.2.2:  Mean (± SE) planktonic populations (log10cfu/g) of C. difficile 
total viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of 
the human gut model. 
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Figure 4.12.2.3: Mean (±SE) biofilm populations (log10cfu/g) of C. difficile total 
viable counts (TVC), spores and cytotoxin (RU) in vessel 1, 2 and 3 of the 
human gut model. 
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4.12.3 Discussion 
The original gut model experimental design prior to biofilm analysis 
comprised clindamycin-induced CDI followed by successful fidaxomicin 
treatment with no recurrence and sporadic spore recovery post-fidaxomicin. 
Indigenous gut microbiota population results were as expected and as 
described previously.  Planktonic C. difficile populations were represented by 
the detection of spores in vessel 3 at the limit of detection.  C. difficile spores 
were recovered from the biofilm in vessels 2 and 3 and vegetative cells from 
vessel 1.  Again, levels recovered in vessel 1 of the biofilm were very low, 
and therefore little significance should be assigned to this observation.  
Spore populations in vessels 2 and 3 were ~0.5-1 log10cfu/g higher than the 
LOD, but still exhibited reduced sessile populations compared with results 
from all other biofilm analysis experiments (although only marginally lower 
than other gut model runs utilising fidaxomicin treatment). 
Fidaxomicin is a novel macrocyclic antimicrobial, which inhibits RNA 
synthesis,recently licensed for the treatment of CDI.  Instillation of 
fidaxomicin during the original gut model experiment elicited rapid 
reduction of C. difficile vegetative cells, with only sporadic spore detection 
for the duration of the experiment.  The presence of this agent within biofilm 
structures in this study demonstrate that biofilms may act as a reservoir for 
fidaxomicin persistence, allowing the subsequent slow release of aggregates 
of biofilm (including fidaxomicin) into the planktonic cultures fluid after 
cessation of antimicrobial instillation, thus preventing regrowth of C. difficile 
vegetative cells and symptomatic disease.  The supra-MIC (MIC 0.25 mg/L) 
levels of fidaxomicin present within the biofilm confer potential antibacterial 
ability.  There are currently no data pertaining to the action of fidaxomicin 
against sessile bacteria. 
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4.13 Conclusions 
Preliminary results detailed in this section highlight for the first time the 
composition of in vitro biofilm structures present within the human gut 
model at a single time point.  These structures are mature and persist for up 
to 13 weeks in vitro despite antimicrobial exposure. 
One of the most difficult situations facing clinicians in treating CDI is the 
management of recurrent infection, which occurs in ~20% of patients243-245.  
Several factors are considered as determinants of disease recurrence 
including C. difficile persistence, colonisation resistance and host immune 
response.  Recurrence of simulated C. difficile germination, proliferation and 
toxin production after successful initial treatment within a human gut model 
has been observed previously272, 515.  Results presented here detail the 
persistence of C. difficile within biofilm structures in a human gut model.  It 
is postulated that this pool of recalcitrant C. difficile may lead to regrowth of 
C. difficile vegetative cells and toxin production, once antimicrobial therapy 
has ceased. 
Indigenous microbiota populations present in planktonic form were also 
largely present in sessile form.  In general, planktonic bacterial counts per 
unit weight/volume exceeded respective sessile counts.  In some 
experiments counts of sessile facultative anaerobes, particularly 
Enterococcus spp. were notably higher than the planktonic counts.  The lower 
ratio of anaerobes to aerobes at the gut mucosal surface compared with the 
lumen has been observed in vivo279.  MacFarlane et al observed similar trends, 
with planktonic anaerobe: facultative anaerobe ratios greater than those in 
the sessile mode of growth446.  P. aeruginosa, a notorious EPS producer, is 
inconsistently recovered from the gut model.  The association of 
P. aeruginosa with E. faecalis has previously been noted528, potentially 
implying a symbiotic relationship between the two organisms.  The presence 
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of P. aeruginosa may lead to recruitment of increased levels of enterococci 
species into biofilm structures. 
In batch culture experiments (chapter 3), C. difficile did not consistently form 
mature biofilm, and intestinal microorganisms did not readily associate with 
glass.  However, in these experiments, mature, mixed-species biofilm were 
consistently harvested from glass vessel walls.  This discrepancy highlights 
the differences between batch and continuous culture systems.  C. difficile is 
able to exist within biofilm structures in the gut model in spore and 
vegetative forms.  However, this may be due to C. difficile associating with 
pre-existing biofilm structures rather than initiating biofilm formation. 
The biofilm mode of growth of C. difficile is highly variable and complex.  
Sessile populations within vessel 1 often produce distinct populations from 
those within vessels 2 and 3.  Distinct differences in C. difficile composition 
and toxin presence have also been observed between planktonic and sessile 
populations.  C. difficile spores often numerically dominated sessile C. difficile 
populations. 
The designs of experiments in which biofilm was analysed were variable.  
Experiments 1 and 4 induced CDI only, whereas other experiments included 
therapeutic treatment, although differences in treatment success were 
evident.  Such differences likely affect biofilm composition and may account 
for the variation in results obtained. 
Biofilm formation and sporulation pathways are interconnected and 
differentially regulated by Spo0A in B. subtilis434.  C. difficile possesses a 
Spo0A orthologue with 56% amino acid homology to that of B. subtilis.  This 
orthologue plays a key role in C. difficile sporulation and biofilm formation454, 
455.  The C. difficile biofilm lifecycle is a complex process, which remains to be 
fully elucidated.  Dawson et al demonstrated that 6-day-old batch culture 
biofilms contained greater numbers of spores compared with 3-day-old 
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biofilms455,  thus providing evidence of heterogenetic C. difficile composition 
in distinct biofilm lifecycle stages.  In addition, Ethapa et al demonstrated 
that C. difficile  Spo0A mutants were defective for biofilm formation within a 
batch culture system 454, demonstrating a possible link between biofilm 
formation and sporulation within C. difficile.  Similar observations in both 
C. difficile 457 and other spore-forming sessile bacteria434, 529, 530 have been 
noted. 
The association between increased biofilm maturity and increased spore 
rather than vegetative forms by other groups provides a possible 
explanation for the high level of spores often observed within mature 
biofilm structures within the gut model 455, 457.  However, it should also be 
noted that conversely, Ethapa et al demonstrated extremely low numbers of 
spores in biofilm and planktonic phases after 3 and 5 days incubation454. 
Whilst the majority of spores within a population initiate rapid germination 
in response to germinants, a sub-population of spores are refractory to these 
stimuli and the germination process is slow.  This response is termed 
superdormancy and has been most extensively characterised in 
Bacillus spp.531-534.  The persistence of a superdormant fraction of C. difficile 
spores after exposure to germinants has been described535, although our 
understanding in this area remains basic.  Sessile spores may display 
analogies to superdormant spores and display increased recalcitrance to 
germination, resulting in high spore populations. 
Spore formation in B. subtilis occurs in apical areas of biofilms, allowing for 
optimal spore dispersal to distinct niches.  Spatial characterisation of 
C. difficile biofilms is unclear however; correlations in spatial organisation 
may also exist, possibly providing greater ease of seeding of spores into the 
planktonic fluid in vitro, or into the lumen of the gastrointestinal tract in vivo. 
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It was expected that spores would remain in a dormant state within the 
non-growing biofilm environment; however, vegetative cells were detected 
within some biofilm structures.  This may be due to germination and 
proliferation of planktonic C. difficile, and subsequent recruitment into 
biofilm structures or true germination of sessile spores.  Lindsey et al have 
previously reported the ability of B. cereus spores to attach to surfaces and 
germinate under favourable and unfavourable nutrient conditions, leading 
to a biofilm comprised of both spores and vegetative cells518.  However, 
vegetative sessile cells may display increased dormancy or a ‘persister’ 
status, compared to planktonic cells as reported with other organisms536, 537. 
Sporulation is an energy intensive process.  A sub-population of B. subtilis 
delay sporulation by differentiation down a pathway which gives rise to 
‘cannibals’435.  In addition to sporulation and biofilm formation, cannibalism 
is also regulated by Spo0A.  Cannibals secrete toxins to which they are 
resistant; these toxins kill a fraction of siblings in order to overcome nutrient 
limitation and delay sporulation, and thus some cells remain in vegetative 
form despite unfavourable conditions.  There are currently no data 
pertaining to the existence of a sub-population of C. difficile cells that may 
possess a survival strategy similar to the B. subtilis cannibals.  However, the 
role of Spo0A in B. subtilis and C. difficile is similar; therefore, it is possible 
that a sub-population of sessile C. difficile differentiate to a pathway distinct 
from that of sporulation, thus remaining in vegetative rather than spore 
form. 
The presence of both vegetative cells and toxin within biofilm structure 
suggests that these vegetative cells may be actively producing toxin.  
Laning457 utilised Western Blot analysis to identify putative toxin antibodies 
in toxigenic, but not non-toxigenic C. difficile batch culture biofilms, and 
showed that toxin concentration increased over time from 1 to 6-day-old 
biofilms.  This suggests that toxigenic sessile C. difficile are able to produce 
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toxin actively.  However, these results should be interpreted with caution as 
this group also observed that 6-day-old biofilms comprised only spores, 
which would not be expected to produce toxin. 
Within the present study, the presence of toxin within biofilm structures, 
despite the absence of cultureable vegetative cells, was observed.  An 
alternative explanation is that biofilms are able to sequester toxin from the 
culture fluid, or that C. difficile within the biofilm were at one time actively 
producing toxin before converting to their spore form, with residual toxin 
remaining present. 
In vessel 1, vegetative forms of C. difficile were sometimes present within the 
biofilm, although toxin production was absent.  C. difficile germination, 
proliferation and toxin production is not always observed within vessel 1 of 
the human gut model525, 538.  Reasons for this remain unclear, but may be 
because of a more acidic pH within this vessel, which is not conducive to 
spore germination539.  Spore germination and proliferation, but not toxin 
production has also previously been observed within this vessel525.  
Repression of toxin production or rapid degradation of toxin may be 
enhanced by the reduced pH within this vessel.  Diminished toxin 
production has previously been associated with low pH levels23, 540, although 
contradictory studies also exist541. 
Toxin is unstable and degrades under certain conditions542.  Bacterial species 
may produce extracellular enzymes that degrade toxin within a biofilm 
structure.  Proteolytic cleavage of toxin A and B by Saccharomyces boulardii 
has previously been described543, 544.  Whilst protease secretion by this 
organism may not be present within the human gut model, it is possible that 
the complex sessile microbial communities, but not planktonic fluid, harbour 
and allow the attainment of protease-producing bacteria in sufficient 
concentrations to cause toxin degradation.  This may in part explain the 
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absence of toxin from within the biofilm whilst present within the planktonic 
culture fluid. 
Transcription of tcdA and tcdB is regulated by environmental factors such as 
temperature and nutrient availability56, 57,58, 59,60.  Biofilms comprise 
microenvironments with distinct conditions.  Certain areas of biofilms may 
be favourable for toxin transcription, which is otherwise absent from the 
planktonic fluid.  Furthermore, the sessile mode of growth may possess a 
distinct phenotype which enables the continued transcription of virulence 
factors including tcdA and tcdB, thus accounting for the presence of toxin 
within biofilms but absence from planktonic phase. 
The biofilm matrix may reduce diffusion of toxins as well as antimicrobials 
into the biofilm structure.  Whilst there is some evidence to suggest that 
reduced susceptibility is elicited by antimicrobial inactivation or reduced 
penetration, there is also confounding evidence to suggest that this is not the 
only pathway422, 545.  Sequestration of antimicrobials may be possible but 
penetration to all areas (particularly the inner biofilm) may be prevented. 
The distinct properties of biofilms from different areas of the gut model may 
explain the absence of toxin in some biofilms, potentially providing a greater 
ability to reduce penetration of toxin, degrade toxin or prevent the residence 
of toxin-producing cells. 
Persistence of antimicrobial agents within biofilm structures after cessation 
of instillation is evident, but not universal, within the human gut model.  
Certain antimicrobials, notably fidaxomicin, appear to display increased 
affinity to associate with biofilms than others.  Reasons for this persistence 
may be modulated by antimicrobial specific characteristics.  When sessile 
populations are considered in terms of total biomass, this provides a 
considerable reservoir of C. difficile for potential subsequent dispersal into 
the planktonic phase.  Treatment of CDI with fidaoxomicin in biofilm 
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analysis experiments 8-10 elicited a reduced C. difficile spore reservoir within 
biofilm structures compared with other biofilm analysis experiments.  
Fidaxomicin treatment also elicited only sporadic recovery of planktonic 
spores.  Allen et al identified that fidaoximicn prevents outgrowth of 
vegetative cells546.  Further work from our group indicates that fidaxomicin 
binds to spore structures despite repeated washing, preventing recovery of 
spores 547.  This suggests that lack of detection of spores from the planktonic 
and biofilm components of the gut model are due to fidaxomicin binding to 
spores, preventing subsequent outgrowth onto agar.  This evidence implies 
that fidaxomicin confers a reduced capacity for regrowth of vegetative cells 
from spores, mediating reduced rates of recurrence.  A pooled analysis of 
two recent phase III clinical trials showed fidaxomicin was not inferior to 
vancomycin for clinical cure and superior over vancomycin for recurrence 
and global cure (p<0.0001)233.  However, subgroup analysis identified an 
insignificant benefit of fidaxomicin over vancomycin for treating 
PCR ribotype 027 infection.  Initial trial reports suggested that fidaxomicin 
therapy was not inferior to vanomcyin for treatment of 
recurrent 027 infection548.  Data presented here provides evidence of 
successful treatment of recurrent CDI and reduced recurrent infection 
following fidaxomicin therapy with a PCR ribotype 027 C. difficile strain. 
It is postulated that prolonged persistence within biofilm structures may 
facilitate subsequent slow release of antimicrobial agent into the planktonic 
fluid, allowing prolonged exertion of inhibitory activity, potentially 
preventing regrowth of C. difficile vegetative cells and reducing the 
likelihood of recurrent infection.  However, the benefits of persistent activity 
against C. difficile may also cause enhanced perturbation of the gut 
microbiota.  Recovery of indigenous gut microbiota is thought to be 
necessary in order to reduce the risk of recurrent infection; therefore, 
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delayed recovery may offset a benefit of persistent antimicrobial activity in 
reducing risk of CDI recurrence. 
These results provide preliminary information on the complex, 
multifactorial existence of biofilm structures within the human gut model.  
These experiments are highly variable and lack a controlled environment; 
thus making reliable conclusions difficult.  However, the data provide 
evidence of the association of C. difficile spore, vegetative cells and cytotoxin 
with biofilm structures, indicating that further investigation is warranted. 
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5.0 Mucin Alginate Investigational Biofilm Human Gut 
Model 
5.1 Background 
The original in vitro human gut model was designed to simulate the various 
stages of CDI; from a healthy state, asymptomatic carriage, induction of CDI, 
simulation of a diseased state, treatment, and post-treatment observation.  
The indigenous gut microbiota and C. difficile populations vary considerably 
during these distinct phases within the system.  In order fully to elucidate 
the sessile mode of growth of C. difficile and the possible role of intestinal 
biofilms in recurrent CDI, it is necessary to monitor the composition of 
biofilm structures within the human gut model longitudinally.  Analysis of 
biofilm from the vessel walls of the gut model is unsuitable for multiple 
analyses; therefore adaptations to the vessel system are needed to provide 
an opportunity for multiple sample points. 
Biofilm analysis (chapter 4.0) and batch culture experiments (chapter 3.0) 
have provided preliminary information on the biofilm association abilities of 
C. difficile and the indigenous gut microbiota on a variety of substratum 
materials, including glass and mucin alginate.  Porcine gastric mucin is 
structurally similar to human epithelial mucin304.  Alginate is an EPS 
produced by mucoid strains of P. aeruginosa.  Alginate and mucin can be 
combined, along with the addition of calcium, to provide durable beads, 
which have previously been used as a substratum material within a short 
term chemostat system447.  The beads are reflective of conditions in vivo and 
allow multiple biofilm sampling opportunities. 
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5.2 Materials and Methodology 
5.2.1 Single Stage Mucin Alginate Gut Model 
5.2.1.1 Single Stage Chemostat Gut Model 
The single stage human gut model comprises of a single glass fermentation 
vessel (280 mL), top fed with a complex growth medium (Appendix A1) at a 
controlled rate (flow rate = 13.2 mL/h) and connected to a waste outlet 
system.  The vessel was maintained at pH 6.8±0.3 using an automatic 
fermenter controller (Biosolo 3, Brighton Systems) delivering 0.5M 
NaOH/HCl.  The vessel was heated using a water jacketed system to 
maintain a temperature of 37° C and continuously sparged with oxygen-free 
nitrogen to ensure anaerobiosis.  Excessive foaming was prevented by the 
addition of 0.5 mL of polypropylene glycol (VWR) ad libitum. 
 
5.2.1.2 Mucin Alginate Bead Preparation 
A MA mixture was prepared as previously described (section 3.2.2.4), fed 
through a peristaltic pump and allowed to fall from a height of 40cm into a 
0.3M CaCl2 solution to form beads (mean diameter 2.9 mm). 
 
5.2.1.3 Preparation of Growth Medium 
Growth medium was prepared in 2 L volumes (section 4.2.2).  The mucin 
alginate investigational experiments utilised one of two growth media; 
original gut model growth medium or biofilm model growth medium.  
Preparation methods of both media are the same although the constituents 
differ (Appendix A1). 
- 192 - 
5.2.1.4 Preparation of Gut Model 
The single vessel was inoculated with faecal emulsion, obtained from an 
existing original gut model.  The original gut model was inoculated with a 
faecal emulsion prepared from C. difficile-negative faeces donated from 
healthy elderly volunteers.  A total volume of 240 mL of faecal emulsion was 
removed from vessels 1-3 of the original model and instilled into the single 
chemostat.  Details of the stage of the original model when faecal emulsion 
was removed as well as the timing of MA bead (50% w/v) instillation into 
the vessel is detailed for each experiment (table 5.1). 
 
5.2.1.5 Clostridium difficile Strains 
The strain used throughout the MA investigation experiments was C. difficile 
PCR ribotype 027 (table 3.0), which was isolated during an outbreak of CDI 
at the Maine Medical Centre, Portland, MA, USA. 
 
5.2.1.6 Sampling Protocol 
Approximately 10 mL of planktonic culture fluid/MA bead mixture were 
removed from the chemostat vessel using a sterile pipette.  Planktonic 
culture fluid was removed from the MA beads and analysed separately. 
 
5.2.1.7 Enumeration of Planktonic Indigenous Gut Microbiota and 
C. difficile 
Planktonic bacterial populations were enumerated as described previously 
(sections 2.1 and 2.2).  Populations were expressed as log10cfu/mL. 
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5.2.1.8 Enumeration of Sessile Indigenous Gut Microbiota and C. difficile 
Two millilitres of CTAB (0.001%) or saline (table 5.1) were added to the MA 
beads, vortexed intermittently for 30 mins, and enumerated as described 
previously (sections 2.1 and 2.2).  Populations are expressed as log10cfu/g of 
beads. 
Table 5.1: Specificities in methodologies used for mucin alginate 
investigation (inv) experiments 1-5 and triple stage mucin alginate 
experiment.  (CD –ve: C. difficile negative; CD +ve: C. difficile positive; MA: 
mucin alginate). 
 Inv 1 Inv 2 Inv 3 Inv 4 Inv 5 Triple 
Growth 
medium 
Biofilm Biofilm 
+ 0.4 g/
L 
glucose 
Original Original Original Original 
Bacterial 
dissociation 
CTAB Saline Saline Saline Saline Saline 
MA bead 
composition 
M:A    
50:50 
M:A    
50:50 
M:A      
50:50 
M:A      
50:50 
M:A      
20:80 
M:A 
50:50 
Bead 
addition 
Day 0 Day 0 Day 8 Day 8 Day 7 Day 7 
Faecal 
emulsion 
V1-3 
(80 mL 
from 
each 
vessel) 
CD -ve 
V1-3 
(80 mL 
from 
each 
vessel) 
CD -ve 
V1-3  
(80 mL 
from 
each 
vessel) 
CD +ve 
V3 only
(240 mL 
from 
V3) 
CD +ve 
V1-3  
(80 mL 
from 
each 
vessel) 
CD -ve 
Fresh 
preparation 
from stool 
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5.3 Investigation 1 
5.3.1 Rationale 
Batch culture experiments (sections 3.2.2 and 3.2.5) have demonstrated the 
capacity of C. difficile and members of the indigenous gut microbiota to 
adhere to MA beads.  However, these experiments were conducted in 
short-term batch culture systems.  Batch culture conditions are known to 
vary considerably from a continuous culture system.  A series of further 
investigational experiments were devised to assess the suitability of MA 
beads for the adaptation of the human gut model. 
 
5.3.2 Experimental Design 
The experimental design timeline is highlighted in figure 5.3.2.1.  Faecal 
emulsion along with 120g (50% w/v) MA beads were instilled into the 
chemostat vessel on day 0.  Growth medium was delivered into the model at 
a controlled rate (flow rate = 13.2 mL/h).  No interventions were made 
for 13 days (period A; figure 5.2.1.1).  See table 5.1 for experimental 
specificities. 
0 13
Period A: Steady state
Time (day)
Mucin alginate bead 
addition
 
Figure 5.3.2.1: Experimental design of single stage mucin alginate human 
gut model investigation 1. 
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5.3.3 Results 
5.3.3.1 Experimental Observations 
MA bead preparation and instillation into the single stage model was 
successful.  Beads settled towards the base of the vessel and overflow of the 
beads out of the vessel outlet port was minimal.  Initial bead-associated 
sampling protocol was successful and sessile bacterial populations were 
obtained on days 1, 3 and 5.  Observations from day 5 onwards 
demonstrated the gradual breakdown and loss of integrity of the MA beads.  
As a result sampling was increasingly difficult, with separation of the 
planktonic fluid and beads problematic. 
 
5.3.3.2 Planktonic Indigenous Gut Microbiota Populations 
The single stage vessel is able to support planktonic indigenous gut 
microbiota populations with Bifidobacterium spp. (~8-10 log10cfu/g) the most 
abundant, and Enterococcus spp. (~2.5-6 log10cfu/g) the least abundant 
bacterial groups (figure 5.3.1.1).  Bacterial populations remained relatively 
steady for the duration of the experiment. 
 
5.3.3.3 Sessile Indigenous Gut Microbiota Populations 
MA beads within the single stage model were able to facilitate adherence of 
all bacterial groups also present within the planktonic fluid.  
Bifidobacterium spp. (~7.0 log10cfu/g) were the most, whilst Enterococcus spp. 
(~2.5-5.5 log10cfu/g) and Clostridium spp. (2.5-3 log10cfu/g) the least abundant 
bacterial groups (figure 5.3.1.2).  Bead-associated bacterial enumeration 
commenced on day 1.  At this early stage populations were similar to those 
subsequently obtained on days 3 and 5. 
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Figure 5.3.1.1: Planktonic populations (log10cfu/mL) (±SE) of indigenous gut 
microbiota in single stage mucin alginate gut model investigation 1. 
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Figure 5.3.1.2: Bead-associated populations (log10cfu/mL) (±SE) of indigenous 
gut microbiota in single stage mucin alginate gut model investigation 1. 
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5.3.4 Discussion 
Initial bead instillation in investigation 1 proved successful, with the rapid 
and stable association of gut microbiota populations to the bead surface.  
Planktonic populations within this system largely reflect those previously 
observed within gut model experiments515, 549.  Exposure of these beads to 
faecal emulsion over 5 days resulted in a loss of structural integrity, which 
restricted further bead-associated sampling. 
 
5.4 Investigation 2-4 
5.4.1 Rationale 
Further investigative experiments were conducted in order to extend the 
lifespan of MA bead structure.  Various adaptations to the experimental set 
up and design were undertaken in investigative experiments 2-4.  These 
include alterations to media, MA bead and faecal emulsion composition, and 
timing of MA bead introduction (table 5.1). 
 
 5.4.2 Experimental Design 
The experimental design timelines for investigation experiments 2-4 are 
highlighted in figures 5.4.2.1-5.4.2.3.  See table 5.1 for experimental details. 
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Period A: Steady state
Time (day)
Mucin alginate bead 
addition
 
Figure 5.4.2.1: Experimental design of single stage mucin alginate human 
gut model investigation 2. 
0 13
Period A: Steady state
Time (day)
Mucin alginate bead 
addition
8
Period B: Rest
28
 
Figure 5.4.2.2: Experimental design of single stage mucin alginate human 
gut model investigation 3. Vertical line represents the last day of each 
period. 
0 13
Period A: Steady state
Time (day)
Mucin alginate bead 
addition
7
Period B: Rest
21
 
Figure 5.4.2.3: Experimental design of single stage mucin alginate human 
gut model investigation 4. Vertical line represents the last day of each 
period. 
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5.4.3 Results and Discussion 
The primary aim of these investigative experiments was to elucidate the 
suitability of MA beads for study of biofilms within an in vitro human gut 
model, and to prolong the duration of MA bead integrity; thus, bacterial 
enumeration results are not discussed here. 
Investigations 2-4 displayed bead survival times of 3, 13 and 6 days, 
respectively (table 5.2).  Therefore, variation in experimental design failed to 
prolong the integrity of the MA bead structure for more than 13 days. 
 
Investigation Growth medium Faecal 
emulsion 
Bead 
addition 
Bead 
survival 
1 Biofilm V1-3 CD –ve Day 0 5 days 
2 Biofilm + 0.4 g/L 
glucose 
V1-3 CD –ve Day 0 3 days 
3 Original V1-3 CD +ve Day 8 13 days 
4 Original V3 CD +ve Day 8 6 days 
 
Table 5.2: Summary of alteration to experimental design and effect on bead 
survival (CD –ve, C. difficile negative; CD +ve, C. difficile positive; V1-3, faecal 
emulsion removed from vessels 1 to 3 of original gut model). 
 
Distinct bacterial populations are known to exist within different regions of 
the colon both in vivo and within the human gut model98, 511, 550.  Removal of 
faecal emulsion from different vessels of the gut model, as well as during 
different periods allowed the assessment of these parameters on MA 
degradation.  Investigations 1-2 utilised faecal emulsion from all three 
vessels of the original gut model obtained during the bacterial equilibrium 
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period.  Investigation 3 also utilised faecal emulsion from all three vessels, 
although the removal of faecal emulsion was during a C. difficile internal 
control period, once C. difficile spores had been added to the faecal slurry.  
Bead degradation from this investigation was evident after 13 days exposure 
to faecal emulsion as opposed to 3 and 5 days in other investigation 
experiments.  The use of faecal emulsion from a more advanced stage of a 
gut model experiment may allow this increased lifespan of the bead 
structure. 
Within a continuous culture in vitro model, planktonic bacterial populations 
must multiply at an adequate rate (i.e. above the dilution rate) to maintain 
colonisation and avoid expulsion from the model.  During early stages of a 
gut model experiment (steady state) bacterial populations compete for 
fermentable substrate in order to establish a population.  Upon equilibration, 
this bacterial community remains relatively stable in the absence of 
interventions.  During initial stages of an experiment raised levels of 
competition and fermentation may exist, which may result in increased 
production of degradative enzymes, including glycosidases.  Faecal 
emulsion from a more advanced stage of a gut model experiment may 
contain a stable population, resulting in a decrease in fermentation products 
and enzymes contributing to mucin degradation. 
Within investigation 3, biofilm gut model growth medium was replaced 
with original gut model growth medium.  These two media types comprise 
both conserved and distinct constituents, which may alter production of 
degradative enzymes within the model.  Furthermore, the mucin 
degradation assay (chapter 3.0) identified that the presence of glucose 
reduces mucin degradation.  Despite inclusion of glucose into the growth 
medium in investigation experiment 2, degradation of MA beads remained 
evident. 
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Vessel 3 of the human gut model represents conditions within the distal 
colon, the region of most physiological relevance in CDI.  These conditions 
include reduced substrate availability.  Investigation 4 was designed to 
determine whether the bacterial populations resident in the distal colon 
(vessel 3) exhibited reduced levels of MA-degradative activity, therefore 
bacterial culture from vessel 3 only (post C. difficile PCR ribotype 027 spore 
inoculation) was inoculated into the chemostat.  However, MA bead 
degradation was evident 6 days after their instillation into the model. 
Faecal emulsion utilised in investigation 4 was removed from the original 
gut model at a similar stage to that used in investigation 3.  Despite this 
similarity, the degradation of MA in investigation 4 was reduced to 6 days, 
demonstrating the variability of MA degradation within a single stage gut 
model system. 
Despite problems within bead degradation, utilisation of the MA bead 
material could potentially provide a wealth of information regarding the 
biofilm mode of growth within an in vitro human gut model, reflective of 
conditions in vivo.  Therefore, further investigations using this substratum 
material were carried out. 
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5.5 Investigation 5 
5.5.1 Rationale 
Numerous attempts to reduce MA degradation and prolong the lifespan of 
the bead structure failed.  The MA bead material comprises equal 
proportions of mucin to alginate.  Degradation of mucin by faecal bacteria 
has been well characterised.  Incorporation of alginate in addition to mucin 
decreased degradation of agar as discussed in chapter 3.0.  It was therefore 
hypothesised that increasing the proportion of alginate to mucin may further 
decrease degradation, allowing the beads to survive longer in the biofilm gut 
model.  The proportion of alginate to mucin was increased to 80:20 for this 
experiment. 
 
5.5.2 Experimental Design 
The experimental design timeline is highlighted in figure 5.5.1.  After a 
steady state period of 13 days (period A; figure 5.5.1.) a single inoculum of 
C. difficile PCR ribotype 027 spores (~107 cfu) were inoculated into the vessel 
on day 14.  Days 14-20 serve as an internal control period to demonstrate 
that spores remain quiescent in the absence of antimicrobial administration 
(period B; figure 5.5.1.).  On day 21 a further inoculum of C. difficile spores 
along with a dosing regimen of ceftriaxone, 150 mg/L, once daily for 7 days  
was instilled into the model (period C; figure 5.5.1).  Thereafter, no further 
interventions were taken (period D; figure 5.5.1).  Planktonic and sessile 
populations were sampled and enumerated intermittently for the duration 
of the experiment.  See table 5.1 for experimental specifics. 
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5.5.3 Mucin Alginate Bead Preparation 
MA beads (20:80 M:A) were prepared by adding 0.8% (w/v) hog gastric 
mucin (Sigma) and 3.2 % (w/v) sodium alginate (Sigma) to warm sterile 
water, stirring continuously until a smooth paste is formed.  The MA 
mixture was fed into peristaltic pump through E1000 tubing as described 
previously (section 3.2.2.4). 
0 13 44
Period A: 
Steady state
Period B: 
Control
Time (day)
20 27
Period C:
Ceftriaxone 
150mg/L 
once daily
7 days
Period E:
Rest
CD 
spores
CD 
spores
CDI induction
Mucin 
alginate bead 
addition
7
 
Figure 5.5.1: Experimental design of single stage mucin alginate human gut 
model investigation 5. Vertical line represents the last day of each period. 
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5.5.4 Results 
5.5.4.1 Experimental Observations 
The integrity of 20:80 M:A bead structure was superior to the 50:50 M:A 
bead type.  Beads remained intact for the full 44 day duration (30 days after 
bead addition) of the experiment.  The bead structure was more robust and 
provided greater sampling ease. 
 
5.5.4.2 Planktonic Indigenous Gut Microbiota Populations 
Between days 0 and 7 all bacterial groups in the planktonic phase 
established a population within the gut model.  During steady state period 
(period A, figure 5.5.1.1a) most bacterial populations remained relatively 
steady with B. fragilis group dominating populations (~9.0 log10cfu/mL) and 
Lactobacillus spp. the least populous bacterial group (~4 – 5 log10cfu/mL).  
Lactobacillus spp. fell to below LOD between days 7 and 23, before 
recovering to initial population levels (~5.5 log10cfu/mL). 
Inoculation of C. difficile spores on day 14 did not affect indigenous gut 
microbiota populations.  Instillation of a further inoculum of C. difficile 
spores on day 21 along with a dosing regimen of ceftriaxone (period C, 
figure 5.5.1.1a) elicited a rapid deleterious effect on most bacterial groups 
(with the exception of facultative anaerobes) and was most notable in 
Clostridium spp. (decline ~7 log10cfu/mL), B. fragilis group (decline 
~7 log10cfu/mL) and Lactobacillus spp. (decline ~5.5 log10cfu/mL).  After initial 
reductions in populations, most bacterial groups recovered to 
pre-ceftriaxone levels by the end of period D.  Bifidobacterium spp. and 
Clostridium spp. remained low or below LOD for the remainder of the 
experiment. 
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5.5.4.3 Sessile Indigenous Gut Microbiota Populations 
Most bead-associated bacterial populations established and maintained a 
population within the C. difficile internal control period (period B, 
figure 5.5.1.1b), with B. fragilis group (~6-7.5 log10cfu/g) and Clostridium spp. 
(~4 – 5 log10cfu/g) the most and least abundant groups, respectively.  
Lactobacillus spp. failed to associate with the MA interface until 
day 23/24 where it reached a population of ~4.5 log10cfu/g before once again 
declining to below the LOD. 
Commencement of ceftriaxone instillation on day 21 elicited a rapid decline 
in all bacterial groups with the exception of Enterococcus spp., which 
maintained a steady population.  LFE demonstrated minor reaction to 
ceftriaxone instillation with an initial population decrease (~2 log10cfu/g) 
before subsequent recovery to pre-ceftriaxone levels of 6 log10cfu/g with a 
similar observation for Bifidobacterium spp.  Clostridium spp. and 
Lactobacillus spp. were the only bacterial groups that failed to recover to 
pre-ceftriaxone populations by the end of the experiment. 
 
5.5.4.4 Planktonic C. difficile Populations 
After introduction of C. difficile spores into the gut model total viable counts 
(TVC) and spores were approximately equivalent at ~4 log10cfu/mL 
(figure 5.5.1.2a).  An initial decline in populations was evident before the 
second inoculum of spores was instilled on day 21, which was concurrent 
with an increase in C. difficile TVC (~4 log10cfu/mL) and spores 
(~1.2 log10cfu/mL).  Subsequent declines in both TVC and spores to below the 
LOD before the cessation of ceftriaxone instillation was evident.  Spores 
remained below the LOD for the remainder of the experiment whilst 7 days 
after ceftriaxone instillation ceased C. difficile TVCs increased to 
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~6 log10cfu/mL.  This increase in TVCs was concurrent with an increase in 
toxin (2.5 RU). 
 
5.5.4.5 Sessile C. difficile Populations 
Initial bead-associated C. difficile TVCs and spores were approximately 
equivalent at ~4 log10cfu/g (figure 5.5.1.2b).  Six days after the introduction of 
C. difficile spores into the gut model, TVCs and spores were below the LOD 
of detection, where they remained until TVCs increased to ~3.2 log10cfu/g 
five days after cessation of ceftriaxone instillation.  An increase in toxin to a 
maximum tire of 2 RU was observed on the final day of the experiment. 
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Figure 5.5.1.1a:  
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Figure 5.5.1.1b: A, planktonic (log10cfu/mL) and B, bead-associated 
(log10cfu/g) (±SE) populations of indigenous gut microbiota in single stage 
mucin alginate gut model investigation 5. Vertical line represents the last 
day of each period. A – steady state; B – internal control; C – ceftriaxone 
instillation; D – rest. 
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Figure 5.5.1.2a:  
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Figure 5.5.1.2b: A, planktonic (log10cfu/mL) and bead-associated populations 
(log10cfu/g) (±SE) of C. difficile in single stage mucin alginate gut model 
investigation 5. Vertical line represents the last day of each period. B – 
internal control; C – ceftriaxone instillation; D – rest. 
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5.5.5 Discussion 
Degradation of mucin by a subpopulation of faecal bacteria has been 
previously characterised309.  Despite attempts to reduce this degradation the 
continued loss of bead integrity was evident in single stage gut model 
experiments.  Alginate is a naturally derived hydrogel-forming 
polysaccharide widely used in tissue engineering551.  Exposure of alginate to 
multivalent cations results in the formation of ionic bridges between 
polymer chains giving rise to a high level of structural integrity.  Alginate is 
sensitive to the action of chelating compounds such as phosphate, citrate and 
lactate 552 and alginate-degradation enzyme, alginate lyase has been isolated 
from marine molluscs, bacteria and brown algae553-556.  Whilst the 
degradation of alginate has been documented, the increased lifespan 
of 20:80 M:A  compared with 50:50 M:A beads observed within this study 
suggests that faecal bacteria-associated degradation of alginate is reduced 
compared with mucin. 
 Altered MA bead composition did not affect bacterial colonisation within the 
single stage chemostat, with the rapid and stable association of bacteria to 
the bead surface.  MA (20:80 M:A) bead-associated bacterial gut microbiota 
populations (figures 5.5.1.1-2) were similar to those observed on 
the 50:50 M:A surface (figures  5.5.1.1-2).  Introduction of beads into the 
model on day 7 did not affect planktonic populations with the exception of 
Lactobacillus spp. which decreased to below LOD.  The introduction of an 
increased biomass into the model results in a degree of expulsion of culture 
fluid from the model system, possibly resulting in the decrease of 
Lactobacillus spp. populations. 
 The tendency for Lactobacillus spp. to exist within biofilms has previously 
been disputed with both in vitro and in vivo data suggesting that this 
bacterial group is either absent or present in reduced numbers within 
intestinal biofilms446, 447.  The sporadic isolation of sessile Lactobacillus spp. 
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from investigation experiment 5 appears to support this notion.  However, 
planktonic Lactobacillus spp. populations were also sporadic; therefore this 
factor is unlikely to be specific to sessile Lactobacillus spp. behaviour. 
 Investigation 5 utilised a more complex experimental design than previous 
experiments.  The prolonged bead survival allowed for antimicrobial 
intervention within the experimental run.  Ceftriaxone instillation (150 mg/L, 
once daily, 7 days) commenced concurrent with instillation of a single 
inoculum of C. difficile spores (period C, figure 5.5.1).  A rapid decline in 
both planktonic and sessile populations was evident one day after 
instillation commenced.  Rates of planktonic and sessile Clostridium spp., 
B. fragilis group and Bifidobacterium spp. population declines were 
comparable, although a ~2.5 log10cfu/mL LFE reduction was observed in the 
planktonic phase compared with a ~1 log10cfu/g sessile reduction.  
Numerous groups have reported that biofilms confer a reduced 
susceptibility to antimicrobials agents399, 400.  LFE populations present within 
the protected environment of the biofilm may be less receptive to the action 
of ceftriaxone.  The reduced susceptibility of sessile E. coli to cepholasporins 
is well documented.  The minimum biofilm eradication concentration of 
cefotaxime, a third generation cephalosporin similar to ceftriaxone, is 
reported as being 256 mg/L (planktonic MIC 1 mg/L)399.  However, similar 
observations have been identified in other indigenous gut microbiota, and 
the reason this phenomenon was only evident in LFE populations within 
this study is unclear. 
Probert and Gibson utilised a MA bead framework within a chemostat 
system and reported higher levels of E. coli detection in biofilm samples 
compared with populations within the culture fluid447, with similar findings 
evident on mucin gels within a two-stage chemostat culture system446. 
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 C. difficile spore preparations (~107 cfu) were inoculated into the model on 
days 14 and 21.  Planktonic and sessile C. difficile spores were detected the 
day after instillation with planktonic populations ~ 1 log10cfu/mL greater 
than sessile populations.  Both planktonic and sessile spores appeared to be 
quickly diluted out of the model.  The wash out of planktonic spores is 
sometimes observed within the original gut model, although rarely so 
rapidly.  However, the absence of sessile spores can not be attributed to the 
dilution factor of the model as MA beads do not exit the model in the same 
manner as the culture fluid.  Low levels of expulsion of the beads from the 
waste outlet port of the model was observed, possibly explaining the 
decrease in bead-associated spores.  Sampling of planktonic and sessile 
populations was carried out one day after initial C. difficile spore inoculation 
(day 15) and again one day after the second instillation of spores concurrent 
with ceftriaxone instillation (day 22).  An increase in planktonic populations 
which coincides with the instillation of a further inoculum of spores was 
observed a day later (day 22).  Sessile C. difficile populations were below the 
LOD between days 21-31; this may be due to an increased timeframe for 
association to the MA bead.  However, planktonic C. difficile possessed lower 
populations than previous single stage (data not shown) and gut model 
experiments270, 512 which should be taken into consideration when analysing 
the absence of bead-associated C. difficile during period C.  The second 
inoculum of spores was concurrent with ceftriaxone instillation although it is 
unlikely that the antimicrobial activity of this agent was responsible for this 
reduced spore population.  Ceftriaxone has not been shown to possess 
anti-spore activity in previous gut model experiments therefore unlikely to 
be the cause of this reduction in C. difficile populations525. 
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5.6 Triple Stage Mucin Alginate Gut Model 
5.6.1 Rationale 
The design of the triple stage human gut model is reflective of condition in 
vivo, with vessel 1 reflective of the high substrate availability of the proximal 
colon, and vessel 3 reflective of the low substrate availability of the distal 
colon.  The high nutrient availability in the proximal colon will support the 
colonisation and proliferation of increased bacterial populations compared 
with the distal colon, so the levels of mucinolytic enzyme producing bacteria 
should be lower in the distal colon.  Therefore, a triple stage human gut 
model was set up to investigate whether mucin alginate beads would 
display increased integrity in the lower substrate environment of vessel 3. 
 
5.6.2 Experimental Design 
The triple stage human gut model was set up and prepared as described in 
section 4.2.1.  Following instillation of the faecal emulsion into all three 
vessels, the model was top fed with a complex growth medium 
(section 4.2.2) at a controlled rate (flow rate = 13.2 mL/h). 
The experimental timeline for this experiment is highlighted in figure 5.6.1.  
The model was left for a steady state period for 13 days to allow bacterial 
populations to equilibrate (period A, figure 5.6.1).  On day 7 of this 
period, 50 % (w/v) 50:50 MA beads were instilled into vessel 3.  
Days 14-20 serve as an internal control period to demonstrate that spores 
remain quiescent in the absence of antimicrobial administration (period B; 
figure 5.61).  On day 21 a further inoculum of C. difficile spores along with a 
dosing regimen of clindamycin, 33.9 mg/L, QD for 7 days were instilled into 
the model (period C; figure 5.6.1).  Planktonic and sessile populations were 
- 213 - 
sampled and enumerated intermittently for the duration of the experiment.  
See table 5.1 for experimental details. 
0 13
Period A: 
Steady state
Period B: 
Control
Time (day)
20 27
Period C:
Clindamycin 
33.9mg/L 
QD 7 days
CD 
spores
CD 
spores
CDI induction
Mucin 
alginate bead 
addition
7
 
Figure 5.6.1: Experimental design of the triple stage mucin alginate human 
gut model investigation. Vertical line represents the last day of each period. 
 
5.6.3 Results 
5.6.3.1 Experimental Observation 
Addition of the 50:50 M:A bead into vessel 3 of a triple stage model 
extended the bead lifespan from 3-13 days within the single stage model 
to 14 days in the triple stage model (day 21 of the experiment) but prevented 
completion of period C.  MA beads settled to the base of the vessel and 
expulsion of beads from the model was minimal.  The pH probe protruded 
into the settlement of MA beads; thus disrupting functionality of the probe. 
 
5.6.3.2 Planktonic Indigenous Gut Microbiota Populations 
All bacterial groups established relatively steady planktonic populations in 
periods A and B (figure 5.6.1.1 and 5.6.1.2) within both vessel 2 and 3.  
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Bifidobacterium spp. dominated (~8 log10cfu/mL) with Clostridium spp. 
(vessel 2) and also LFE (vessel 3) displaying the least abundant populations 
by the end of the steady state period (period A). 
 
5.6.3.3 Sessile Indigenous Gut Microbiota Populations 
MA beads were introduced into vessel 3 of the gut model on day 7.  By 
day 9 all bacterial groups had associated with the bead surface with 
populations remaining steady during period B (figure 5.6.1.3).  
B. fragilis group (~6.5 log10cfu/g) and LFE (~3.8 log10cfu/g) were the most and 
least numerous bacterial populations adherent to MA beads, respectively. 
 
5.6.3.4 Planktonic C. difficile Populations 
Within all 3 vessels, TVCs were equal to spore populations, and toxin was 
absent for the duration of the experiment (figures 5.6.1.4-6).  C. difficile total 
cell populations in vessels 1, 2 and 3 were ~5 log10cfu/g, ~ 5 log10cfu/g and 
~4.5 log10cfu/g, respectively, and these populations were maintained for the 
duration of the experiment. 
 
5.6.3.5 Sessile C. difficile Populations 
Bead-associated C. difficile TVCs and spores were equivalent for the duration 
of the experiment, and toxin was absent throughout (figure 5.6.1.7).  
C. difficile populations decreased from ~3 log10cfu/g on day 15 to 
~1.7 log10cfu/g on day 21. 
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Figure 5.6.1.1: Planktonic populations (log10cfu/mL) (±SE) of indigenous gut 
microbiota in vessel 2 of the triple stage mucin alginate biofilm gut model 
investigation. Vertical line represents the last day of each period. 
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Figure 5.6.1.2: Planktonic populations (log10cfu/mL) (±SE) of indigenous gut 
microbiota in vessel 3 of the triple stage mucin alginate biofilm gut model 
investigation. Vertical line represents the last day of each period. 
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Figure 5.6.1.3: Bead-associated populations (log10cfu/g) (±SE) of indigenous 
gut microbiota in vessel 3 of the triple stage mucin alginate biofilm gut 
model investigation. Vertical line represents the last day of each period. 
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Figure 5.6.1.4: Planktonic populations (log10cfu/mL) (±SE) of C. difficile in 
vessel 1 of the triple stage mucin alginate biofilm gut model investigation. 
- 217 - 
0
1
2
3
4
5
6
7
8
14 15 16 17 18 19 20 21
lo
g
1
0
c
fu
/m
L
Day
TVC
Spores
Toxin
 
Figure 5.6.1.5: Planktonic populations (log10cfu/mL) (±SE) of C. difficile in 
vessel 2 of the triple stage mucin alginate biofilm gut model investigation. 
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Figure 5.6.1.6: Planktonic populations (log10cfu/mL) (±SE) of C. difficile in 
vessel 3 of the triple stage mucin alginate biofilm gut model investigation. 
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Figure 5.6.1.7: Bead-associated populations (log10cfu/g) (±SE) of C. difficile in 
vessel 3 of the triple stage mucin alginate biofilm gut model investigation. 
 
5.6.4 Discussion 
The human gastrointestinal tract comprises distinct regions which confer 
unique environments.  The proximal colon displays increased substrate 
availability and low pH whilst the converse is true in the distal colon.  The 
physiology and ecology of bacteria growing in the proximal colon is distinct 
from those in the distal colon.  Bacterial metabolism and hydrolytic enzyme 
production differs between bacterial populations.  Environmental conditions 
and metabolism end products within vessel 3 of the gut model will vary 
from those in vessel 1.  As a result it was hypothesised that the unique 
conditions within vessel 3 may confer an increased lifespan of MA beads. 
MA beads were previously instilled in a high substrate vessel, which elicited 
the rapid degradation of the beads (3-13 days).  MA beads in the triple stage 
experiment were instilled into vessel 3 (distal colon) and prolonged the 
lifespan of the beads to 14 days.  Whilst this was an improvement of 
- 219 - 
previous 50:50 M:A bead experiments, 14 days remains insufficient for the 
aims of this study. Pure and mixed culture studies demonstrate that 
synthesis of hydrolytic enzymes is catabolite regulated, and is therefore 
dependent on carbohydrate concentrations.  Macfarlane et al established that 
mucin degradation is greatest  in substrate-limited environments446, 
potentially explaining the continued degradation of mucin within vessel 3 of 
the triple stage mucin alginate experiment. 
MA beads were able to support bacterial adherence of all groups 
enumerated, including Lactobacillus spp.  Both planktonic and sessile 
indigenous gut microbiota populations remained stable in the absence of 
antimicrobial intervention and showed similarity with 
investigation 5 results. 
Within the triple stage experiment both planktonic and sessile C. difficile 
populations behaved in a similar manor; C. difficile existed as spores only 
and remained detectable for the duration of the experiment.  Planktonic 
C. difficile spore populations were ~1.5 log10cfu/mL greater than their biofilm 
counterparts, an observation commonly encountered during biofilm analysis 
studies.  This is hypothesised to be due to an increased proportion of biofilm 
pellet weight owing to extracellular material, rather than bacterial mass. 
The planktonic mode of growth of C. difficile described here mimics 
observations consistently observed within the original gut model 512; with 
C. difficile spores remaining quiescent in the absence of antimicrobial 
pressure.  Distinct differences in planktonic compared with sessile bacterial 
characteristics are well documented292.  However, within this study the 
sessile mode of growth largely mirrored the planktonic mode of growth. 
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5.7 Conclusions 
The gastrointestinal tract is lined by a mucosal surface covered largely by 
mucus.  In healthy adults this mucus layer harbours sessile bacterial 
communities which exist within biofilm structures.  These mucins 
structurally resemble the porcine mucus utilised in this study304, however the 
structural integrity of mucus alone is insufficient for immersion within the 
faecal emulsion of a gut model.  The combination of alginate, an EPS 
produced by P. aeruginosa, and mucin has been successfully utilised as an 
adhesion framework previously447.  The formation of the bead structure in 
this experiment is carried out in the presence of 0.3M CaCl2.  Ca2+ stabilizes 
the crossbridges between alginate, increasing mechanical stability557. 
A series of experiments were conducted in order to extend the integrity of 
MA beads within an in vitro human gut model.  Single stage mucin alginate 
experiments using 50:50 M:A beads were initially carried out to provide 
preliminary information.  After the continued degradation of beads within a 
single stage model, a triple stage model was utilised with the aim to reduce 
degradation.  In addition, the composition of the beads was altered to 
increase the proportion of alginate to mucin (20:80 M:A). 
Carbohydrate structures present on mucins provide highly diverse binding 
sites for microbial adhesion, as well as an energy source.  Within this study 
high levels of gut microbiota were found in association with the MA beads.  
The degradation of mucin within the highly competitive environment of the 
gut model has been consistently observed by bacteria that utilise mucin 
components as a major energy source and establish a population on MA 
beads, thus providing an ecological advantage of colonisation of mucin 
structures308, 499, 558, 559. 
Sessile populations within these experiments largely reflect planktonic 
populations with B. fragilis group dominating populations and 
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Enterococcus spp. and Clostridium spp. the least populous groups for both 
modes of growth.  All bacterial groups enumerated during these 
experiments were detected in association with MA beads.  The association of 
Bifidobacterium spp. with mucin within continuous culture systems has only 
been reported within nutrient-limited conditions446, a characteristic not 
observed within MA gut model systems reported here.  During batch MA 
experiments MA bead adherence was not observed for all bacterial groups.  
This observation is possibly mediated by the difference in conditions 
between batch and continuous culture systems. 
The association of C. difficile with mucus has previously been reported123, 
124,117.  Whilst evidence suggests that C. difficile is able to colonise mucus the 
ability of this organism to degrade components of mucins remains to be fully 
elucidated.  C. difficile is characteristically able to ferment simple 
monosaccharide sugars137 as well as N-acetylneuraminic acid  and 
N-acetlyglucosamine560; both are found in large amounts in the side chains of 
mucin, however C. difficile is unable to cleave the monosaccharides from the 
oligosaccharide chains.  The lack of neuraminidase, a glycoside hydrolase 
enzyme, has been identified for this pathogen561, 562.  These data suggest that 
C. difficile is unable to utilise mucin as an energy source, but can associate 
with mucus in mixed-species communities, possibly utilising simple 
carbohydrate structures cleaved from mucin structures by other organisms. 
C. difficile is able to adhere to MA beads within batch and single and triple 
stage continuous culture systems, and generally maintains populations for 
the duration of the experiment. 
C. difficile planktonic and sessile behaviour was varied throughout these 
continuous culture experiments.  This may in part be due to the variation in 
the method of C. difficile introduction into the model.  Variations in 
experimental set up, growth media, faecal emulsion, and bead composition 
- 222 - 
may all play a role in this inconsistent behaviour.  The aim of these 
experiments was to assess the suitability of the MA bead design to adapt the 
original gut model.  The analysis of bacterial behaviour was secondary; 
therefore, appropriate experimental control necessary for such investigation 
was absent.  Results presented here pertaining to bacterial behaviour should 
be interpreted within caution and only used as an additional observation. 
Submerging the beads within a faecal emulsion results in rapid degradation, 
which was consistently observed in the MA investigation experiments.  
Further experiments to elucidate the mechanisms involved in this 
degradation were carried out and are highlighted in chapter 3.0.  Results 
from the mucin degradation experiment highlight the sequential 
degradation of mucin glycoproteins by a sub-population of faecal bacteria.  
This degradation was reduced by the combination of mucin with alginate.  
Investigative experiment 5 was designed to test this theory.  
A 20:80 mucin:alginate mixture was used to form the bead framework.  This 
construction increased the lifespan of the bead for a minimum of 30 days, 
whilst facilitating the adhesion of indigenous gut microbiota to the bead 
surface.  The increased timeframe of bead survival provided an extended 
period for biofilm formation; however macroscopic biofilm structures were 
not evident, despite the presence of visible biofilm on the glass walls of the 
chemostat vessels. 
Whilst the MA investigation experiments were being conducted, analysis of 
the biofilm from the vessel walls of the original model was on-going 
(chapter 4.0).  Biofilm formation was greatest in vessel 1 (also observed by 
Macfarlane et al 446) of the triple stage model, with the liquid-air interface 
facilitating the greatest biofilm biomass.  The MA beads were fully 
submerged within the faecal emulsion, possibly explaining the lack of visible 
biofilm formation.  It is speculated that the adherence of the bacterial 
populations apparent on the bead structure may represent the immature 
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stages of biofilm formation (reversible and irreversible adhesion) with 
maturation processes absent.  The liquid-air interface has been shown to 
provide favoured biofilm formation for B. cereus, with the formation of 
biofilm pellicles345.  In order to understand the biofilm mode of growth fully 
it is necessary for the sessile processes to be active.  The presence of a mature 
biofilm with distinct microcolonies encased within a matrix is a fundamental 
characteristic of a biofilm.  Other biofilm traits such as the upregulation of 
certain phenotypic traits may rely on increased cell density.  The 
bead-associated bacterial populations observed in the presnt experiments 
may lack these vital attributes. 
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6.0 Substratum Material Investigation 
6.1 Background 
Further substratum material investigation is necessary in order to ascertain a 
suitable design for mature biofilm growth within an in vitro human gut 
model.  Information gained in these preliminary MA experiments provides 
information on the composition of bacterial adherence to this material.  This 
information, along with other published work can be used to ensure 
adherent populations on other materials closely mimic MA-associated and in 
vivo mucosa-associated populations. 
 
6.2 Single Stage Glass and Magnetic Bead Investigation 
6.2.1 Rationale 
Alternative substratum materials, which were inert and non-degradable 
were investigated. Biofilm formation is consistently observed on the glass 
vessels of the original gut model.  Whilst this substratum material is inferior 
to MA in mimicking conditions in vivo, it may facilitate the formation of 
mature biofilms that could provide valuable biofilm-associated 
characteristics otherwise absent from the immature biofilm structures 
present on MA beads.  Biofilm composition on the glass vessels of the model 
have previously been analysed (chapter 4.0) and demonstrate mature biofilm 
strucutre and bacterial populations similar to those on MA beads and other 
published work292, 294, 446, 563.  However, one of the major limitations of this 
work was the destructive nature of the sampling process, only allowing the 
biofilm to be analysed at the end of an experiment. 
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A variety of substratum materials were considered for this investigation 
including cellulose and polystyrene, but disregarded due to a lack of 
suitability for this project.  Reports of cellulose degradation by anaerobic 
bacteria were noted564 and polystyrene was hypothesised to float on the 
surface of the culture fluid, thus allowing for their expulsion from the vessel 
through the waste outlet port. 
Glass beads were initially investigated as they are inert, non-degradable, 
readily available and allowed multiple sampling opportunities.  MA beads 
were problematic in that they sometimes floated to the top of the vessel, 
where they exited through the waste outlet port.  Glass beads are sufficiently 
dense to remain submerged within the model.  Magnetic beads, covered in 
polytetrafluoroethylene (PTFE) material were also investigated as they 
potentially provided greater ease of sampling. 
 
6.2.2 Materials and Methodology 
6.2.2.1 Single Stage Chemostat Gut Model 
The single stage gut model comprises of a single glass fermentation vessel 
(280 mL), top fed with a complex growth medium and was set up as 
described in section 5.2.1.1. 
 
6.2.2.2 Magnetic and Glass beads 
One hundred and twenty grams of glass beads (2 mm diameter) and 1 g of 
PTFE-covered magnetic beads (2 mm diameter) were introduced into the 
vessel via the sample port. 
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6.2.2.3 Sampling Protocol 
Planktonic culture samples were removed from the vessel via a sample port 
secured by a glass stopper on days 0 and 25.  Bead-associated bacterial 
populations were sampled on day 25 only.  The chemostat lid system was 
detached and glass beads removed from the vessel using a sterile scoop and 
magnetic beads removed using a sterile magnet. 
 
6.2.2.4 Enumeration of Planktonic Indigenous Gut Microbiota 
Planktonic bacterial populations were enumerated as described previously 
(section 2.2) and populations expressed as log10cfu/mL. 
 
6.2.2.5 Enumeration of Sessile Indigenous Gut Microbiota 
Glass and magnetic beads were weighed independently (as described in 
section 3.2.2.9).  Glass and magnetic beads were resuspended in 5 mL 
and 2 mL saline, respectively, and vortexed intermittently for 30 mins.  
Bacteria were enumerated as described previously (section 2.2) and 
expressed as log10cfu/g of beads. 
 
6.2.2.6 Experimental Design 
The experimental design timeline is highlighted in figure 6.2.1.  Faecal 
emulsion along with 120 g glass and 1 g magnetic beads were instilled into 
the chemostat vessel via the sample point on day 0 and the media pump 
started.  Original gut model growth medium (section 4.2.2; Appendix A1) 
was delivered into the model at a controlled rate.  No interventions were 
made for 25 days (period A; figure 6.2.1).  Vessel contents were not 
magnetically stirred for this experiment. 
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Figure 6.2.1: Experimental design of single stage glass and magnetic bead 
substratum investigation. 
 
6.2.3 Results 
6.2.3.1 Experimental Observations 
Both glass and magnetic beads immediately sank to the base of the vessel 
where they remained for the duration of the experiment.  Magnetic stirring 
of the vessel contents was not in operation in this experiment in order to 
prevent localisation of the magnetic beads.  The natural stirring effect of the 
gas flow was insufficient to mobilise the beads, and sedimentation of 
particulate matter within the culture fluid was evident within the vessel and 
concentrated within the vicinity of the beads. 
Upon removal of the beads from the vessel, macroscopic biofilm formation 
was not evident.  Due to the density of the bead materials sampling at 
numerous time points was not possible; removal of the beads was only 
conceivable upon disruption of the vessel structure. 
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6.2.3.2 Planktonic Indigenous Gut Microbiota Populations 
Planktonic indigenous gut microbiota populations were enumerated on 
day 0 and 25.  Planktonic populations on day 25 were generally equivalent 
to or greater than corresponding populations on day 0, with the exception of 
B. fragilis group and Lactobacillus spp. (figure 6.2.3.1).  Notably, 
Enterococcus spp. populations were ~3.5 log10cfu/mL greater on 
day 25 compared with day 0. 
On day 0, B. fragilis group (~8.4 log10cfu/mL) and Lactobacillus spp. 
(~7.7 log10cfu/mL) were the dominant bacterial groups with Enterococcus spp. 
(~4.4 log10cfu/mL) and Clostridium spp. (~5.9 log10cfu/mL) the least populous. 
On day 25 LFE (~8.7 log10cfu/mL) and Enterococcus spp. (~7.9 log10cfu/mL) 
dominated bacterial populations with Lactobacillus spp. (~5.9 log10cfu/mL) 
and Clostridium spp. (~5.8 log10cfu/mL) displaying the lowest populations. 
 
6.2.3.3 Sessile Indigenous Gut Microbiota Populations 
Sessile gut microbiota populations adherent to magnetic beads within the 
single stage chemostat vessel outnumbered those adherent to glass beads for 
all bacterial groups by ~0.5 – 1.5 log10cfu/g (figure 6.2.3.2).  LFE and 
Enterococcus spp. were the prevalent and B. fragilis group, Lactobacillus spp. 
and Clostridium spp. the least common bacterial groups adherent to both 
glass and magnetic beads.  Relative sessile bacterial populations were 
comparable with those of the planktonic bacterial populations on 
day 25 (figure 6.2.3.2), although sessile populations were ~0.5 - 1 log10cfu/g 
and ~0.5 – 2.5 log10cfu/g lower on magnetic and glass beads, respectively. 
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Figure 6.2.3.1: Mean (±SE) planktonic populations (log10cfu/mL) of 
indigenous gut microbiota on days 0 and 25 of the single stage substratum 
material investigation. 
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Figure 6.2.3.2: Mean (±SE) sessile populations (log10cfu/g) of indigenous gut 
microbiota on glass and magnetic beads on day 25 of the single stage 
substratum material investigation. 
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6.3 Single Stage Liquid/Air Interface Investigation 
6.3.1 Rationale 
The substratum materials investigated to date proved unsuitable for this 
study.  Upon close observation of biofilm formation on the glass walls and 
attachments of the original gut model, it was noted that maximum biofilm 
formation was present on solid surfaces at the liquid/air interface.  Since 
minimal biofilm was observed on the substratum materials investigated to 
date, all of which were submerged below the level of the liquid, substratum 
materials which extend across the liquid/air interface were investigated.  
Mature biofilm formation has consistently been observed on glass objects 
within the original gut model therefore this material was investigated in this 
experiment. 
 
6.3.2 Materials and Methodology 
6.3.2.1 Single Stage Chemostat Gut Model 
The single human gut model comprises of a single glass fermentation vessel 
(280 mL), top fed with a complex growth medium and was set up as 
described in section 5.2.1.1. 
 
6.3.2.2 Glass Rod  
Prior to sterilisation and faecal emulsion inoculation, two glass pipettes were 
inserted into the chemostat vessel. These items extended across the liquid/air 
interface. 
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6.3.2.3 Sampling Protocol 
Planktonic bacterial populations were sampled regularly for the duration of 
the experiment (as described in section 4.2.5).  Glass rod-associated bacterial 
populations were sampled on days 41 and 55.  One glass pipette per biofilm 
sample point was removed from the sampling port using sterilised tweezers. 
 
6.3.2.4 Enumeration of Planktonic Indigenous Gut Microbiota and 
C.  difficile 
Planktonic bacterial populations were enumerated as described previously 
(sections 2.1 and 2.2).  Populations were expressed as log10cfu/mL. 
 
6.3.2.5 Enumeration of Sessile Indigenous Gut Microbiota and C. difficile 
The glass pipette was transferred into a 15 mL centrifuge tube 
containing 10 mL of pre-reduced sterile saline.  The tube was vortexed 
thoroughly until the pipette was devoid of macroscopic biofilm.  The pipette 
was removed and discarded and bacteria enumerated as described 
previously (sections 2.1 and 2.2) and expressed as log10cfu/g. 
 
6.3.2.6 Experimental Design 
Substratum materials were present within the model upon instillation of the 
faecal emulsion on day 0.  The experimental design is highlighted in 
figure 6.3.1.  Briefly, after inoculation with faecal emulsion, gut microbiota 
populations were allowed to equilibrate for 25 days (period A), before a 
single inoculum of C. difficile spores were added to vessel 1 of the model on 
day 25.  A second inoculum of C. difficile spores were inoculated into the 
model on day 32.  At this point a dosing regimen of ceftriaxone (150 mg/L, 
once daily, 7 days) commenced (period C).  Following commencement of 
- 232 - 
ceftriaxone dosing no further interventions were made until C. difficile 
germination, proliferation and high toxin production was observed 
(period D).  Instillation of metronidazole (9.6 mg/L, TD, 7 days) commenced 
on day 44.  Following cessation of therapeutic instillation the model was left 
without intervention for 13 days (period F).  Biofilm was sampled on 
days 41 and 55. 
Planktonic indigenous gut microbiota (periods A-F, vessels 2 and 3), 
C. difficile TVC, spores, cytotoxin (periods B-F, all vessels) and antimicrobial 
activity (periods C-F, all vessels) were monitored during the experiment. 
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Figure 6.3.1: Experimental design of single stage liquid/air interface 
investigation. Vertical line represents the last day of each period. 
 
6.3.3 Results 
6.3.3.1 Experimental Observations 
Insertion of glass pipettes into the chemostat vessel did not interfere with the 
working system.  Macroscopic biofilm formation was visible at the liquid-air 
interface upon removal of the pipettes on day 41 and 55.  The removal of 
macroscopic biofilm structures from the surface of the pipettes was 
successful. 
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6.3.3.2 Planktonic Indigenous Gut Microbiota Populations 
All indigenous gut microbiota populations were present from the onset of 
the experiment with a steady increase in most populations within period A 
(figure 6.3.3.1).  Bifidobacterium spp. predominated populations with 
Enterococcus spp. the least numerous by the end of period A.  Most bacterial 
groups maintained a steady population during C. difficile spores instillation 
(period B), with the exception of B. fragilis group, Bifidobacterium spp. and 
Clostridium spp. which decreased by ~1-2 log10cfu/mL. 
Instillation of a second inoculum of C. difficile spores on day 32, concurrent 
with the commencement of ceftriaxone dosing regimen (period C) elicited a 
rapid deleterious effect on LFE and Clostridium spp. (~4 log10cfu/mL and 
~3 log10cfu/mL LFE and Clostridium spp. respectively), with minor declines in 
Bifidobacterium spp. and Lactobacillus spp.  In contrast, Enterococcus spp. 
increased markedly (~4 log10cfu/mL) during period C, peaking at 
~9 log10cfu/mL.  Following ceftriaxone cessation, all bacterial groups 
recovered to pre-dosing levels by the end of period D, although 
Enterococcus spp. levels remained elevated. 
Metronidazole instillation commenced on day 44 (period E).  This resulted in 
minor fluctuations in bacterial populations, although Enterococcus spp. 
declined by ~3.5 log10cfu/mL by the end of period D, before rapidly 
recovering 6 days after metronidazole instillation ceased. 
 
6.3.3.3 Sessile Indigenous Gut Microbiota Populations 
Sessile indigenous gut microbiota populations were enumerated on 
days 41 (awaiting C. difficile germination and toxin production, period D, 
figure 6.3.1) and 55 (recovery after metronidazole treatment, period F, 
figure 6.3.1) only.  Sessile populations of all bacterial groups were evident at 
both time points, with the exception of Clostridium spp. when no result was 
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obtained on day 41 (figure 6.3.3.2).  Planktonic populations were generally 
higher than their sessile counterparts on days 41 and 55, although the 
converse was true for facultative anaerobes and Enterococcus spp. on day 41.  
Marked differences between planktonic and sessile populations were 
evident in B. fragilis group, Bifidobacterium spp. and Lactobacillus spp. with 
maximum variances of 1.76, 1.45 and 1.23 log10cfu, respectively. 
 
6.3.3.4 Planktonic C. difficile Populations 
C. difficile remained primarily as spores during internal control period 
(period B, figure 6.3.3.3).  Following commencement of ceftriaxone 
instillation (period C), C. difficile spores declined to below LOD, one day 
after dosing cessation.  A similar decrease in TVCs was evident, declining to 
~1.7 log10cfu/mL, 3 days after dosing cessation.  Thereafter, C. difficile 
germination was detected.  C. difficile populations increased sharply to peak 
viable counts of ~6.5 log10cfu/mL, with cytotoxin production evident on 
day 40 and peaking at 5 RU on day 44.  C. difficile spores were detected 
sporadically at around the LOD during periods D and E.  On day 5 of 
metronidazole instillation (period E), TVCs were equal to spore counts with 
subsequent decrease in toxin levels to 0.5 RU, 2 days after cessation of 
metronidazole instillation.  Regrowth of C. difficile vegetative cells proceeded 
the day after metronidazole cessation, increasing to and remaining at 
~6.5 log10cfu/mL for the duration of the experiment.  A similar increase in 
spores and toxin was noted with spore populations and toxin levels peaking 
and persisting at ~4.5 log10cfu/mL and 3 RU, respectively. 
 
6.3.2.5 Sessile C. difficile Populations 
Sessile C. difficile population enumeration was carried out on 
days 41 and 55 of this experiment.  Within planktonic populations C. difficile 
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germination and toxin production was evident at both time points 
(figure 6.3.3.3).  Sessile C. difficile germination and toxin production was 
apparent on day 41, with TVCs of ~6.5 log10cfu/g and spore levels below the 
LOD (figure 6.3.3.4).  On day 55, once again C. difficile germination and toxin 
production was evident, although to a lesser degree than day 41, with TVCs 
and spore levels of ~6.7 and ~4 log10cfu/g, respectively.  Toxin was detected 
within the biofilm on days 41 and 55 at levels of 2 and 1.5 RU, respectively. 
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Figure 6.3.3.1: Planktonic populations (log10cfu/mL) (±SE) of indigenous gut 
microbiota in the single stage liquid/air interface investigation. Vertical line 
indicates the last day of each period. B – internal control, C – ceftriaxone 
instillation, D – CDI induction, E – metronidazole instillation, F – rest. 
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Figure 6.3.3.2: Sessile populations (log10cfu/g) (±SE) of indigenous gut 
microbiota in the single stage liquid/air interface investigation. NR – no 
result 
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Figure 6.3.3.3: Planktonic C. difficile TVC and spore populations (log10cfu/g) 
and toxin (RU) in the single stage liquid/air interface investigation. Vertical 
line indicates the last day of each period.  Dashed line indicates the 
approximate LOD. B – internal control, C – ceftriaxone instillation, D – CDI 
induction, E – metronidazole instillation, F – rest. 
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Figure 6.3.3.4: Mean (±SE) planktonic and biofilm C. difficile TVC and spore 
populations (log10cfu/g) and toxin (RU) in the single stage liquid/air interface 
investigation. 
 
6.4 Discussion 
Many factors govern the ability of bacteria to adhere to surfaces, including 
substratum material physicochemical properties, fluid hydrodynamics and 
aqueous medium characteristics.  The process of biofilm growth is 
dependant on the initial colonisation/attachment rate of organisms, the 
subsequent growth and further recruitment of organisms, and the level and 
rate of detachment of sessile populations.  This process can be described 
using the following formula: 
accumulation rate = attachment rate + growth rate – detachment rate 565. 
Biofilm growth rate increases as a factor of flow rate as a greater cellular 
mass will come into contact with the surface, although efficient adherence of 
these cells may be reduced and mass detachment increased due to higher 
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shear forces.  The extent of biofilm accumulation increases at low fluid 
velocities 566-568, whilst biofilm detachment increases as a factor of biofilm 
mass and increased flow velocity 566.  Furthermore, biofilm accumulation is 
positively influenced by increased surface roughness569, 570, due to the 
diminished shear forces and increased surface area associated with rough 
surfaces. 
Stoodley et al340 demonstrated that laminar flow conditions elicit arrival at 
maximal surface coverage sooner than those growing under turbulent 
conditions with maximal coverage of biofilm grown under laminar 
conditions less than those grown when turbulent flow was present.  The 
authors postulated that this reduced maturation may be due to decreased 
nutrient and cellular supply. 
The present study demonstrates the formation of mature mixed-species 
biofilms on glass surfaces.  A macroscopic thin, plaque-like biofilm forms on 
the submerged portion of the glass materials with a dense biofilm structure 
evident at the liquid/air interface.  Within the milieu of the chemostat vessel, 
bacterial cells are potentially attracted to organic nutrients which 
concentrate on solids surfaces571.  The original vessel design is magnetically 
stirred, thus creating a shear force within the vessel with potentially 
increased shear forces on the outer edges of the vessel (vessel wall).  In 
addition, each vessel is continuously sparged with nitrogen gas, causing 
increased levels of fluid turbidity at the air-liquid interface. 
Other properties such as the pH 341, nutrient level340, ionic strength342 and 
temperature343 may also play a role in colonisation.  Nutrient level and pH 
variation exist within different vessels of the gut model, with increased 
substrate availability and low pH in vessel 1, and low substrate availability 
and high pH in vessel 3.  Within the original gut model, greatest biofilm 
biomass is observed within vessel 1.  Stoodley et al utilised a biofilm reactor 
system to generate mixed-species biofilms with glucose as the limiting 
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nutrient.  Under high glucose concentrations biofilm biomass increased 
rapidly.  Stanley et al341 demonstrated that attachment of motile and 
non-motile P. aeruginosa cells to stainless steel coupons increased from 
pH 4.8 to 7.  Observations within the human gut model suggest that high 
nutrient availability is more conducive to increased biofilm biomass than the 
potential negative influence of decreased pH associated with vessel 1.  These 
factors may potentially lead to increased biofilm accumulation rates 
observed at the liquid/air interface at the vessel wall. 
Dexter et al first outlined the role of surface wettability, or hydrophobicity 
on upon bacterial adhesion572.  Hydrophobic and non-polar surfaces (such as 
Teflon) have been shown to facilitate more rapid attachment of bacteria than 
hydrophilic materials (such as glass),335-337 573  although contradictory data is 
also evident572, 574, 575.  PTFE/Teflon is a high molecular weight synthetic 
polymer with a low coefficient of friction, widely utilised in industry due to 
its ‘non-stick’ properties.  Reports of increased bacterial adhesion to this 
material are unexpected, suggesting that microbial adherence is regulated by 
factors in addition to substratum physicochemical properties.  Submergence 
of materials within liquid environments, such as the faecal culture fluid 
within the gut model, may elicit the rapid conditioning of these surfaces.  
This conditioning film may mask the properties of the underlying material.  
In addition, the hydrophobicity and charge of adherent bacteria plays a role 
in the rate of adherence to material types.  Together, these factors may 
explain the increased bacterial adhesion to PTFE compared with glass 
surfaces observed within this study and by others. 
The populations of glass-adherent bacterial groups (figure 6.3.3.2 & 4) 
appear comparable to MA-associated populations (figures 5.5.1.2 & 4), 
indicating that glass-adherent biofilms posses characteristics similar to those 
on an in vivo realistic material (MA).  These results indicate that the 
substratum material (glass) and system design (rod/pipette) highlighted in 
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this section provides a means to facilitate the formation of a mature 
mixed-species biofilm which reflects sessile populations observed 
previously446, 447.  This system design can be modified to adapt the original 
gut model for the study of both the planktonic and biofilm modes of growth 
of C. difficile and the indigenous gut microbiota. 
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7.0 Biofilm Gut Model Redesign Reproducibility 
Experiments 
7.1 Background 
The human gut model successfully simulates the different stages of CDI.  
In vitro biofilm composition must be analysed at each stage of infection in 
order to elucidate the role that biofilms may play in these stages of 
simulated CDI fully.  Removal of biofilm from the original gut model vessel 
walls (chapter 4.0) only permits biofilm sampling at the end stage of the 
infection process.  Therefore, in order to maximise the number and 
frequency of biofilm sample points, adaptation of the human gut model 
vessel design was necessary. 
Results and observations from previous gut model experiments have 
highlighted greatest biofilm formation at the liquid/air interface, and 
analysis of different substratum materials indicated that glass was conducive 
to mature biofilm formation.  In order to maximise biofilm 
formation/maturation and number of sampling points, a rod system was 
implemented.  This allowed independent formation and analysis 
of 18 different rod-associated biofilms.  However, in order to compare 
biofilm composition at different time points, it was necessary to determine 
the reproducibility of the model in terms of consist biofilm formation and 
composition across all rods, regardless of position within the vessel. 
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7.2 Biofilm Gut Model Vessel Design 
A schematic representation of the redesigned vessel system is depicted in 
figures 7.2.1 and 7.2.2 with photographic visualisation in figure 7.2.3.  Vessel 
system dimensions were altered to maximise the inclusion of rods.  The 
diameter was increased to 98 mm and working depth reduced to 40 mm.  
This ensured the vessel volume was maintained at 300mL.  
Ground/’roughened’ or smooth glass rods were inserted into the vessel 
through the lid and positioned to ensure the sampling portion of the rod 
extended across the liquid/air interface.  Rods were screwed into the lid 
system and anaerobic atmosphere maintained by the delivery of nitrogen 
gas to the vessel via a circular pipe, with drilled holes interspersed on the 
surface to encourage even distribution of gas flow across the rods.  Upon 
removal of rods, replacement screw caps were placed onto the lid to 
maintain the integrity of the system.  The blue circles represent the glass 
rods and their distribution throughout the vessel system (figure 7.2.1).  The 
positions of other necessary ports are also highlighted. 
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Figure 7.2.1: Schematic diagram of the redesigned biofilm human gut model from a bird’s eye view. S: smooth glass rod;  
G: ground/’roughened glass rod
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Figure 7.2.2: Schematic diagram of the redesigned biofilm human gut model vessel from a side-on view. 
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Figure 7.2.3: Photograph of the redesigned biofilm human gut model vessel. 
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7.3 Single Stage Biofilm Gut Model Reproducibility 
Experiments 
7.3.1 Materials and Methodology 
7.3.1.1 Experiments 1 and 2 
7.3.1.1.1 Single Stage Chemostat Biofilm Gut Model 
The biofilm redesign model was assembled as a single stage model as 
described previously 5.2.1.1.  Alterations to certain conditions were made: 
the vessel was maintained at pH 5.5 and 1 % (v/v) PEG introduced to the 
growth medium to reduce foaming.  The experimental design is outlined in 
figure 7.3.1.  Briefly, eighteen rods were positioned within the vessel, 
nine consisted of smooth glass rods, and nine consisted of ground glass rods.  
Their relative positions within the vessel are highlighted in figure 7.2.1.  
Preparation of gut model growth medium is highlighted in 4.2.2. 
 
7.3.1.1.2 Planktonic Sampling and Enumeration Protocol 
Planktonic culture fluid was removed from the planktonic sample port on 
the biofilm vessel into a Wasserman tube and transferred to an anaerobic 
cabinet.  Planktonic indigenous gut microbiota, C. difficile TVCs and spores 
and cytotoxin titres were measured throughout the experiment as described 
in sections 2.1, 2.2 and 2.4 and expressed as log10cfu/mL (or log10cfu/g when 
analysed alongside sessile populations). 
 
7.3.1.1.3 Sessile Sampling Protocol  
Loosely-adherent planktonic bacteria and true biofilm bacterial populations 
were determined independently.  Following careful removal from the vessel, 
rods were gently rinsed by pipetting 5 mL pre-reduced sterile saline along 
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the length of the rod and run-off collected in a sterile Wasserman tube.  This 
solution was enumerated as a loosely-adherent population.  The rod was 
then transferred into a separate Wasserman’s tube containing 5 mL 
pre-reduced sterile saline.  The bacterial communities remaining on the rod 
were removed from the glass rods by vortexing intermittently for 
approximately two minutes, and enumerated as true biofilm populations.  
Biofilm was fully removed from the glass rod and suspended in saline; the 
rod was removed and discarded. 
 
7.3.1.1.4 Sessile Enumeration Protocol 
Samples of loosely-adherent and true biofilm samples (1 mL) were taken for 
each rod and centrifuged in a pre-weighed eppendorf at 16000 g for 10 mins.  
The supernatant was stored at 4˚C for cytotoxin assay (section 4.2.7) and the 
weight of the remaining pellet determined.  Loosely adherent and true 
biofilm indigenous gut microbiota, C. difficile TVCs and spores were 
enumerated as described in section 2.1 and 2.2 and converted to log10cfu/g of 
pellet.  Cytotoxin quantification was performed as described in sections 2.4. 
 
7.3.1.1.5 Experimental Design 
Pooled human faecal emulsion (sections 2.5-2.7) was added to the single 
vessel, media pump was started and the system was left without 
intervention to until bacterial populations were in steady state (period A, 
figure 7.3.1).  On day 31 a single inoculum of C. difficile PCR 
ribotype 027 spores were added to the vessel (period B).  The model was left 
without interventions until day 46 when all 18 rods were removed from the 
model for analysis. Planktonic bacterial populations were determined at 
regular intervals for the duration of the experiment. 
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This experiment was repeated using a distinct faecal donation pool and 
results from each experiment were analysed separately due to inter-
individual differences in faecal bacterial composition.  The only alteration to 
experiment 2 was the continuous sparging of the growth medium with 
oxygen free nitrogen to limit the growth of P. aeruginosa observed in the 
initial experiment (experiment 1). 
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Figure 7.3.1: Experimental design of single stage biofilm gut model 
experiments 1 and 2. Vertical line represents last day of each period. 
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7.3.2 Results 
7.3.2.1 Experiment 1 
7.3.2.1.1 Experimental Observations 
Biofilm formation was observed at the liquid-air interface on all rods 
(figure 7.3.2.1.1).  Minimal biofilm formed on the area of the rods submerged 
under the liquid level within the vessel.  Due to the fragile nature of the 
glass rods, one was broken during the experiment; therefore, only 17 rods 
were analysed.  Variation in biofilm biomass was observed between rods 
with total pellet weight from 1 mL of re-suspended biofilm ranging 
from 0.034 to 0.122 g with an average (±SE) weight of 0.068±0.007 g 
(figure 7.3.2.1.5). 
Smooth rods were utilised in rod positions 1,3,5,7,9,11,13,15,17 (figure 7.2.1) 
and ‘roughned’/ground rods were used for the remaining rods.  No 
discernible difference in the amount (figure 7.3.2.1.5) or composition (figure 
7.3.2.1.4) of biofilm removed from the two rod materials was noted. 
 
7.3.2.1.2 Planktonic Indigenous Gut Microbiota Populations 
Gut microbiota populations remained relatively steady within the steady 
state period of the experiment (period A, figure 7.3.2.1.2), although 
Enterococcus spp., LFE and Clostridium spp. populations fluctuated slightly.  
B. fragilis group. populations were below LOD from day 18 onwards. 
The addition of C. difficile spores on day 32 did not greatly affect gut 
microbiota populations, although there was a temporary decline in the 
populations of Clostridium spp., which may have been attributable to a pH 
disturbance on day 33 (period B, figure 7.3.2.1.2).  Clostridium spp. quickly 
recovered to pre-C. difficile inoculation populations.  All other populations 
remained relatively steady for the duration of the experiment. 
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7.3.2.1.3 Sessile Indigenous Gut Microbiota Populations 
Populations of bacterial groups present on each rod are highlighted in 
figure 7.3.2.1.4.  Each point represents the populations present on a single 
rod.  Sessile communities of all enumerated bacterial groups, except 
B. fragilis group were present on the glass rods.  Variation of sessile bacterial 
populations across all 17 rods were minimal (table 7.1), with standard errors 
of variation of most bacterial groups ≤ 0.18 log10cfu/g.  Enterococcus spp. 
demonstrated greatest variation, with a population standard error 
across 17 rods of 0.3 log10cfu/g (table 7.2).  Enterococcus spp. population 
variation between rods 1-12 (SE ±0.05 log10cfu/g) appears minimal and 
comparable to that of other bacterial groups.  However, increased variation 
was evident on rods 13-17 (SE ±0.57 log10cfu/g), a trend not observed for 
other bacterial groups on these particular rods.  Lactobacillus spp. dominated 
biofilm populations (mean 9.88 log10cfu/g) with Enterococcus spp. 
(mean 5.03 log10cfu/g) the least abundant bacterial group. 
 
7.3.2.1.4 Planktonic C. difficile Populations 
C. difficile TVCs were equal to spore levels for the duration of the 
experiment, indicating the absence of vegetative cells (figure 7.3.2.1.3).  
C. difficile TVCs reduced from ~5 log10cfu/mL on day 31 to sporadic detection 
at around the LOD from day 43.  Cytotoxin was not detected for the 
duration of the experiment. 
 
7.3.2.1.5 Sessile C. difficile Populations 
Rod-associated C. difficile populations comprised primarily spores on 
all 17 rods.  C. difficile TVCs ranged from 2.54 to 5.14 log10cfu/g, with a mean 
and standard error of 3.76±0.17 log10cfu/g.  C. difficile spores ranged 
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from 3.44 to 5.25 log10cfu/g, with a mean and standard error 
of 4.18±0.11 log10cfu/g (figure 7.3.2.1.4). 
 
 
Figure 7.3.2.1.1: Mature biofilm structure on a single rod taken from the 
biofilm gut model on day 46. 
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Figure 7.3.2.1.2: Planktonic populations (log10cfu/mL) of indigenous gut 
microbiota in experiment 1 of the single stage biofilm redesign gut model 
experiment. Vertical line represents the last day of each period. * pH 
disturbance. 
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Figure 7.3.2.1.3: Planktonic populations (log10cfu/mL) of C. difficile in 
experiment 1 of the single stage biofilm redesign gut model experiment. 
Vertical line represents the last day of each period. Dashed line: ~ limit of 
detection.
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Figure 7.3.2.1.4: Sessile populations (log10cfu/g) of indigenous gut microbiota on rods 1-17 within the single stage redesign biofilm gut 
model experiment 1.  Standard errors (± log10cfu/g) for populations on each rod displayed. Each point represents populations present 
on each rod. B. fragilis group – no result. 
- 254 - 
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
W
e
ig
h
t (
g
)
Rod number
True
Loose
 
Figure 7.3.2.1.5: Pellet weights (g) of 1 mL culture of re-suspended loose, true and total biofilm from rods within the single stage 
biofilm human gut model experiment 1. 
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Bacterial group Mean 
(log10cfu/g) 
Range 
(log10cfu/g) 
Standard error 
(log10cfu/g) 
Facultative anaerobes 8.66 1.41 0.07 
Lactose-fermenting 
Enterobacteriaceae 
6.42 1.78 0.11 
Enterococcus spp. 5.03 3.87 0.30 
Total anaerobes 9.44 0.85 0.06 
Clostridium spp. 7.59 1.33 0.09 
Bifidobacterium spp. 
Bacteroides fragilis group 
8.61 
NR 
0.87 
NR 
0.06 
NR 
Lactobacillus spp. 9.88 1.61 0.10 
C. difficile TVC 3.74 2.60 0.18 
C. difficile spores 4.19 1.80 0.11 
Table 7.1: Mean, range and standard error (log10cfu/g) of populations of 
indigenous gut microbiota and C. difficile on rods 1-17 in the single stage 
biofilm redesign gut model experiment 1. TVC – total viable counts;  
NR – no result. 
Rods Mean  
(log10cfu/g) 
Range 
(log10cfu/g) 
Standard error 
(log10cfu/g) 
1-17 5.03 3.87 0.3 
1-12 4.3 0.62 0.05 
13-17 6.78 2.167 0.57 
Table 7.2: Mean, range and standard error of populations of 
Enterococcus spp. on rods within the single stage biofilm redesign gut model 
experiment 1. 
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7.3.2.2 Experiment 2 
7.3.2.2.1 Experimental observations 
No major problems were encountered during the experimental run and the 
system performed as previously (experiment 1).  On day 46 of the 
experiment glass rods were removed from the vessel.  All 18 rods facilitated 
the growth of biofilm as observed in the first reproducibility experiment.  
The macroscopic biofilm mass differed amongst rods with total pellet weight 
ranging from 0.021 to 0.082 g with an average (±SE) weight of 0.046±0.004 g 
(figure 7.3.2.2.4). 
No correlation between biofilm biomass levels on different rods were 
evident between experiments 1 and 2, indicating that differences in biofilm 
biomass are not a result of their position within the vessel. 
 
7.3.2.2.2 Planktonic Indigenous Gut Microbiota Populations 
Gut microbiota populations remained relatively stable within the steady 
state period (period A), with the exception of B. fragilis group which 
fluctuated at levels around the LOD (figure 7.3.2.2.1).  Bifidobacterium spp. 
dominated the bacterial community. 
Instillation of C. difficile spores on day 32 did not greatly affect gut 
microbiota populations, although Enterococcus spp. populations gradually 
declined from ~5 log10fu/mL to ~2 log10cfu/ml before recovering to 
~4 log10cfu/mL before the cessation of the experiment.  All other populations 
remained steady for the further duration of the experiment. 
 
7.3.2.2.3 Sessile Indigenous Gut Microbiota Populations 
Glass rods supported sessile growth of all bacterial groups enumerated in 
this study with the exception of B. fragilis group (figure 7.3.2.2.3).  
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Bifidobacterium spp. were the dominant bacterial group (mean 9.18 log10cfu/g) 
and Enterococcus spp. the least populous group (mean 5.16 log10cfu/g – 
table 7.3).  All enumerated populations were constant across all 18 rods 
(figure 7.3.2.2.5), with standard errors of ≤ 0.16 log10cfu/g. 
 
7.3.2.2.4 Planktonic C. difficile Populations 
Planktonic C. difficile TVCs were equivalent to spore counts throughout the 
duration of the experiment, demonstrating the absence of vegetative cells.  
C. difficile TVCs declined from an initial population of 5.3 log10cfu/mL to 
around the LOD from day 43 onwards (figure 7.3.2.2.2). 
 
7.3.2.2.5 Sessile C. difficile Populations 
Rod-associated C. difficile TVCs were equal to or less than spore counts on 
all 18 rods, with minimal variation between rods (figure 7.3.2.2.3).  TVCs and 
spores ranged from 3.58 to 5.78 log10cfu/g (± SE 0.14 log10cfu/g) 
and 5.22 to 6.91 log10cfu/g (± SE 0.11 log10cfu/g), respectively). 
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Figure 7.3.2.2.1: Planktonic populations (log10cfu/mL) of indigenous gut 
microbiota of the single stage biofilm redesign gut model experiment 2. 
Vertical line represents the last day of each period. 
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Figure 7.3.2.2.2: Planktonic populations (log10cfu/mL) of C. difficile of the 
single stage biofilm redesign gut model experiment 2. Vertical line 
represents the last day of each period. 
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Figure 7.3.2.2.3: Sessile populations (±SE) (log10cfu/g) of indigenous gut microbiota on rods 1-17 within the single stage redesign 
biofilm gut model experiment 2.  Standard errors (± log10cfu/g) for populations on each rod displayed. Each point represents 
populations present on each rod. B. fragilis group – no result. 
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Figure 7.3.2.2.4: Pellet weights (g) of 1mL culture of re-suspended loose, true and total biofilm from rods within the single stage 
biofilm human gut model experiment 2. 
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Bacterial group Mean 
(log10cfu/g) 
Range 
(log10cfu/g) 
Standard error 
(log10cfu/g) 
Facultative anaerobes 8.99 2.25 0.02 
Lactose-fermenting 
Enterobacteriaceae 
8.96 2.24 0.15 
Enterococcus spp. 5.16 1.91 0.13 
Total anaerobes 10.03 1.63 0.10 
Clostridium spp. 8.07 2.59 0.16 
Bifidobacterium spp. 
Bacteroides fragilis group 
9.18 
NR 
1.93 
NR 
0.10 
NR 
Lactobacillus spp. 8.73 1.928 0.11 
C. difficile TVC 4.97 2.20 0.14 
C. difficile spores 6.20 1.69 0.11 
 
Table 7.3: Mean, range and standard error (log10cfu/g) of populations of 
indigenous gut microbiota on rods 1-18 in the single stage biofilm redesign 
gut model experiment 2. TVC – total viable counts; NR – no result. 
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7.3.3 Discussion 
The redesigned single stage biofilm gut model provided a successful system 
in which to study the growth of mixed-species biofilm.  Maximal biofilm 
formation was macroscopically evident at the liquid/air interface on each 
rod.  Despite the minimum solid-liquid-air surface area of the glass rod 
system utilised within the biofilm model system, biomass of mature biofilm 
structures was sufficient for analysis.  Although attempts were made to 
ensure a homogenous environment for biofilm formation, variation in 
biofilm biomass was evident across the 18 rods, although no relationship 
between rod position and biofilm biomass was evident between 
experiments 1 and 2.  Microenvironments within the model were evident, 
with variations in gas flow turbidity.  Shear forces and turbidity levels 
within culture fluids control biofilm formation, with turbid environments 
eliciting increased biofilm formation340, potentially explaining the variation 
observed within this study. 
Both smooth and ‘roughened’ rods were incorporated within the system.  
Increased surface roughness has been reported as conducive to increased 
cellular adhesion570.  Whilst initial adherence rate is uncharacterised within 
this study; biofilm biomass in experiment 1 and 32 (figures 7.3.2.1.5 and 
7.3.2.2.4) demonstrates weak evidence to support this theory, particularly 
amongst rods 3 – 13 within experiment 1 (figure 7.3.2.1.5).  In future 
experiments only rough rods will be used. 
Although biomass variation was evident amongst rods, counts of bacterial 
groups (per g of biofilm) were consistent.  Therefore, any variation between 
rod populations at different time points are likely caused by distinct 
differences in biofilm composition due to outside pressure rather than part 
of any inherent variation in biofilm populations amongst different rods 
within the model. 
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Previous gut model investigations were maintained at pH 6.8, reflecting 
conditions of the distal colon in vivo.  However, single stage chemostat 
models represent a high substrate availability environment more analogous 
to that of the proximal colon.  In order to maintain an environment fully 
reflective of the proximal colon the pH was maintained at 5.5 in this 
experiment.  As a result, conditions, and therefore bacterial populations are 
distinct from previous experiments. 
Slight variation (average, 0.8 log10cfu/g; maximum < 2.5 log10cfu/g) in 
indigenous gut microbiota populations was evident between 
experiments 1 and 2.  Differences between faecal bacterial compositions 
between individuals are well documented279.  Donor pools used in the two  
experiments varied, which likely contribute to the differences observed in 
populations in the two experiments. 
Decreased number and stability of B. fragilis group populations within 
vessel 1 of the gut model compared with vessels 2 and 3 have previously 
been noted98.  Furthermore, detection of Bacteroides spp. within distinct 
regions of the colon of sudden death victims are variable 294.  Reasons behind 
these differences are unclear but may be mediated by the reduced pH, 
increased substrate availability and resulting unique fermentation profile 
within different regions of the model511.  Variation of behaviour of other 
bacterial groups, notably C. difficile germination and toxin production within 
vessel 1, compared with vessels 2 and 3 has previously been observed within 
the gut model525, 538, 576. 
Biofilm structures harbour heterogeneous microenvironments.  Bacteria 
existing in outer areas often possess distinct characteristics from inner 
structure populations434.  Biofilm detachment, particularly swarming/seeding 
processes, results in the existence of biofilm-associated bacteria in the 
processes of detachment.  These organisms may display planktonic rather 
than sessile attributes.  In addition, planktonic bacteria may form a weak 
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association with biofilm structures without possessing sessile traits.  These 
bacterial populations may contribute to sessile populations enumerated in 
this study, whilst not comprising a true biofilm state.  Categorisation of loose 
and strongly adherent biofilm populations was performed to differentiate 
between characteristics of these two populations.  However, differences with 
these two groups (data not shown) were inconsistent. 
During the rinsing procedure to isolate loose bacterial populations, large 
clumps of biofilm often became detached from the rod, thereby skewing the 
loose biofilm-associated results.  The fragile nature of some biofilm 
structures prevented the reliable characterisation of these two groups.  As a 
result, this procedure was abandoned for future reproducibility experiments 
and all rod-associated bacterial populations enumerated together. 
An increased level of variation in Enterococcus spp. populations was 
observed within experiment 1.  P. aeruginosa is an opportunistic pathogen 
isolated from the lungs of cystic fibrosis sufferers and often persists despite 
long-term antimicrobial therapy, owing to the formation of biofilm 
structures.  The bacterium is aerobic although it can survive in anaerobic 
environments where nitrate is available as a terminal electron acceptor in the 
electron transport chain.  Within the gut model, sections of biofilm often 
display a green pigment, presumptively due to pseudomonal growth.  
Within the single stage gut model, green pigmentation was observed in 
biofilms on rods associated with increased Enterococcus spp. variation 
(rods 13-17, figure 7.3.2.1.4).  The association of Enterococcus spp. with 
P. aeruginosa has previously been noted within triple stage analysis 
experiments (chapter 4.0) and within other groups528.  It is postulated that 
this may elicit increased Enterococcus spp. recruitment into these biofilm 
structures.  Such variation rod-associated bacterial groups (experiment 1 and 
2) or in Enterococcus spp. (experiment 2) within the biofilm vessel have not 
been observed therefore are unlikely to have occurred in experiment 1.  
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However, the recruitment of pseudomonas due to increased Enterococcus 
spp. on these particular rods cannot be ruled out.   
Initial reproducibility validation of the rod system indicates the suitability of 
this design for biofilm analysis.  Glass rods reliably facilitated biofilm 
formation in all areas of the vessel.  Rods could be removed and analysed 
with ease and bacterial populations across all rods were very consistent. 
- 266 - 
7.4 Triple Stage Biofilm Gut Model 
7.4.1 Materials and Methodology 
7.4.2.1 Experiments 1 and 2 
7.4.2.1.1 Background 
Once the suitability of the redesigned biofilm gut model was determined 
further reproducibilty experiments were designed.  CDI affects the distal 
colon and vessel 3 of the gut model is analogous to this region, therefore the 
redesigned vessel system was placed in this position.  The biofilm vessel 
design was maintained from that of the initial single stage reproducibility 
experiments; however, a more complex experimental design was 
incorporated into this experimental process, allowing for longitudinal 
monitoring of biofilm formation.  Biofilm detachment protocols were 
evaluated within this study to determine the most efficient procedure for 
removal of biofilm from ground glass rods. 
 
7.4.2.1.2 Triple Stage Biofilm Gut Model 
The biofilm redesign model was set up as a triple stage model as described 
previously 4.2.1, however, vessel 3 was replaced with the redesigned biofilm 
vessel (figure 7.4.2.2).  Alterations to certain conditions were made: 1% PEG 
was added to the growth medium to reduce foaming in vessel 1.  The 
experimental design is outlined in figure 7.4.2.1.  Briefly, eighteen ground 
glass rods were positioned within the vessel and their relative positions are 
shown in figure 7.2.1.  Preparation of gut model growth medium is 
described in 4.2.2.  In order to ensure maximal biofilm recovery from the 
rods, the use of sonication and vortexing were investigated in experiment 1 
to determine which method provided greatest biofilm removal from the 
surface of the rod. 
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7.4.2.1.3 Planktonic Sampling and Enumeration Protocol 
Planktonic indigenous gut microbiota, C. difficile TVCs and spores, and 
cytotoxin were enumerated as described in 7.3.1.1.2.  At biofilm sampling 
time points planktonic populations were also expressed as log10cfu/g. 
 
7.4.2.1.4 Sessile Sampling and Enumeration Protocol 
Rods were submerged with 5 mL of pre-reduced sterile saline, vortexed 
(experiment 1 and 2) or sonicated (experiment 1 only) thoroughly for 
~ 5 mins and rod removed and discarded.  Sessile gut microbiota, C. difficile 
TVCs, spores and cytotoxin were enumerated from all 18 rods 
(at three separate time points, figure 7.4.2.1) within vessel 3 of the triple 
stage gut model as described in sections 2.1 and 2.2. 
 
7.4.2.1.5 Experimental Design 
The biofilm model was left to allow bacterial populations to equilibrate 
for 19 days (figure 7.4.1, period A).  On day 20, rods 1-6 (sample point Z) 
were selected as representative of all areas of the vessel and removed and 
bacterial populations enumerated.  A single inoculum of C. difficile PCR 
ribotype 027 spores were added to vessel 1 of the model on day 21 and the 
system was left without further interventions until rods 7-12 (sample point 
W) were sampled on day 27.  The remaining rods were sampled on 
day 42 (sample point W).  Planktonic indigenous gut microbiota 
(periods A-C, vessels 2 and 3), C. difficile total viable counts, spores and 
cytotoxin (periods B and C, vessels 1-3) were monitored during the 
experiment. 
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This experiment was repeated using a distinct faecal donation pool and 
results from each experiment were analysed separately due to inter-
individual differences in faecal bacterial composition. 
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Figure 7.4.2.1: Experimental design of triple stage biofilm gut model. 
Vertical line represents last day of each period. 
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Figure 7.4.2.2: Photograph of the triple stage biofilm gut model.  Vessel 3 represents the desgined biofilm vessel.  
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7.4.2 Results 
7.4.2.1  Experiment 1 
7.4.2.1.1 Planktonic Indigenous Gut Microbiota Populations 
Planktonic indigenous gut microbiota populations rapidly established a 
stable population within vessel 3, and remained predominantly steady for 
the duration of the experiment (figure 7.4.2.1.1).  Gut microbiota populations 
were dominated by Bifidobacterium spp. and Clostridium spp., whereas 
Enterococcus spp. and LFE were less numerous. 
 
7.4.2.1.2 Sessile Indigenous Gut Microbiota Populations 
Indigenous gut microbiota populations adherent to rods at time points Z-U 
are graphically depicted in figures 7.4.2.1.5 & 7.4.2.1.6.  Planktonic 
populations (log10cfu/g) for each bacterial group at time points Z-X are also 
depicted.  Bacterial group populations across the 6 rods at each time point 
displayed minimal variation, with standard errors of ≤ 0.31 log10cfu/g at all 
time points (table 7.4).  LFE dominated gut microbiota populations, and 
Bifidobacterium spp. were the most numerous obligate anaerobe.  Standard 
error variation of bacterial groups generally increased from time points Z-X.  
No result was obtained for time point X due to failure of selective agar for 
this bacterial genera. 
 
7.4.2.1.3 Planktonic C. difficile Populations 
C. difficile populations initially remained quiescent in all vessels of the gut 
model (figures 7.4.2.1.2-7.4.2.1.2.4).  However, 5 days after C. difficile spore 
instillation, TVCs began to increase by ~1 log10cfu/mL relative to spore 
populations and maintained this level for the duration of the experiment.  
C. difficile spore populations decreased from peak levels 
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of 5.2, 5.2 and 4.6 log10cfu/mL in vessels 1, 2 and 3, respectively to 
~3 log10cfu/mL by the end of the experiment.  Cytotoxin was not detected 
throughout the experiment in any vessel. 
 
7.4.2.1.4 Sessile C. difficile Populations 
Sessile sampling timepoint Z occurred one day prior to C. difficile spores 
instillation, therefore C. difficile populations were absent.  C. difficile spores 
were present with biofilm structures (mean TVCs 6.2 log10cfu/g), six days 
after spore introduction into the model (time point Y, figure 7.4.2.1.7).  
C. difficile populations existed in spore form only, with little variation 
amongst rods (standard error: TVCs and spores 0.13 and 0.19 log10cfu/g, 
respectively). 
On the final day of the experiment (day 46, time point X), mean sessile 
C. difficile TVCs had declined to 4.4 log10cfu/g (time point X, figure 7.4.2.1.7).  
C. difficile populations remained as spores.  Variation of C. difficile 
populations amongst rods at time point X was greater than other bacterial 
groups with TVC and spore standard errors of 0.4 and 0.28 log10cfu/g, 
respectively.
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Figure 7.4.2.1.1: Planktonic (log10cfu/mL) ± SE populations of indigenous gut 
microbiota in vessel 3 of the redesigned triple stage biofilm gut model 
experiment 1.  Z-U biofilm/rod sampling points. Vertical line represents the 
last day of each period. 
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Figure 7.4.2.1.2: Planktonic (log10cfu/mL) ± SE C. difficile populations in 
vessel 1 of the redesigned triple stage biofilm gut model experiment 1. 
Vertical line represents the last day of each period. 
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Figure 7.4.2.1.3: Planktonic (log10cfu/mL) ± SE C. difficile populations in 
vessel 2 of the redesigned triple stage biofilm gut model experiment 1.  
Vertical line represents the last day of each period. 
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Figure 7.4.2.1.4: Planktonic (log10cfu/mL) ± SE C. difficile populations in 
vessel 3 of the redesigned triple stage biofilm gut model experiment 1.  
Vertical line represents the last day of each period. 
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Figure 7.4.2.1.5: Populations (log10cfu/g) ± SE of obligate anaerobes on rods 
within the triple stage biofilm gut model experiment 1 at time points Z-X. 
Planktonic populations of each bacterial group (log10cfu/g) present at each 
time point are represented by a line in the appropriate colour. 
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Figure 7.4.2.1.6: Populations (log10cfu/g) ± SE of facultative anaerobes on 
rods within the triple stage biofilm gut model experiment 1 at time points 
Z- X. Planktonic populations of each bacterial groups (log10cfu/g) present at 
each time point are represented by a line in the appropriate colour. 
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Figure 7.4.2.1.7: Populations (log10cfu/g) ± SE of C. difficile on rods within the 
triple stage biofilm gut model experiment 1 at time points Z- X. Planktonic 
populations of each bacterial groups (log10cfu/g) present at each time point 
are represented by a line in the appropriate colour. 
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Figure 7.4.2.1.8: Pellet weight of 1 mL of re-suspended biofilm within the 
triple stage biofilm human gut model experiment 1 at time points Z-X. 
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Bacterial group Mean 
1-6 
SE 
1-6 
Mean 
7-12 
SE 
7-12 
Mean 
13-18 
SE 
13-18 
Facultative anaerobes 9.71 0.07 9.22 0.20 9.60 0.08 
Lactose-fermenting 
Enterobacteriaceae 
9.70 0.11 9.57 0.14 9.49 0.09 
Enterococcus spp. 7.94 0.30 7.57 0.09 NR NR 
Total anaerobes 9.48 0.06 10.32 0.06 9.51 0.10 
Clostridium spp. 7.82 0.09 9.27 0.15 6.72 0.28 
Bifidobacterium spp. 
Bacteroides fragilis group. 
8.29 
7.97 
0.06 
0.24 
9.07 
8.82 
0.15 
0.17 
7.79 
7.27 
0.18 
0.31 
Lactobacillus spp. 8.03 0.10 8.49 0.12 7.52 0.14 
C. difficile TVC NR NR 6.19 0.13 4.49 0.40 
C. difficile spores NR NR 6.62 0.19 5.53 0.28 
 
Table 7.4: Mean (log10cfu/g) and standard error (SE) of populations of 
indigenous gut microbiota on rods 1-6 (sample point Z), 7-12 (sample 
point Y) and 13-18 (sample point X) in the triple stage biofilm redesign gut 
model experiment 1. NR – no result 
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7.4.2.2 Experiment 2 
7.4.2.2.1 Planktonic Indigenous Gut Microbiota Populations 
Indigenous gut microbiota populations within vessel 3 of the gut model 
remained steady during period A.  Instillation of C. difficile spores (day 21, 
period B) did not substantially affect microbiota populations 
(figure 7.4.2.2.1). 
 
7.4.2.2.2 Sessile Indigenous Gut Microbiota Populations 
Sessile viable counts of enumerated bacterial groups on rods 1-6 (sample 
point Z), 7-12 (sample point Y) and 13-18 (sample point X) were consistent, 
with a maximum standard error of 0.35 log10cfu/g between Enterococcus spp. 
(figure 7.4.2.2.6 and table 7.5).  Biofilm communities were dominated by LFE, 
with Enterococcus spp. the least numerous bacterial group for all time points.  
Rod-associated populations for each bacterial group remained largely steady 
across the 3 time points, although Clostridium spp., B. fragilis group and 
Bifidobacterium spp. populations reduced slightly at time point X 
(~1-2 log10cfu/g decline).  Variations (SE) of sessile populations at time point 
X were generally more pronounced compared with previous time points.  
Only two results for Clostridium spp. were obtained at time point X due to 
contamination of media.   
 
7.4.2.2.3 Planktonic C. difficile Populations 
Upon instillation of C. difficile spores into the gut model, populations 
remained as spores for ~5 days before TVCs and spores diverged, indicating 
the presence of low level vegetative cells in addition to spores 
(figures 7.4.2.2.2-4).  C. difficile spore populations declined from peak levels 
of 5.7, 4.9 and 4.2 log10cfu/mL in vessels 1, 2 and 3 respectively to 
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~ 3 log10cfu/mL by the end of the experiment.  Cytotoxin was detected on the 
penultimate day of the experiment at a level of 2 RU in vessels 2 and 3. 
 
7.4.2.2.4 Sessile C. difficile Populations 
Following C. difficile spore instillation (day 21; post time point Z), C. difficile 
populations existed solely as spores, with no indication of vegetative cell 
presence within all rod-associated biofilm structures at time points X and Y 
(figure 7.4.2.2.7).  Variation between populations present on each rod was 
minimal (max standard error 0.14 log10cfu/g).  C. difficile decreased from a 
mean population of 5.4 to 4.8 log10cfu/g at time points Y and X, respectively.  
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Figure 7.4.2.2.1: Planktonic (log10cfu/mL) ± SE populations of indigenous gut 
microbiota in vessel 3 of the redesigned triple stage biofilm gut model 
experiment 2.  Z-U rod/biofilm sampling points. Vertical line represents the 
last day of each period. 
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Figure 7.4.2.2.2: Planktonic (log10cfu/mL) ± SE populations of C. difficile in 
vessel 1 of the redesigned triple stage biofilm gut model experiment 2. 
Vertical line represents the last day of each period. 
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Figure 7.4.2.2.3: Planktonic (log10cfu/mL) ± SE populations of C. difficile in 
vessel 2 of the redesigned triple stage biofilm gut model experiment 2. 
Vertical line represents the last day of each period. 
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Figure 7.4.2.2.4: Planktonic (log10cfu/mL) ± SE populations of C. difficile in 
vessel 3 of the redesigned triple stage biofilm gut model experiment 2. 
Vertical line represents the last day of each period. 
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Figure 7.4.2.2.5: Populations (log10cfu/g) ± SE of obligate anaerobes on rods 
within the triple stage biofilm gut model experiment 2 at time points Z-X. 
Planktonic populations of each bacterial groups (log10cfu/g) present at each 
time point are represented by a line in the appropriate colour. 
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Figure 7.4.2.2.6: Populations (log10cfu/g) ± SE of facultative anaerobes on 
rods within the triple stage biofilm gut model experiment 2 at time points 
Z-X. planktonic populations of each bacterial groups (log10cfu/g) present at 
each time point are represented by a line in the appropriate colour. 
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Figure 7.4.2.2.7: Populations (log10cfu/g) ± SE of obligate anaerobes on rods 
within the triple stage biofilm gut model experiment 2 at time points Z - X. 
Planktonic populations of each bacterial groups (log10cfu/g) present at each 
time point are represented by a line in the appropriate colour. 
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Figure 7.4.2.2.8: Pellet weight of 1mL of re-suspended biofilm within the 
triple stage biofilm human gut model experiment 2 at time points Z-X. 
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Bacterial group Mean 
1-6 
SE 
1-6 
Mean 
7-12 
SE 
7-12 
Mean 
13-18 
SE 
13-18 
Facultative anaerobes 9.22 0.06 9.80 0.15 9.61 0.09 
Lactose-fermenting 
Enterobacteriaceae 
9.10 0.05 9.80 0.15 9.54 0.17 
Enterococcus spp. 6.36 0.34 6.75 0.33 6.34 0.35 
Total anaerobes 9.87 0.02 10.21 0.15 9.72 0.11 
Clostridium spp. 8.24 0.09 8.37 0.09 6.24 0.07 
Bifidobacterium spp. 
Bacteroides fragilis group. 
8.46 
7.87 
0.04 
0.08 
7.97 
8.58 
0.13 
0.05 
7.26 
7.38 
0.30 
0.28 
Lactobacillus spp. 7.87 0.08 7.42 0.18 6.81 0.26 
C. difficile TVC NR NR 5.38 0.13 4.79 0.14 
C. difficile spores NR NR 5.51 0.14 4.83 0.12 
 
Table 7.5: Mean and standard error (SE) (log10cfu/g) of populations of 
indigenous gut microbiota on rods 1-6 (sample point Z), 7-12 (sample point 
Y) and 13-18 (sample point X) in the triple stage biofilm redesign gut model 
experiment 2. 
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7.4.3 Discussion 
The triple stage human gut model is designed to reflect the changing 
conditions of the proximal to distal human colon.  In addition to 
microbiological and metabolic differences, it is also evident that biofilm 
structures vary within different vessel environments of the gut model.  
Vessel wall-associated biofilm biomass is greater in the high substrate 
environment of vessel 1 and reduced sequentially from vessel 1 to 3.  
However, rod-associated biofilm biomass within the single stage compared 
with triple stage redesigned biofilm gut model did not show such variation. 
As noted in the single stage vessel, biofilm biomass was variable, although 
bacterial group populations (log10cfu/g) remained consistent across rods.  
The triple stage experimental design allowed the investigation of sessile 
communities at three distinct time points.  The biofilm lifecycle is a dynamic 
process.  Stages of the biofilm lifecycle varied between structures on 
individual rods, resulting in differences in biofilm biomass.  The final stage 
of biofilm development is dispersal of attached cells into the surrounding 
environment, mediating bacterial survival and disease transmission.  Within 
this study, rod-associated biofilm biomass generally decreased as the 
experiment progressed (figures 7.4.2.1.8 and 7.4.2.2.8).  Biofilm detachment is 
regulated by factors such as pH, nutrient availability and sheer forces362, 364, 
577, therefore decreased biofilm mass may be due to biofilm communities 
reaching increased structural stability and optimal biomass. 
Maximal biofilm removal is desirable for this study.  Hence, investigations 
were carried out to determine the optimal and most suitable biofilm removal 
techniques from glass rods.  Previous investigations identified vortexing as 
providing maximal recovery of C. difficile populations from MA beads 
(chapter 3.0).  Within this investigation there appeared to be no obvious 
difference in the use of vortex or sonication to remove mixed-species 
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biofilms from ground glass rods.  The vortex technique proved greatest ease 
of use, therefore will be utilised in future experiments. 
Within the original gut model an internal control period was designed to 
demonstrate the quiescent nature of C. difficile spores within the triple stage 
gut model in the absence of antimicrobial intervention.  During this period, 
C. difficile spores were instilled into the model, C. difficile TVCs were 
equivalent to spore counts, indicating that only spores were present.  Within 
this investigation, planktonic C. difficile TVCs increased above spore levels 
by ~1-2 log10cfu/mL in all vessels, 4-5 days after spore instillation, 
demonstrating the presence of low levels (~1-2 log10cfu/mL) of planktonic 
C. difficile vegetative/active cells within the model.  Whilst germination of 
C. difficile spores appeared evident, proliferation of vegetative cells remained 
restricted, particularly in experiment 1. 
Persistence of C. difficile spores (without washout of the continuous model 
system) has previously been observed within the original gut model (during 
the post-treatment period).  However, increased TVCs compared within 
spores, as observed in this experiment, were less pronounced within the 
original gut model515, 578.  Planktonic C. difficile populations may be 
maintained by the continued seeding of C. difficile spores from biofilm 
structures.  It is possible that low level turnover (germination and outgrowth 
but minimum proliferation) of C. difficile spores is present, preventing 
washout of this population, allowing maintenance of a community, 
explaining the presence of low levels of vegetative cells. 
Reasons for the inconsistent behaviour of C. difficile remain unclear.  Within 
the redesign reproducibility experiments, following C. difficile instillation, no 
further interventions were made for the duration of the experiment, whilst 
within the original gut model, the internal C. difficile control period is limited 
to 7 days before clindamycin instillation commences.  C. difficile vegetative 
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cells are susceptible to clindamycin (PCR ribotype 027 MIC = 0.5 mg/L), 
therefore active clindamycin prevents proliferation of these cells.  Low level 
C. difficile spore turnover may potentially be a natural process in the 
presence of certain environmental stimuli, explaining observations within 
this study. 
Whilst the presence of increased TVCs compared with spores was evident 
within planktonic C. difficile communities, there was no evidence of this trait 
within biofilm populations (figures 7.4.2.1.7 and 7.4.2.2.7), although it is 
possible that within the biofilm, sporulation of these vegetative cells may be 
occurring, thus preventing their detection.  Sessile bacteria possess distinct 
metabolic and phenotypic characteristics from their planktonic counterparts, 
including reduced growth rate.  The recruitment of quiescent spores into a 
dormancy-inducing biofilm structure enhances the likelihood of spores 
remaining inactive. 
C. difficile spores germinate in response to external stimuli such as pH, heat 
and nutrients such as glycine and taurocholate32, 170, 539.  Conditions within 
planktonic fluid of the human gut model may vary markedly from the 
protected environment of biofilms, potentially eliciting the diverse 
behaviour of C. difficile between the two phases. 
Furthermore, sessile C. difficile spore populations maintained increased 
population levels compared with planktonic populations.  These sessile 
spores may be shed as part of the natural lifecycle of biofilms, seeding spores 
into the planktonic environment.  The persistence of C. difficile in spore form 
may mediate increased transmission of C. difficile. 
Low level cytotoxin production was evident within the planktonic fluid of 
vessels 2 and 3 in experiment 2, but absent from biofilm structures.  Active 
vegetative cells, were present within the planktonic phase, whilst absent 
from biofilm structures.  Despite the presence of toxin within the planktonic 
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fluid surrounding the biofilms, sequestration of this toxin into biofilm 
structures was not evident.  Reduced penetration of antimicrobial agents 
and biocides into biofilms has been previously reported 406, 579, although 
conflicting evidence also exists545.  Similar mechanisms which confer reduced 
penetration of antimicrobials potentially reduce penetration or deactivation 
of toxin (or germinants) from the planktonic fluid, preventing detection of 
toxin (or vegetative cells) within biofilms as observed in this experiment. 
Decreased populations of sessile compared within planktonic samples were 
observed for many bacterial groups, particularly at more advanced time 
points.  Increased sessile populations compared within planktonic 
counterparts have previously been observed here and by others446, 
particularly amongst facultative anaerobes such as Enterococcus spp.   
No result was obtained for Enterococcus spp. at time point X in experiment 1 
due to failure of selective media for this genera.  However, full results for 
Enterococcus spp. were obtained in experiment 2.  This highlights the 
importance of experimental repetition. 
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7.5 Conclusions 
Baines et al evaluated and validated the triple stage chemostat gut model to 
study CDI 98.  Whilst biofilm structures are evident within the gut model, 
analysis of this parameter within the original model design is not feasible.  
Glass rods that create a solid-air-liquid interface for biofilm formation were 
incorporated into a chemostat vessel.  Biofilm structures present on glass 
rods provided a means to sample and analyse distinct biofilm structures 
independently.  Despite reduced levels of biofilm biomass from 
vessel 1 to 3 within the triple stage gut model, biofilm structures on glass 
rods within vessel 3 proved sufficient for analysis within this study.  Biofilm 
consistently formed macroscopic structures on all glass rods over extended 
periods.  Whilst variation in biofilm biomass was evident between rods, 
populations of bacterial groups (log10cfu/g of biofilm) remained relatively 
consistent between rods at each sampling point.  Despite design intervention 
within vessel 3 of the gut model, the planktonic mode of growth of C. difficile 
and the indigenous gut microbiota reflected observations within the original 
gut model.  Furthermore, rod-associated sessile C. difficile and gut 
microbiota populations were comparable to those observed within previous 
investigations (chapters 4.0-6.0). 
The redesigned biofilm chemostat model has been validated for 
reproducible and consistent formation of mixed-species intestinal biofilms.  
Optimal biofilm formation and removal techniques have been determined.  
This model can be utilised for the analysis of sessile mixed-species 
communities longitudinally, potentially providing information of the role of 
biofilms in CDI. 
- 289 - 
8.0 Triple Stage Biofilm Human Gut Model of Simulated 
Clostridium difficile Infection 
8.1 Background 
The original gut model system has proven a successful in vitro model of CDI; 
however, it is unable to reflect the extensive and complex bacterial 
communities that colonise intestinal mucosal surfaces in biofilm structures 
accurately.  The triple stage biofilm human gut model has been developed to 
facilitate the formation and analysis of biofilm communities in vitro, allowing 
the investigation of the biofilm mode of growth of C. difficile and the 
indigenous gut microbiota in CDI.  Therefore, this biofilm model can now be 
used to investigate the effects of CDI induction and treatment on sessile, as 
well as planktonic, bacterial populations. 
 
8.2 Materials and Methodology 
8.2.1 Triple Stage Biofilm Gut Model Set Up 
The biofilm redesign model was set up as a triple stage model as described 
previously (sections 4.2.1 and 7.4.2.1.2).  The experimental design is outlined 
in figure 8.2.1.  Briefly, eighteen ‘roughened’ glass rods were positioned 
within the vessel (relative positions are highlighted in figure 7.2.1).  
Preparation of gut model growth medium is described in section 4.2.2. 
 
8.2.2 Planktonic Sampling and Enumeration Protocol 
Planktonic indigenous gut microbiota, C. difficile TVCs and spores and 
cytotoxin were enumerated as described in section 7.3.1.1.2.  At biofilm 
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sampling points planktonic populations are also expressed as log10cfu/g.  
Antimicrobial activity was enumerated as described in section 4.2.8. 
 
8.2.3 Sessile Sampling and Enumeration Protocol 
Sessile gut microbiota, C. difficile TVCs and spores and cytotoxin were 
enumerated from all 18 rods (at six separate time points, figure 8.2.1) within 
vessel 3 of the triple stage gut model.  Rods were submerged in 5 mL of 
pre-reduced sterile saline, vortexed thoroughly for ~2 mins and rod 
removed and discarded.  The biofilm suspension was centrifuged at 3000 g 
for 10 mins, supernatant discarded and pellet resuspended in 2mL 
pre-reduced sterile saline.  Rod-associated parameters were enumerated as 
described in sections 2.1, 2.2 and 2.4.  Antimicrobial activity was enumerated 
as described in 4.2.8. 
 
8.2.4 Experimental Design 
Once the biofilm model was set up and the media pump started the system 
was left to allow bacterial populations to equilibrate for 20 days 
(figure 8.2.4 period A).  During period A, planktonic gut microbiota 
populations were monitored every 2 days.  A single inoculum of C. difficile 
PCR ribotype 027 spores (~107 cfu) were inoculated into vessel 1 of the model 
on day 21 (period B).  From this point onwards planktonic gut microbiota, 
C. difficile TVCs, spores and cytotoxin were monitored daily.  The system 
was left without further intervention until rods 1-3 were sampled on 
day 27 (27:time point Z).  Sessile gut microbiota, C. difficile TVCs, spores and 
cytotoxin were quantified.  On day 28 a further inoculum of 
C. difficile 027 spores (107 cfu) were instilled to vessel 1 of the gut model 
along with a dosing regimen of clindamycin (33.9mg/L QD 7 days – 
period C).  Antimicrobial activity was monitored from this point onwards.  
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Clindamycin (33.9 mg/L, QD, 7 days) was instilled to reflect the 
concentration in faeces of patients and volunteers514.  Rods 4-6 and 7-9 were 
sampled on days 35 (35:time point Y) and 41 (41:time point X), respectively.  
In addition to enumerated parameters at time point Z, antimicrobial activity 
was also monitored in sessile communities from hereon.  Once high level 
cytotoxin titre (≥4RU) was observed within the planktonic fluid (period D), 
instillation of vancomycin commenced (125 mg/L, QD, 7 days – period E).  
Following cessation of vancomycin instillation, gut microbiota, C. difficile 
TVCs, spores populations, cytotoxin titres and antimicrobial activity were 
monitored for a further 24 days (period F).  A further three rods were 
sampled at each time point; W, V and U, on days 52, 59 and 73, respectively. 
Planktonic indigenous gut microbiota (periods A-F, vessels 2 and 3), 
C. difficile total viable counts, spores and cytotoxin (periods B-F, vessels 1-3) 
and antimicrobial agents (periods C-F, vessel 1-3) were monitored during 
the experiment.  
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Figure 8.2.1: Experimental design of triple stage biofilm gut model of simulated CDI. Vertical lines represent the last day of each 
period.  Vertical line represents the last day of each period. 
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8.3 Results 
8.3.1 Planktonic Indigenous Gut Microbiota Populations 
Indigenous gut microbiota bacterial groups reached steady state by the end 
of period A in vessels 2 and 3 (figures 8.3.1 and 8.3.2).  Bifidobacterium spp. 
were the most abundant bacterial group with Enterococcus spp. the least 
abundant during period A. 
The instillation of C. difficile spores on day 21 (period B) did not appear to 
affect gut microbiota populations with levels remaining steady.  
Clindamycin instillation (period C) elicited a precipitous decline in 
Bifidobacterium spp. in both vessel 2 and 3 (~8 log10cfu/mL decline), with 
populations declining to below LOD, 4 days after instillation commenced.  A 
less marked decline was evident in B. fragilis group (vessel 2, 
~2.5 log10cfu/mL; vessel 3, ~1 log10cfu/ml), Clostridium spp. (vessel 2, 
~2.5 log10cfu/mL; vessel 3, ~2 log10cfu/ml) and Lactobacillus spp. (vessel 2, 
~2 log10cfu/mL; vessel 3, ~1.5 log10cfu/ml).  Viable counts of bacterial groups 
began to recover by the end of period C, with the exception of 
Bifidobacterium spp., with viable counts increasing by the end of period D.  
Vancomycin instillation (period E) commenced eight days after clindamycin 
cessation, resulting in profound decreases in B. fragilis group 
(~6-6.5 log10cfu/mL) and Bifidobacterium spp. (~6 log10cfu/mL) viable counts in 
vessels 2 and 3.  Smaller declines in Enterococcus spp., LFE and Clostridium 
spp. were evident, although Lactobacillus spp. populations increased 
(~1-1.5 log10cfu/mL).  Most bacterial groups recovered to, or exceeded 
pre-vancomycin levels ~9 days after dosing cessation, except 
Bifidobacterium spp. which recovered after 18-21 days (period F). 
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8.3.2 Sessile Indigenous Gut Microbiota Populations 
Rod-associated bacterial populations were monitored at six different time 
points (Z-U, figure 8.2.4).  Time point  Z was the final day of period B, 
pre-clindamycin instillation; Y, one day after clindamycin dosing ceased;  X, 
during planktonic simulated CDI; W, after completion of vancomycin 
dosing; V, during the recovery period; U, during recurrent planktonic 
disease.  Sessile gut microbiota figures (figures 8.3.6 and 8.3.7) also present 
planktonic (log10cfu/g) populations obtained at that time point and will be 
referred to here.  Bacterial group populations on each rod at time point Z 
display little variation (figures 8.3.6 and 8.3.7).  LFE (average 9.2 log10cfu/g) 
dominated sessile bacterial populations, with B. fragilis group 
(average 8.1 log10cfu/g) the least populous group. 
Clindamycin instillation commenced eight days prior to time point Y and 
elicited a deleterious effect on gut planktonic microbiota, most notably 
Bifidobacterium spp. which declined below LOD, three days previous to 
biofilm sampling, Y.  However, sessile Bifidobacterium spp. populations, 
whilst declining (~5 log10cfu/g), maintained an average population 
of 3.9 log10cfu/g.  More modest decreases in sessile Lactobacillus spp. 
(~1.5 log10cfu/g), Clostridium spp. (~1 log10cfu/g), Enterococcus spp. 
(~1 log10cfu/g) and B. fragilis group (~1 log10cfu/g) were also noted.  Sessile 
populations at time point X, remained at similar levels to time point Y, 
although Bifidobacterium spp. increases by ~1.5 log10cfu/g.  Vancomycin 
instillation commenced ten days before biofilm sampling point  W, resulting 
in a marked decline in sessile B. fragilis group and Bifidobacterium spp. to 
below the LOD, whilst Lactobacillus spp. increased by ~2.5 log10cfu/g.  Similar 
trends were also noted for planktonic populations, although planktonic 
Clostridium spp. also declined to below LOD, whilst sessile populations 
remained at 7.9 log10cfu/g.  Planktonic and sessile Bifidobacterium spp. 
population remained below LOD at time point V.  B. fragilis group began to 
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recover with sessile and planktonic populations increasing to 5.1 log10cfu/g 
and 8.9 log10cfu/g, respectively.  All bacterial groups established sessile 
populations by the completion of the experiment; counts of facultative 
anaerobic groups and B. fragilis group, and Clostridium spp. populations 
remained marginally lower than initial (Z) levels. 
 
8.3.3 Planktonic C. difficile Populations 
C. difficile was not isolated during the steady state period (period A).  
C. difficile populations were comprised primarily of spores during the 
internal control period (period B) in all vessels, declining from ~5-5.5 to 
~3 log10cfu/mL as vessel contents were diluted (figures 8.3.3-5).  Cytotoxin 
was not detected (period B).  A second inoculum of C. difficile spores 
concurrent with the start of clindamycin instillation (period C) was instilled 
on day 28.  C. difficile population initially comprised spores primarily until a 
marked increase in TVCs relative to spore counts was observed in 
vessels 2 and 3, five days after instillation cessation.  TVCs peaked at 
~6.5 log10cfu/mL, one day previous to peak cytotoxin titre of 4RU in vessel 3.  
Vancomycin instillation elicited a rapid decline in TVCs in vessels 2 and 3, 
with only spores remaining after two days (~2 log10cfu/mL decline in 
vessels 2 and 3).  Cytotoxin decreased to below LOD, 5 days after the start of 
vancomycin instillation within vessel 3.  Vancomycin did not demonstrate 
an effect on C. difficile spore populations within vessel 1, which remained as 
spores for the remainder of the experiment in vessel 1, although TVCs 
increased relative to spores ~14-16 days after vancomycin cessation within 
vessels 2 and 3.  Subsequent increase in cytotoxin was observed, reaching 
peak titres of 4 RU in vessels 2 and 3. 
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8.3.4 Sessile C. difficile Populations 
Sessile C. difficile data (figure 8.3.8) also presents planktonic (log10cfu/g) 
populations obtained at that time point.  Rod-associated C. difficile 
populations remained primarily as spores for the duration of the 
experiment.  At time point Z, C. difficile rod-associated populations 
demonstrated consistent populations across the three rods, with populations 
comprising spores primarily (~5.8 log10cfu/g).  Cytotoxin was not detected 
with biofilm structures.  Instillation of a second inoculum of C. difficile 
spores, alongside a dosing regimen of clindamycin, did not greatly affect 
sessile C. difficile populations, although slightly increased variation amongst 
rods was noted (SE time point Z, 0.05-0.09 log10cfu/g; SE time point 
Y, 0.36-0.37 log10cfu/g).  Cytotoxin was not detected. 
During simulated planktonic CDI, sessile C. difficile maintained a consistent 
population, comprising primarily of spores (~5.5 log10cfu/g).  Cytotoxin was 
detected at low levels (1 RU) within 1 of the 3 rods.  During time points W 
and V, C. difficile populations remained as spores at ~5.5 log10cfu/g with no 
toxin detected.  During recurrent planktonic infection (time point U), sessile 
C. difficile populations remained in spore form, although levels dropped by 
~0.5 log10cfu/g.  Cytotoxin was detected in 1 of the 3 rods at low levels 
(2 RU). 
 
8.3.5 Antimicrobial activity 
Clindamycin was detected within the planktonic phase of all three vessels of 
the gut model, peaking at a concentration of 64.9, 50.7 and 50.8 mg/L in 
vessel 1, 2 and 3, respectively (figure 8.3.9).  Detection of clindamycin 
activity continued 1, 2 and 3 days after dosing cessation in vessels 1, 2 and 3, 
respectively.  Rods from time point Y (day 35) were sampled and analysed, 
- 297 - 
one day after dosing cessation.  Clindamycin activity could not be detected 
within rod-associated biofilm structures. 
Vancomycin activity was detected within the planktonic fluid throughout 
period E and continued to be detected for three days after dosing cessation 
in all three vessels (figure 8.3.10).  Concentrations peaked on the final day of 
instillation (day 49) at concentrations of 330.2, 317.8 and 270.3 mg/L in 
vessels 1, 2 and 3, respectively.  Vancomycin activity within biofilm 
structures per rod (time point W, day 52) ranged from 38.7 to 43.4 mg/L 
(figure 8.3.11).  Planktonic antimicrobial activity on day 52 within 
vessel 3 was 6.05 mg/L. 
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Figure 8.3.1: Planktonic populations (log10cfu/mL, ±SE) of indigenous gut 
microbiota in vessel 2 of the triple stage biofilm gut model. Vertical line 
represents the last day of each period. A – steady state, B – internal control, 
C – clindamycin instillation, E – simulated CDI, F - rest 
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Figure 8.3.2: Planktonic populations (log10cfu/mL, ±SE) of indigenous gut 
microbiota in vessel 3 of the triple stage biofilm gut model. Vertical line 
represents the last day of each period. A – steady state, B – internal control, 
C – clindamycin instillation, E – simulated CDI, F - rest 
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Figure 8.3.3: Planktonic populations (log10cfu/mL, ±SE) of C. difficile within 
vessel 1 of the triple stage biofilm gut model. Vertical line represents the last 
day of each period. B – internal control, C – clindamycin instillation, E – 
simulated CDI, F – rest. Dashed line - ~LOD 
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Figure 8.3.4: Planktonic populations (log10cfu/mL, ±SE) of C. difficile within 
vessel 2 of the triple stage biofilm gut model. Vertical line represents the last 
day of each period. B – internal control, C – clindamycin instillation, E – 
simulated CDI, F – rest. Dashed line - ~LOD 
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Figure 8.3.5: Planktonic populations (log10cfu/mL, ±SE) of C. difficile within 
vessel 3 of the triple stage biofilm gut model. Vertical line represents the last 
day of each period. B – internal control, C – clindamycin instillation, E – 
simulated CDI, F – rest. Dashed line - ~LOD. 
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Figure 8.3.6: Sessile obligate anaerobic microbiota populations (±SE) from rod/biofilm sampling points Z-U within the triple biofilm 
human gut model. Planktonic populations of each bacterial groups (log10cfu/g) present at each time point are represented by a line in 
the appropriate colour; dashed line, approximate limit of detection. 
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Figure 8.3.7: Sessile (and planktonic) facultative anaerobic microbiota populations (±SE)  from rod/sampling points Z-U.  Planktonic 
populations of each bacterial groups (log10cfu/g) present at each time point are represented by a line in the appropriate colour; dashed 
line, approximate limit of detection. 
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Figure 8.3.8: Sessile C. difficile populations (±SE) from rod/biofilm sampling points Z-U within the triple biofilm human gut model. 
Planktonic populations of each bacterial groups (log10cfu/g) present at each time point are represented by a line in the appropriate 
colour.
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Figure 8.3.9: Concentration (mg/L) of clindamycin within the planktonic 
culture fluid of the biofilm gut model. * Sessile clindamycin antimicrobial 
activity not detected. 
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Figure 8.3.10: Concentration (mg/L) of vancomycin within the planktonic 
culture fluid of the biofilm gut model. * Sessile vancomycin concentration 
data also available (figure 8.3.11). 
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Figure 8.3.11: Concentration (mg/L) of vancomycin (±SE) within biofilm 
structures on 3 rods at time point W (day 52). 
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Figure 8.3.12: Pellet weight of 1mL of re-suspended biofilm within the triple 
stage biofilm human gut model at time points Z-U. 
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8.4 Discussion 
Recurrence of simulated CDI after initial successful vancomycin treatment 
has previously been observed within the original gut model.  Biofilm 
communities are known to play a role within other chronic infections, such 
as chronic otitis media 429 and periodontitis 580.  It was therefore hypothesised 
that biofilm structures within the gut model may play a role in the 
recurrence of symptomatic CDI. 
The original gut model utilises a well established experimental design which 
has been maintained for this study.  In addition, biofilm sampling points 
were introduced at key times.  Due to the finite number of rods within the 
vessel and precautions taken to minimise sessile population bias, a 
maximum of six biofilm time points were included.  Rod sample point Z was 
taken after the initial C. difficile spore inoculation (day 27, period B) to 
demonstrate recruitment of C. difficile into biofilm structures.  Previous 
vreproducibility experiments (chapter 7.0), highlighted the mature nature of 
rod-associated biofilms after 21 days, therefore providing a well established 
biofilm to facilitate C. difficile recruitment.  Rod sample point Y was chosen 
after completion of a clindamycin dosing regimen to provide information on 
the effect of administration of this antimicrobial on sessile gut microbiota 
populations.  A third rod sample point, X was chosen during simulated 
planktonic CDI to determine the behaviour of sessile C. difficile during this 
key period of disease.  Upon successful treatment (elicited by vancomycin, 
period F), rod sampling (W) was carried out to determine whether successful 
treatment was also evident within biofilms.  Sample points V and U were 
designed to provide information on the possible recurrence of CDI. 
Continuous culture systems, such as the one described here, operate under a 
controlled flow rate (f=13.2mL/hr, in this study), thus allowing bacterial 
growth to be maintained at a steady state.  Within the gut model 
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experiments described here period A is designed to allow populations to 
reach this steady state, after which interventions may be made.  Differences 
in bacterial growth phase (i.e. exponential versus stationary) will affect the 
dynamics of the culture vessel.  Whilst all efforts are taken to ensure that 
bacterial populations reach steady state, slight fluctuations (≤ 1 log10cfu/mL) 
were evident within period A of this experiment (figures 8.3.1 and 8.3.2).  
This may be due to inherent variation in the bacterial enumeration protocol.   
In the absence of antimicrobial intervention (period B), sessile and 
planktonic gut microbiota and C. difficile behaved in a similar manner.  
Planktonic populations of obligate species were marginally greater than 
sessile populations, whilst sessile facultative populations were greater than 
planktonic facultative species.  A similar trend has previously been observed 
within the biofilm gut model (chapter 7.0) and biofilm analysis (chapter 4.0) 
experiments.  This is possibly mediated by experimental methods and 
increased aerobic handling time required to process samples for this 
experiment.  Alternatively, the presence of these rods increases the surface 
area of rod-adherent bacteria exposed to the liquid-air interface.  It is 
possible that this area of the vessel is less anaerobic than submerged areas, 
possibly eliciting the increased adherence of facultative species.  However, 
similar observations have been noted by other groups279, 446. 
Planktonic gut microbiota populations within the model behaved in 
response to clindamycin as observed previously272, 515, 525, with a notable 
deleterious effect on Bifidobacterium spp. and more modest declines in 
B. fragilis group and Clostridium spp.  Similar declines in these groups were 
also evident in sessile communities.  However, although planktonic 
Bifidobacterium spp. were below the LOD, sessile communities were still 
detected at 3.9 log10cfu/g.  At biofilm sampling point Y (period D), 
planktonic B. fragilis group and Clostridium spp. had recovered to 
pre-clindamycin levels.  However, sessile populations of these groups 
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remained at reduced levels.  These differences in behaviour of sessile and 
planktonic gut microbiota populations suggests that clindamycin elicits a 
similar effect on both communities, although the effect and recovery of 
sessile populations may be delayed compared with planktonic populations.  
Reduced susceptibility of biofilms to antimicrobial agents is a well defined 
characteristic of sessile communities399, 581.  To date, little work exists 
investigating the exposure of mixed-species intestinal biofilms to 
antimicrobial agents, with the majority of groups focussing on simple single 
species biofilms399. 
Clindamycin successfully induced planktonic C. difficile germination, 
proliferation and toxin production.  Simulated planktonic CDI was evident, 
five days after cessation of clindamycin dosing, whilst gut microbiota 
remained perturbed. Clindamycin demonstrates an in vitro activity against 
vegetative C. difficile (PCR ribotype 027 planktonic MIC 1 mg/L), potentially 
preventing germination until sub-MIC levels remained within the system.  
This was achieved four days after dosing cessation within vessel 3. 
Behaviour of C. difficile within planktonic communities was as previously 
observed272, 525.  However, distinct differences between the planktonic and 
biofilm modes of growth were evident, with sessile C. difficile communities 
remaining in spore form, a characteristic observed previously in biofilm gut 
model reproducibility experiments (chapter 7.0) and biofilm analysis 
(chapter 4.0) experiments.  Mechanisms and conditions necessary to induce 
CDI remain to be fully elucidated.  CDI is frequently associated with the use 
of antimicrobial agents, leading to the assumption that the disruption of the 
gut microbiota may play a role in the pathogenesis of C. difficile.  
Clindamycin-induced perturbation of planktonic gut microbiota is evident 
within the gut model.  Instillation of spores concurrent with administration 
of antimicrobial agents leads to CDI, whilst this is not the case in the absence 
of antimicrobial administration.  This gut microbiota disruption was also 
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evident within sessile communities but did not elicit germination and 
proliferation of sessile spores.  At biofilm sample point W (day 52), 
clindamycin was detected within planktonic fluid at a level of 50.8 mg/L.  
However, within biofilm structures no clindamycin activity was detected.  
Despite the absence of detectable clindamycin within the biofilm, 
antimicrobial disruption of sessile communities appears evident. 
Studies on exposure of S. aureus582 and Propionibacterium acnes583 biofilms to 
clindamycin highlight the planktonic MIC/sessile MBEC values 
as 0.25/>128 mg/L and 0.125/512 mg/L, respectively, indicating the increased 
resistance of sessile organisms to antimicrobial administration compared 
with planktonic populations. Another study reported biofilm-associated cell 
survival after clindamycin exposure as 20-99 %584.  This highlights the 
complex nature of the biofilm mode of growth. 
Numerous microenvironments exist within biofilms that differ with respect 
to pH, oxygen concentration, nutrient availability, and cell density.  This 
results in heterogeneity in metabolic and reproductive activity among cells 
located in different parts of the biofilm.  Initial treatment often effectively 
kills bacteria on the outer margins of the biofilm, whilst metabolically 
inactive cells located in the interior of the biofilm may be resistant to the 
actions of antimicrobial agents that target actively growing cells415.  
Bifidobacterium spp. and B. fragilis group, which demonstrated a 
susceptibility to antimicrobial administration, may localise on the outer 
margins of the biofilm, leaving them susceptible to clindamycin action.  
C. difficile spores, which did not demonstrate a response to clindamycin 
instillation or perturbation of gut microbiota, may reside within a heavily 
protected portion of the biofilm.  Furthermore, the release and detection of 
germinants that are required for efficient germination may have been 
prevented from accessing the spores. 
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Following planktonic C. difficile germination, proliferation and toxin 
production, planktonic Bifidobacterium spp. populations began to recover to 
pre-clindamycin levels, although this was at a greater rate than sessile 
recovery, providing further evidence for the delayed reaction of sessile 
compared with planktonic communities.  This is potentially due to the 
delayed action of antimicrobial agents on sessile communities.  The increase 
in biofilm populations is likely mediated by recruitment of planktonic cells 
into these structures rather than the active proliferation of sessile 
populations due to the inherent dormant, slow-growing nature of these 
communities.  Recruitment of planktonic cells requires the planktonic 
population to increase in number to then facilitate transfer to the biofilm 
mode of growth. 
Vancomycin is a first line option for CDI treatment, and has been utilised as 
a treatment option on numerous occasions within the original gut model, 
therefore is the most useful agent to use in this study.  Planktonic C. difficile 
viable counts declined rapidly and re-converged with spore counts 2 days 
after vancomycin instillation, with cytotoxin reduced to undetectable levels 
after five days.  Sessile C. difficile, which remained as spores, were not 
affected by vancomycin instillation, potentially due to the absence of 
anti-spore activity of vancomycin.  Vancomycin instillation elicited a marked 
deleterious effect on planktonic B. fragilis group and Bifidobacterium spp. and 
an increase in Lactobacillus spp., as previously observed within the gut 
model272, 525.  Clostridium spp. levels were sporadic, a trend often observed 
with this bacteria group.  Similar declines and increases in sessile 
communities were also observed during periods W and V, demonstrating 
the proficient effect of vancomycin upon sessile populations.  Delay in the 
response of sessile communities to vancomycin instillation was not evident 
at time point W.  This may be caused by the increased length of time of 
biofilm analysis following vancomycin cessation (+ 3 days), whereas time 
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point Y was one day after clindamycin instillation ceased.  Alternatively, it 
has been reported that vancomycin displays a more profound action against 
sessile communities compared with clindamycin.  Vancomycin and 
clindamycin displayed an 81 and 64% kill rate against sessile S. aureus, 
respectively584. 
Vancomycin activity within the rod-associated biofilm structures at time 
point W averaged at ~40 mg/L, demonstrating the penetration of this agent 
within the biofilm structures.  This level is approximate to the in vitro MIC 
(16-32 mg/L) of vancomycin to B. fragilis group, providing the potential of 
antimicrobial activity of vancomycin on sessile B. fragilis organisms, as 
observed within this experiment.  Successful penetration of vancomycin into 
biofilm structures has previously been reported.  Exposure of S. epidermidis 
biofilms to increasing concentrations of vancomycin elicited increased 
vancomycin detection within biofilms585.  As concentration of vancomycin 
within biofilms increased, the number of viable sessile bacteria decreased.  
Furthermore, an increased concentration of vancomycin was detected within 
biofilms compared to the surrounding incubating medium.  The authors 
postulated that this is potentially mediated by the biofilm matrix trapping 
and concentrating vancomycin molecules in a manner similar to that used to 
trap and concentrate nutrients.  Within this study, increased levels of 
vancomycin were also evident within biofilm structures compared with 
planktonic fluid. 
Vancomycin treatment of planktonic simulated CDI was initially successful 
with C. difficile populations remaining as spores post-treatment.  Recurrence 
of disease was evident 14-16 days after vancomycin cessation, with an 
increase in C. difficile viable counts and toxin.  Sessile C. difficile populations 
remained in spore form.  Sessile population levels were maintained at 
~5 log10cfu/g from time point Z through to U, despite fluctuations in 
planktonic populations, demonstrating the highly stable nature of sessile 
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C. difficile populations.  Recurrence following vancomycin instillation within 
the original gut model has previously been observed515, 586, but not always474, 
512, 525. 
Sub-inhibitory levels of vancomycin promote increased S. epidermidis biofilm 
density 587,588.  It is postulated that exposure of low concentrations of 
vancomycin may affect expression of genes involved in biofilm production, 
providing a means by which bacteria protect themselves from 
antimicrobials.  Studies involving C. difficile biofilms demonstrate that 
exposure to supra-MIC levels (and to lesser extent sub-MIC levels) of 
vancomycin over three days induced biofilms formation 454.  However, 
biofilm pellet weights (figure 8.3.12) post-vancomycin exposure (time point 
W) did not display increased biomass compared within other time points. 
Early signs of recurrence were evident between days 63 - 68.  However, at 
this point most gut microbiota populations had recovered to pre-dosing 
levels.  Bifidobacterium spp. levels began to recover, reaching populations 
of 4 - 4.5 log10cfu/g between days 63 - 64 in vessels 2 and 3 respectively.  
Despite recovery of gut microbiota, CDI recurrence was evident, suggesting 
recurrence is a complex process not only reliant on colonisation resistance of 
the gut microbiota. 
Biofilm dispersal mechanisms are important factors for microbial survival, 
allowing single organisms or biofilm aggregates to colonise new niches371, 372.  
Many factors are thought to mediate this dispersal including regulatory 
systems (e.g. quorum sensing)364, active dispersal mechanisms (e.g. matrix 
degrading enzymes)577 and changes in nutrient levels589.  Various dispersal 
mechanisms are in continued operation within the biofilm lifecycle.  The 
persistence of a stable population of C. difficile spores within biofilms was 
observed in this study.  Within B. subtilis, gene expression is described as a 
dynamic process during biofilm development.  Cells expressing certain 
genes localised at distinct regions of a biofilm, with spores located at upper 
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aerial structures434.  This provides an ideal nidus for B. subtilis spores and 
their seeding into the surrounding environment.  B. subtilis and C. difficile 
sporulation (and potentially biofilm formation) are regulated by Spo0A, of 
which they share 56% amino acid homology.  C. difficile may potentially 
display similar cellular expression pathways and spatial biofilm architecture. 
Deakin et al163 demonstrated that Spo0A is required for recurrence of CDI 
within a murine model.  Vancomycin-treated mice, after initial treatment 
success, suffered multiple episodes of recurrent infection in those mice 
infected with wild-type strains but not those with spo0A mutations, 
indicating that spores are a persistence and transmission factor.  
Interestingly, wild type C. difficile was not detected in the intestinal tract of 
mice receiving vancomycin therapy, but was detected within environmental 
sites.  Clearly this study is in contrast to the persistence of C. difficile spores 
outlined within the in vitro biofilm gut model.  Differences between the two 
model systems exist, in particular pertaining to gut microbiota composition, 
highlighting the complexity of recurrent infection and the need to 
investigate the process further. 
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9.0 Conclusions 
Recurrent CDI is a major problem in healthcare facilities worldwide and 
gaining a greater understanding of the reasons behind treatment failure and 
recurrent disease is invaluable in reducing this burden249.  Biofilms have 
been identified as causing chronic infections430 and our knowledge of the 
existence of multispecies biofilms on mucosal surfaces, including the 
gastrointestinal tract294 provide evidence that the existence of these 
structures may play a role in recurrent CDI.  Analysis and evaluation of 
mucosal biofilms in vivo is difficult due to the physical inaccessibility of this 
area in healthy patients.  Therefore, this project was designed to develop and 
characterise an in vitro model of the planktonic and biofilm communities of 
the human colon, providing an opportunity to study the role that biofilms 
may play in recurrent CDI. 
Various in vitro model designs were evaluated in this study.  The reliable 
formation of biofilms which could be sampled for extended periods was a 
key aim of this project.  The use of MA beads proved unsuccessful due to 
bacterial-mediated degradation of this substratum material.  Glass beads 
provided the longevity required for the project, although the formation of 
mature biofilms was absent.  Observation of increased biofilm biomass at the 
solid/liquid/air interface lead to the incorporation of glass rods into the 
vessel design.  This model design was validated for the reliable formation 
and consistent populations of bacterial groups across all rods. 
The original human gut model was initially validated against the intestinal 
contents of sudden death victims and subsequently evaluated to study 
CDI98.  The redesigned biofilm model maintains this basic model design, 
providing validated information on the planktonic communities within the 
model.  The redesigned model provides preliminary validation work on the 
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biofilm structures within the system; however, validation against the 
mucosal biofilm communities of intestinal contents from sudden death 
victims was not feasible during this study.  Separate studies investigating the 
intestinal mucosal biopsy samples display similarities between sessile 
communities present within the biofilm gut model292, 294, 563, proving a degree 
of confidence in the results obtained in the present study.  Limitations in the 
model system are acknowledged; the system is unable to reflect the 
immunological and secretory processes observed in vivo.  Also, the 18 rods 
facilitating biofilm formation are unable to reflect the large surface area of 
the mucosal surface of the human colon accurately. 
Intestinal planktonic populations within the redesigned gut model were also 
present in sessile form during steady state periods, with planktonic 
populations displaying increased obligate anaerobic populations compared 
with sessile populations and the converse true for facultative anaerobes.  
Instillation of antimicrobial agents elicited a rapid effect on planktonic gut 
microbiota populations.  A deleterious effect was also observed against 
sessile populations, although they demonstrated delayed reaction to, and 
recovery from, antimicrobial administration.  This was potentially mediated 
by reduced antimicrobial penetration through the biofilm matrix or reduced 
efficacy against the slow growing sessile mode of growth409, 411. 
The reduced susceptibility of sessile bacteria to antimicrobial agents has 
previously been reported358, 399, although many conflicting reports exist400, 590.  
Many researchers use simple CBD experiments to determine this effect, 
exposing sessile and planktonic communities to antimicrobial agents 
separately at a single time point.  Results from this project indicate that 
sessile communities display delayed response to antimicrobial exposure.  
Appropriately designed CBD experiments using multiple time points may 
demonstrate a similar observation, possibly explaining the conflicting results 
obtained by researchers to date. 
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Simple batch culture microtiter tray-associated C. difficile biofilm formation 
is highly variable and inconsistent and appears to be dependent on 
incubation time.  Characterisation of complex mixed-species biofilms within 
the continous original gut model system provided useful preliminary 
information on the existence of C. difficile vegetative cells, spores and 
cytotoxin within mature biofilm structures.  The behaviour of C. difficile 
within this continuous system was variable, potentially mediated by 
previous and current planktonic behaviours which differ due to differences 
in complex experimental designs. 
Attempts to screen the pure culture biofilm forming abilities of a panel of 
C. difficile isolates on abiotic surfaces provided inconsistent results.  Positive 
biofilm formation was obtained, although the degree of biofilm biomass 
varied between repeat experiments under the same conditions.  
Furthermore, incubation time and media appeared to affect results, as 
observed by other groups454. 
Differing conditions within the original gut model appeared to affect 
behaviour of sessile C. difficile, with differences observed in sessile properties 
between vessels 1, and 2 and 3.  This behaviour does not appear to be 
restricted to sessile populations, with planktonic C. difficile demonstrating 
variable behaviours, particularly in vessel 1 of the model.  Vessel 1 is a high 
substrate environment with a low pH and elicits greatest biofilm formation.  
Nutrient level and composition, bacterial population density and pH may 
mediate the variable behaviour of both planktonic and sessile C. difficile.  In 
addition, gut microbiota populations, notably planktonic B. fragilis group 
demonstrate distinct population differences in vessel 1 compared with 
vessels 2 and 3. 
Sessile C. difficile often possess increased populations of spores compared 
with planktonic populations within the same vessel, an observation noted 
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during analysis of vessel wall- and rod-adherent biofilms within the gut 
model, as well as by other groups455, 457.  Vegetative forms have been 
observed within mature mixed-species biofilms structures in this study and 
pure culture structures by other researchers355, 454.  It is postulated that both 
biofilm formation and sporulation pathways of C. difficile are regulated by 
Spo0A, as observed in B subtilis529, 591, possibly mediating this observation. 
Use of the redesigned biofilm gut model allows the biofilm mode of growth 
of C. difficile to be monitored at distinct phases of CDI, with sessile C. difficile 
remaining in dormant spore form for the duration of the experimental 
design.  Biofilm analysis work (chapter 4.0) analysed biofilm structures at 
only a single time point.  However, experimental designs of each of these 
experiments were diverse, providing information on the sessile mode of 
growth of C. difficile after successful treatment, during recurrence, after and 
during initial CDI simulation.  Collectively the information obtained in these 
biofilm analysis experiments provides information on the biofilm mode of 
growth of C. difficile at these distinct time points.  Whilst increased levels of 
spores were often observed within biofilm compared with planktonic phases 
in these experiments, this behaviour was more consistent within the biofilm 
redesign model. 
Sessile C. difficile are known to exist in both spore and vegetative form.  The 
work presented here does not provide information on whether sessile spores 
demonstrate and ability to germinate into vegetative form or whether 
vegetative cells from the planktonic fluid were recruited into the biofilm. 
The maintenance of a dormant C. difficile spore state within the redesigned 
biofilm model, but presence of low levels of biofilm-associated toxin, and 
high levels of planktonic toxin, indicates the active sequestration of 
planktonic-associated toxin into the biofilm.  Mucosal biofilms potentially 
cover toxin receptors; therefore the presence of toxin within these structures 
possibly mediates the localisation of toxin in close proximity to receptors.  
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However, persistence of biofilm-associated toxin was not prolonged and at 
low levels, suggesting a minimal impact on contribution to disease.  
However, the presence of pseudomembranous legions on the mucosal 
surface in vivo suggests that the action of toxins is evident at this site.  It is 
possible that disruption of the mucosal biofilm, possibly by antimicrobial 
therapy, allows access of toxins to the mucosal epithelial and their receptors.  
Alternatively, extensive mucosal biofilms in vivo may facilitate the 
sequestration of toxin at concentrations greater than those obsesrved in this 
study. 
Removal of mature biofilms from the in vitro gut model demonstrated a 
profound persistence of some antimicrobial agents (fidaxomicin and 
oritavancin), but not others (clindamycin and co-amoxiclav).  Mechanisms of 
persistence were not determined from this study, but indicate variations in 
structure and properties of antimicrobial agents.  Interestingly, fidaxomicin 
and oritavancin both displayed an apparent anti-spore activity, 
demonstrated by sporadic detection of spores within the original gut model 
and adherence of these agents to spores, which is postulated to prevent the 
outgrowth of vegetative cells515, 522, 527, 547.  Persistence of these agents for 
prolonged periods within biofilms, in close proximity to spores, may elicit an 
advantageous pharmacodynamic property, thus preventing germination of 
these spores into vegetative form.  Such properties may be of focus for 
development of novel treatment options.  Persistence of C. difficile spores 
within biofilm structures in the redesigned gut model may have implications 
in vivo.  Detachment processes associated with the biofilm lifecycle may 
possibly mediate the seeding of these spores into the colonic lumen.  Once 
antimicrobial therapy has ceased, if conditions are favourable, these spores 
may germinate into their vegetative form, proliferate and release toxin, 
leading to recurrence of symptomatic disease. 
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The biofilm human gut model identifies the presence and characterises the 
behaviour of C. difficile during different disease stages, indicating the 
importance of biofilms in CDI.  The biofilm mode of growth of C. difficile is a 
complex, multifactorial lifestyle, which remains to be fully elucidated.  Data 
presented in this study and by other355, 454, 457, 592 provide preliminary 
information within this field.  Recurrent CDI is a major problem for 
healthcare facilities worldwide, with rates of recurrence of ~20%243.  This 
project identifies the potential role of biofilms in recurrence of CDI, 
necessitating the need for further work to understand the role that these 
biofilm structures may play in CDI and recurrent infection fully, potentially 
proving the opportunity to analyse the efficacy of novel CDI treatment 
therapies on sessile, in addition to planktonic communities.  Furthermore, 
utilisation of this model system to investigate other parameters of intestinal 
biofilms is possible.  Additional validation in the form of a comparative 
study on biofilm communities in healthy human subjects with biofilm 
populations within the biofilm gut model would provide a further level of 
confidence in previous and future results. 
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List of Abbreviations 
 
Abbreviation Full text 
ADP 
AHL 
Amox 
ATCC 
BD 
Adenosine diphosphate 
Acyl-homoserine lactone 
Co-amoxiclav 
American Type Culture Collection 
Twice daily 
BHI Brain heart infusion 
BSAC 
CBD 
CC 
British Society for Antimicrobial Chemotherapy 
Calgary biofilm device 
Cytotoxigenic culture 
CCEYL 
CCEYLM 
CD 
CDAD 
c-di-GMP 
Cycloserine cefoxitin egg yolk lysozyme agar 
Cycloserine cefoxitin egg yolk lysozyme moxifolxacin agar 
Clostridium difficile 
Clostridium difficile-associated diarrhoea 
3’, 5’-cyclic diguanylic acid 
CDI 
CDRN 
CDT 
Clostridium difficile infection 
Clostridium difficile ribotyping network 
Clostridium difficile transferase 
CFU 
Clinda 
CLSM 
CTA 
CTAB 
Colony forming units 
Clindamycin 
Confocal laser scanning microscopy 
Cytotoxin assay 
Cetyltrimethylammonium bromide 
DMEM  Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic acid 
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Abbreviation Full text 
ELISA Enzyme-linked immunosorbent assay 
EPS Extra polymeric substance 
ESMID European Society of Clinical Microbiology and Infectious 
Diseases 
FBA 
FDX 
Columbia blood agar 
Fidaxomicin 
 
FiSH 
GDH 
GM 
HBSS-EDTA 
Fluorescent in situ hybridisation 
Glutamate dehydrogenase 
Geometric mean 
Hanks balanced salt solution- containing 0.25 g/L 
trypsin-EDTA 
HIV Human immunodeficiency virus 
IgA, IgM, IgG 
LFE 
Immunoglobulins A, M and G 
Lactose-fermenting Enterobacteriaceae 
LGI 
LOD  
Leeds General Infirmary 
Limit of detection 
MA   
Met 
MBEC 
MIC 
MLST 
MLVA 
MRD 
NA 
NAAT 
NAP1  
Mucin alginate 
Metronidazole 
Minimum biofilm eradication concentration 
Minimum inhibitory concentration 
Multilocus sequence typing 
Multilocus variant analysis 
Modified Robbin’s device 
North American Pulsotype 
Nucleic acid amplification test 
North American pulsotype 
NCCLS National Committee for Clinical Laboratory Standards. 
NCTC 
NR 
National Collection of Type Cultures 
No result 
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Abbreviation Full text 
PAGE 
PaLoc 
PBS 
PCR 
PEG 
PFGE 
PHE 
Polyacrylamide gel electrophoresis 
Pathogenicity locus 
Phosphate buffered saline 
Polymerase chain reaction 
Polyethyl glycol 
Pulsed-field gel electrophoresis 
Public Health England 
PMC 
PMN 
PPMO 
PTFE 
QD 
RCM 
REA 
Pseudomembranous colitis 
Polymorphonuclear leukocytes 
Potentially pathogenic microorganism 
Polytetrafluroethylene 
Four times daily 
Robinson’s cooked meat 
Restriction endonuclease 
RNA Ribonucleic acid 
RR Risk ratio 
rRNA 
RU 
SCFA 
SE 
TD 
TSB 
TVC 
Vanc 
Ribosomal RNA 
Relative unit 
Short chain fatty acid 
Standard error 
Three times daily 
Tryptone soy broth 
Total viable counts 
Vancomycin 
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Appendix A 
Bacteriological Culture Medium Used For This Project 
Media were autoclaved at 123° C for 15 minutes after which resazurin 
(Sigma; 0.005 g/L) and where required, glucose (Sigma; 0.4 g/L) were 
filter-sterilised and added to the medium through 0.22 μm syringe filters. 
A.1 Gut model growth medium 
Original Gut Model Growth Medium 
Constituent g/L Product code Supplier 
Starch (potato) 3.0 5/7960/53 Fisher 
Pectin 2.0 416862500 Oxoid 
Yeast extract 2.0 LP0021 Oxoid 
Peptone water 2.0 CM0009 Oxoid 
Sodium hydrogen carbonate, (NaHCO3) 2.0 71631 Sigma 
Arabinogalactan  1.0 10830 Sigma 
Bile salts no. 3 0.5 B8756 Sigma 
Cysteine HCl  0.5 C1276 Sigma 
Tween 80 2.0 mL/L P1754 Sigma 
Vitamin K 10 μL/L V3501 Sigma 
Sodium chloride 0.1 S7653 Sigma 
Potassium dihydrogen phosphate 
(KH2PO4) 
0.04 EC23183245 Fisher 
di-potassium monohydrogen phosphate 
(K2HPO4) 
0.04 10203 AnalR 
Magnesium sulphate, (MgSO4.6H20) 0.01 M1880 Sigma 
Calcium chloride, (CaCl2) 0.01 C3881 Sigma 
Haemin 0.005 51280 Sigma 
Glucose 0.4 G8270 Sigma 
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Biofilm Gut Model Growth Medium 
Constituent g/L Product code Supplier 
Starch 5.0 5/7960/53 Merck 
Peptone water 5.0 CM0009 Oxoid 
Tryptone 5.0 LP0042 Oxoid 
Yeast extract 4.5 LP0021 Oxoid 
Sodium chloride (NaCl) 4.5 S7653 Sigma 
Potassium chloride, (KCl) 4.5 P9333 Sigma 
Casein 3 C7078 Sigma 
Pectin 2 416862500 Acros organics 
Xylan 2 X0505 Sigma 
Arabinogalactan 2 W325406 Sigma 
Sodium hydrogen carbonate, 
(NaHCO3) 
1.5 71631 Sigma 
Magnesium sulphate, (MgSO4.6H20) 1.25 M1880 Sigma 
Guar gum 1 G4129 Sigma 
Inulin 1 57614 Fluka 
Cysteine HCl 0.8 C1276 Sigma 
Potassium dihydrogen phosphate 
(KH2PO4) 
0.5 EC23183245 Fisher 
di-potassium monohydrogen 
phosphate (K2HPO4) 
0.5 10203 AnalR 
Bile salts no. 3 0.4 B8756 Sigma 
Calcium chloride, (CaCl2) 0.15 C3881 Sigma 
Iron (II) sulphate (FeSO4.7H20) 0.005 21,549-2 Sigma 
Haemin 0.05 51280 Sigma 
Vitamin K 10 μL/L V3501 Sigma 
Tween 80 1.0 μL/L P1754 Sigma 
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A.2 Liquid Culture Medium, Diluents and Buffers 
Unless otherwise stated, all media were autoclaved at 123° C (15 mins) prior 
to use. 
Brain Heart Infusion Broth 
Brain Heart Infusion broths (CM225, Oxoid) were prepared according to the 
manufacturer’s instructions. 
Formulation g/L 
Calf brain infusion solids 12.5 
Beef heart infusion solids 5.0 
Proteose peptone 10.0 
Glucose 2.0 
Sodium chloride 5.0 
Di-sodium phosphate 2.5 
 
Cetylmethylammonium Bromide (CTAB) 
Haxadecyltrimethylammonium bromide (H9151, Sigma) was prepared to a 
concentration of 0.001% w/v. 
Cooked Meat Medium 
Cooked meat medium (CM0081, Oxoid) was prepared according to the 
manufacturer’s instructions. 
Peptone Water 
Peptone water (CM0009, Oxoid) was prepared according to the 
manufacturer’s instructions. 
 
 
Formulation g/L 
Peptone 10.0 
NaCl 5.0 
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Phosphate Buffered Saline 
Phosphate buffered saline (PBS) (P4417, Sigma) was prepared according to 
the manufacturer’s instructions.   
Saline 
Saline (S7653, Sigma) was prepared according to the manufacturer’s 
instructions. 
Schaedler’s Anaerobic Broth 
Schaedler’s anaerobic broth (CM496, Oxoid) was prepared according to the 
manufacturer’s instructions. 
 
Formulation g/L 
Tryptone soya broth 10.0 
Special peptone 5.0 
Yeast extract powder 5.0 
Glucose 5.0 
Cysteine HCl 0.4 
Haemin 0.01 
Tris buffer  0.75 
 
Tryptic Soy Broth 
Tryptic soy broth (T8907, Oxoid) was prepared according to the 
manufacturer’s instructions. 
Formulation g/L 
Casein  17.0 
Soya peptone 3.0 
Sodium chloride 5.0 
Dipotassium phosphate 2.5 
Dextrose 2.5 
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A.3 Solid Media Used For Gut Microbiota Identification and 
Enumeration 
Unless otherwise stated, all solid media were autoclaved at 123° C 
(15 minutes), cooled to 50oC prior to the addition of supplements and 
distributed into 90 mm triple vented Petri dishes (Sarstedt) 
Nutrient Agar 
Nutrient agar (CM0003, Oxoid) was prepared according to the 
manufacturer’s instructions.  Inoculated plates incubated aerobically. 
Formulation g/L 
Lab-Lemco powder 1.0 
Yeast extract 2.0 
Peptone 5.0 
Sodium chloride 5.0 
Agar 15.0 
 
MacConkey Agar 
MacConkey Agar No. 3 (CM115, Oxoid) was prepared according to the 
manufacturer’s instructions. Inoculated plates incubated aerobically. 
Formulation g/L 
Peptone 20.0 
Lactose 10.0 
Bile salts No.3 1.5 
Sodium chloride 5.0 
Neutral red 0.03 
Crystal violet 0.001 
Agar 15.0 
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Kanamycin Aesulin Azide Agar 
Kanamycin Aesculin Azide Agar (CM0591, Oxoid) was prepared according 
to the manufacturer’s instructions and supplemented with 20 mg/L 
kanamycin (K4000, Sigma) and 10 mg/L aztreonam (150415, MP 
Biomedicals) following autoclaving. Inoculated plates incubated aerobically. 
Formulation g/L 
Tryptone 20.0 
Yeast Extract 5.0 
Sodium Chloride 5.0 
Sodium Citrate 1.0 
Aesculin 1.0 
Ferric Ammonium Citrate 0.5 
Sodium Azide 0.15 
Agar 10.0 
 
Fastidious Anaerobe Agar 
Fastidious anaerobe agar (LAB090, LabM) was prepared following the 
manufacturer’s instructions.  Following cooling to 50° C 10% sterile horse 
blood (BHB400, E & O) was added. Inoculated plates incubated 
anaerobically. 
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Formulation g/L 
Peptone mix 23.0 
Sodium chloride 5.0 
Sodium bicarbonate 0.4 
L-cysteine HCl 0.4 
Starch 1.0 
Glucose  1.0 
Sodium pyruvate 1.0 
Arginine 1.0 
Sodium succinate 0.5 
Ferric pyrophosphate 0.3 
Haemin 0.005 
Vitamin K 0.004 
Bacteriological agar 12.0 
 
Bile Aesulin Agar 
Bile Aesculin Agar base (CM888, Oxoid) was prepared according to the 
manufacturer’s instructions and supplemented with 5 μg/mL haemin 
(H5533, Sigma) and 20 µL/L vitamin K1 (V3501, Sigma) prior to autoclaving.  
Following cooling to 50° C, 7.5 mg/L vancomycin (V2002, Sigma), 1 mg/L 
penicillin G (13752, Fluka) and 75 mg/L kanamycin (K4000, Sigma) were 
added to the molten agar.  Inoculated plates incubated anaerobically. 
 
Formulation g/L 
Peptone 8.0 
Bile salts 20.0 
Ferric citrate 0.5 
Aesculin 1.0 
Agar 15.0 
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LAMVAB agar 
LAMVAB was prepared as described by Hartemink et al. (1997).  Briefly, the 
medium consisted of three solutions (A, B, and C). 
Solution A (500mL) was prepared with 104.4 g/L MRS Broth (CM359, 
Oxoid), supplemented with 0.5 g/L cysteine hydrochloride (C1276, Sigma) 
prior to autoclaving. 
 
MRS Broth 
Formulation g/L 
Peptone 10.0 
Lab-Lemco powder 8.0 
Yeast extract 4.0 
Glucose 20.0 
Sorbitan mono-oleate 1 mL 
Dipotassium hydrogen phosphate 2.0 
Sodium acetate 3H20 5.0 
Triammonium citrate 2.0 
Magnesium sulphate 7H20 0.2 
Magnesium sulphate 4H20 0.05 
 
Solution B consisted of 40g/L Agar Technical No 3 (LP0013, Sigma) prepared 
in a 500 mL volume.  Both Solutions A and B were sterilised by autoclaving 
at 121° C for 15 minutes. 
Following cooling, solutions A and B were mixed, 1mL vancomycin (V2002, 
Sigma) was added to the molten agar and the solution adjusted to 
pH 5.0+/- 0.1 using 4 M HCl (Sigma).  Inoculated plates incubated 
anaerobically. 
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Beerens Agar 
Beerens Agar was made by adding 42.5 g/L Columbia Agar base (CM331, 
Oxoid); 5 g Agar Technical No.3) (LP0013, Oxoid); 5 g/L glucose (G7528, 
Sigma); 0.5 g/L cysteine HCl (C1276, Sigma) to sterile distilled water. The 
mixture was heated to 100° C and then cooled to 55-60° C before the 
addition of 5 mL/L propionic acid (P1386, Sigma) and adjustment to pH 5. 
Inoculated plates incubated anaerobically. 
Columbia Agar base 
 
Formulation g/L 
Special peptone 23.0 
Starch 1.0 
Sodium chloride 5.0 
Agar 10.0 
 
Brazier’s Agar (CCEYL(M)) 
Brazier’s CCEY agar base (LAB 160, LabM) was supplemented with 8 mg/L 
cefoxitin and 250 mg/L cycloserine, supplied as lyophilised vials (X093, 
LabM, 2% lysed horse blood (BHB400, E and O) and 5 mg/L lysozyme 
(L6876, Sigma), with 2 mg/L moxifloxacin (Bayer) for CCEYLM, following 
autoclaving and cooling to 50° C. Agar plates were prepared according to 
the manufacturer’s instructions. Inoculated plates incubated anaerobically. 
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Formulation g/L 
Peptone mix 23.0 
Sodium chloride 5.0 
Soluble starch 1.0 
Agar 12.0 
Sodium bicarbonate 0.4 
Glucose 1.0 
Sodium pyruvate  1.0 
Cysteine HCl 0.5 
Haemin 0.01 
Vitamin K 0.001 
L-arginine 1.0 
Soluble pyrophosphate 0.25 
Sodium succinate 0.5 
Cholic acid 1.0 
p-hydroxyphenylacetic acid 1.0 
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A.4 Solid Media Used in Antimicrobial Bioassays 
Wilkins Chalgren 
Wilkins-Chalgren anaerobe agar (CM619, Oxoid) was prepared according to 
the manufacturer’s instructions. 
 
Formulation g/L 
Tryptone 10.0 
Gelatin peptone 10.0 
Yeast extract 5.0 
Glucose 1.0 
Sodium chloride 5.0 
L-arginine 1.0 
Sodium pyruvate 1.0 
Menadione 0.0005 
Haemin 0.005 
Agar 10.0 
 
Mueller Hinton Agar 
Mueller Hinton agar (CM0337, Oxoid) was prepared according to the 
manufacturer’s instructions. 
 
Formulation g/L 
Beef, dehydrated infusion  300.0 
Casein hydrolysate 17.5 
Starch  1.5 
Agar 17.0 
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Antibiotic Medium Number 1 
Antibiotic medium number 1 agar (CM619, Oxoid) was prepared according 
to the manufacturer’s instructions. 
 
Formulation g/L 
Beef, dehydrated infusion  300.0 
Casein hydrolysate 17.5 
Starch  1.5 
Agar 17.0 
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Appendix B 
Media, Solutions and Additives Used in the Culture of Vero 
Cells 
Dubecco’s Modified Eagle’s Medium (DMEM) (D6546, Sigma) was supplied 
in sterile 500 mL bottles and stored at 4oC. 
Formulation g/L  Formulation g/L 
Calcium chloride  0.265  L-lysine HCl 0.146 
Iron (III) nitrate  0.0001  L-methionine 0.03 
Potassium chloride  0.4  L-phenylalanine 0.066 
Magnesium sulphate  0.09767  L-serine 0.042 
Sodium chloride  6.4  L-threonine 0.095 
Sodium hydrogen carbonate  3.7  L-tryptophan 0.016 
Sodium dihydrogen 
phosphate  
0.109  L-tyrosine 0.10379 
Phenol Red Na 0.015  L-valine 0.094 
Pyruvate Na 0.11  D-pantothenate 1/2 Ca 4 
D-glucose 4.5  Choline chloride 0.004 
L-arginine HCl 0.084  Folic acid 0.004 
L-cysteine 0.0626  myo-inositol 0.0072 
L-glutamine 0.584  Niacinamide 0.004 
Glycine 0.03  Pyridoxine HCl 0.004 
L-histidine HCl.H2O 0.042  Riboflavin 0.0004 
L-isoleucine 0.105  Thiamine HCl 0.004 
L-leucine 0.105    
Media Additives 
Newborn calf serum (N4637, Sigma) was collected from animals up 
to 10 days old and was tested to ensure that free from viruses and 
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mycoplasmas. This additive was stored at –20oC in 25 mL volumes to give 
a 10% concentration when added to 500 mL DMEM. 
Antibiotic/antimycotic solution (A5955, penicillin 100 U/mL, 
streptomycin 100 mg/L ,  amphotericin B 0.25 mg/L) was supplied as 100X 
liquid solution.  This mixture was stored at –20° C in 5 mL volumes to give 
an appropriate concentration when added to 500 mL DMEM. 
L-Glutamine (G7513, Sigma) was supplied as a 200 mM liquid solution.  This 
was stored at -20° C in separate volumes and diluted 1:100 in 500 mL 
supplemented DMEM. 
Solutions 
Hank’s Balanced Salts Solution (H9394, Sigma) was supplied in 
sterile 500 mL bottles. 
 
Formulation g/L 
Potassium chloride (KCl) 0.4 
Potassium hydrogen phosphate (KH2PO4) 0.06 
Sodium chloride (NaCl) 8 
Sodium hydrogen carbonate (NaHCO3) 0.35 
Sodium hydrogen phosphate (Na2HPO4) 0.04788 
D-glucose 1 
Phenol Red 0.011 
  
Trypsin (T4174, Sigma) was supplied as 10x liquid solution containing 5.0 g 
porcine trypsin and 2 g EDTA• 4Na per liter of 0.9% sodium chloride.  This 
was stored at –20° C in and diluted 1:10 in HBSS to yield a 1X solution. 
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Appendix C 
Addresses of Suppliers of Chemicals, Reagents and Equipment 
 
Supplier Address 
Acros Organics Thermo Fisher Scientific UK, 
Bishop Meadow Road, 
Loughborough, 
Leicestershire, 
LE11 5RG, 
UK 
Bayer Bayer plc. 
Pharmaceutical Division, 
Bayer House, 
Strawberry Hill, 
Newbury, 
Berkshire, 
RG14 1JA 
UK 
Beckton Dickinson Beckton Dickinson, 
The Danby Building, 
Edmund Halley Road, 
Oxford Science Park, 
Oxford, 
OX4 4DQ 
UK 
Bigger Trading Ltd Bigger Trading Ltd. 
34A Station Road, 
Cuffley, 
Hertfordshire, 
EN6 4HE 
UK 
Bioconnections Bioconnections, 
Thorp Arch Estate, 
Wetherby, 
Leeds, 
LS23 7BJ, 
UK 
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Supplier Address 
Brighton Systems Brighton Systems Ltd. 
44 Meeching Road, 
Newhaven, 
East Sussex, 
BN9 9RH 
UK 
Don Whitely Scientific, Ltd. Don Whitely Scientific, Ltd. 
14 Otley Rd, 
Shipley, 
West Yorkshire, 
BD17 7SE, 
UK 
E and O Laboratories E and O Laboratories, 
Burnhouse, 
Bonnybridge, 
FK4 2HH, 
Scotland  
Gibco Life Technologies , 
3 Fountain Drive, 
Inchinnan Business Park, 
Paisley, 
PA4 9RF 
UK 
Grant Instruments Grant Instruments, 
Sherpreth, 
Cambridgeshire, 
SG8 6GB, 
UK 
Fisher Scientific Thermo Fisher Scientific UK, 
Bishop Meadow Road, 
Loughborough, 
Leicestershire, 
LE11 5RG, 
UK 
Fluka Sigma-Aldrich Co. Ltd. 
Fancy Road, 
Poole, 
Dorset, 
UK, 
BH12 4QH. 
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Supplier Address 
LabM Topley House, 
52 Wash Lane,  
Bury, 
Lancs, 
BL9 6AS 
Life Technologies Life Technologies Ltd. 
3 Fountain Drive, 
Inchinnan Business Park, 
Paisley, 
Scotland 
PA4 9RF 
Merck Merck KgaA, 
64271 Darmstadt, 
Germany. 
Millepore Corporation Millepore Corporation 
290 Concord Road, 
Billerica, 
MA, 
USA 
Molecular Devices Molecular Devices, 
660-665, 
Winnersh Triangle, 
Winnersh, 
Berkshire, 
RG41 5TS 
UK 
Nunc Thermo Scientific NUNC™ and 
NALGENE® 
75 Panorama Creek, 
Rochester, 
New York 
14625 
USA 
Oxoid Oxoid Ltd., 
Basingstoke, 
Hampshire, 
RG24 8PW 
UK 
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Supplier Address 
Priorclave Ltd Priorclave Ltd, 
129-131 Nathan Way, 
West Thamesmead Business Park, 
London, 
SE28 0AB, 
UK 
Pro-lab Diagnostics Pro-lab Diagnostics, 
7 Westwood Court, 
Neston, 
CH64 3UJ 
UK  
Sigma Sigma-Aldrich Co. Ltd., 
Fancy Road, 
Poole, 
Dorset, 
UK, 
BH12 4QH. 
Soham Scientific Soham Scientific, 
Muncey’s Mill, 
37 Mildenhall Road, 
Fordham, 
Ely, 
Cambridgeshire, 
CB7 5NP 
UK 
VWR International VWR International Ltd. 
Hunter Boulevard, 
Magna Park, 
Lutterworth, 
Leicestershire, 
LE17 4XN 
UK 
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Appendix D 
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Appendix D1: Mean populations (± SE) of C. difficile PCR ribotype 078 in 
planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in 
biofilm gut model growth medium. (TVC, total viable counts; LOD, 
~ 2 log10cfu/g, ~ 1.5 log10cfu/mL). 
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Appendix D2: Mean populations (± SE) of C. difficile PCR ribotype 106 in 
planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in 
biofilm gut model growth medium. (TVC, total viable counts; LOD, 
~ 2 log10cfu/g, ~ 1.5 log10cfu/mL). 
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Appendix D3: Mean populations (± SE) of C. difficile PCR ribotype 078 in 
planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in brain 
heart infusion broth. (TVC, total viable counts; LOD, ~ 2 log10cfu/g, 
~ 1.5 log10cfu/mL). 
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Appendix D4: Mean populations (± SE) of C. difficile PCR ribotype 106 in 
planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in BHI 
(TVC, total viable counts; LOD, ~ 2 log10cfu/g, ~ 1.5 log10cfu/mL). 
- 380 - 
0
1
2
3
4
5
6
0 1 2 3
lo
g
1
0
c
fu
/m
L
 (
lo
g
1
0
c
fu
/g
 B
)
Day
Planktonic TVC Biofilm TVC Planktonic spore Biofilm spore
 
Appendix D5: Mean populations (± SE) of C. difficile PCR ribotype 078 in 
planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in saline. 
(TVC, total viable counts; LOD, ~ 2 log10cfu/g, ~ 1.5 log10cfu/mL). 
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Appendix D6: Mean populations (± SE) of C. difficile PCR ribotype 106 in 
planktonic (log10cfu/mL) and biofilm (log10cfu/g) form when grown in saline. 
(TVC, total viable counts; LOD, ~ 2 log10cfu/g, ~ 1.5 log10cfu/mL). 
